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ABSTRACT 
 
 
 
Hip and knee arthroplasty are increasingly common surgical procedures in Australia, with more 
than 85,000 expected to be performed this year. Compared to the general public, people who 
undergo a hip or knee arthroplasty are at an increased risk of developing blood clots (also known 
as a venous thromboemboli or VTE) as both procedures activate all three aspects of Virchow’s risk 
triad during the pre-, peri- and postoperative period. 
Importantly, VTE are considered one of the most common causes of preventable death in 
Australian hospitals. Whilst there are mechanical and pharmacological measures that can be 
employed to prevent VTE (known collectively as thromboprophylaxis), and many national and 
international bodies have released thromboprophylaxis guidelines over the years, previous studies 
have reported consistent underutilisation of thromboprophylaxis both in Australia and overseas.
 
The overarching objective of this thesis was to examine thromboprophylaxis prescribing patterns in 
Australia, and the factors that influence them.  
To achieve this aim, a number of complementary studies were conducted, including both 
qualitative and quantitative work. Retrospective reviews were conducted at six hospitals across 
three states to explore prescribing patterns; the results indicated that while anticoagulant 
thromboprophylaxis is routinely used in hospital, its continuation at discharge is not habitual – 
despite recommendations by contemporary guidelines to extend therapy usually beyond the 
inpatient period. Interestingly, prescribing patterns were generally found to be more aligned with 
recent contemporary recommendations than recommendations existent at the time of prescribing, 
indicating practice preceded guidelines. 
A survey exploring hospital protocols and local prescribing practices identified that only 50% 
of the 143 Australian hospitals surveyed had thromboprophylaxis protocols and that their 
alignment with published literature varied considerably. Surprisingly, private hospitals tended to 
base their guidelines on the National Health and Medical Research Council (NHMRC) Guideline, 
whereas public hospitals were more likely to favour individual or collective surgeon preferences. 
Where they existed, adherence to hospital protocols was apparently high (86%), and predictably 
trended to increase in hospitals with adherence strategies in place (91% vs. 79%).  
Two online surveys were conducted with orthopaedic surgeons practising in Australia. Whilst 
the first survey was limited by its small number of respondents (25), it identified that individual 
prescribing preferences vary significantly, with many surgeons perceiving guideline 
recommendations (including those of the NHMRC Guideline) as inappropriate. Although few 
respondents believed that pharmacological prophylaxis prevents fatal pulmonary emboli, and many 
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responded that VTE risk is low following arthroplasty, all participants routinely prescribed 
pharmacological prophylaxis postoperatively. In addition to bleeding concerns and a perceived low 
VTE risk, the third strongest barrier to thromboprophylaxis use was the belief that study evidence 
is not applicable to real-world inpatient populations. Along this line, a number of surgeons 
expressed suspicions that industry funding was heavily biasing guideline recommendations, either 
directly by sponsoring guideline authors or indirectly by sponsoring associated research. The 
second survey had a significantly larger number of respondents (221), and maintained the results of 
the first study. 
Semi-structured interviews were used to explore surgeons’ preferences, opinions and 
experiences in greater detail. Moreover, to complement these views and to gain a better 
understanding of real practice, these interviews were supplemented by interviews with Tasmanian 
based orthopaedic interns, general practitioners (GPs) and clinical pharmacists. While a surgeon’s 
opinion was identified to be greatly moulded by their training and collective experience, and not by 
contemporary guidelines, other health professionals’ opinion were more inclined to be shaped by 
guidelines. The interviews also identified that even though participants differed in their 
thromboprophylaxis preferences and opinions, they all strongly agreed that thromboprophylaxis 
should be tailored to the individual patient. All surgeons expressed familiarity with at least one 
contemporary guideline; however, other health professionals generally did not. This lack of 
knowledge and familiarity naturally impairs their ability to contribute to postoperative care. 
Additionally, hospital to community communication was described as slow and unreliable by 
participants, further disadvantaging GPs from being able to effectively contribute to VTE 
prevention after discharge. 
Rather than awaiting the formulation of a Tasmanian based protocol (which was attempted by 
an outside group early on in the research), another strategy to optimise thromboprophylaxis use 
would be to instigate a statewide strategy to increase the uptake of the NHMRC Guideline. One of 
the biggest barriers identified in this research to the adoption of guidelines such as the NHMRC 
Guideline is the perception that they impose a ‘one size fits all’ approach to thromboprophylaxis 
by making ‘carte blanche recommendations’. In reality, the NHMRC Guideline takes a 
comprehensive approach to VTE prophylaxis and, unbeknown to many health professionals, 
actually addresses the many concerns they expressed in the studies in this thesis. A quick ready-
reference tool developed from the NHMRC Guideline could assist greatly in overcoming 
communication and knowledge obstacles described in this thesis; and a suggestion of what this 
ready-reference tool could look like is included. 
Passively disseminating clinical practice guidelines has been ineffective at optimising 
thromboprophylaxis use to date, both in Tasmania and interstate, potentially leaving many patients 
exposed to a higher risk of VTE. A clear understanding of the factors that influence 
thromboprophylaxis prescribing and guideline adoption is essential. Together, the studies 
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contained in this thesis identified many barriers to thromboprophylaxis use and guideline adoption, 
including: concerns over bleeding complications (and associated potential underreporting), the 
scope of industry influence, and the threat of guidelines being too prescriptive, threatening 
professional autonomy and thereby posing a potential medico-legal liability to surgeons. These 
barriers should be addressed in forthcoming editions of the NHMRC Guideline to encourage 
uptake of its recommendations and ensure optimal outcomes for patients. 
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CHAPTER ONE: INTRODUCTION 
 
 
 
1.1 Thesis Background 
Venous thromboemboli (VTE) are the most common cause of preventable death in Australian 
hospitals.
1
 There are a number of factors that increase a person’s risk of developing VTE, including 
advanced age, obesity, medications and surgery.
2
 Two such surgical procedures that significantly 
increase VTE risk, independent of other risk factors, are hip and knee arthroplasty.
2
 
Fortunately, there are mechanical and pharmacological measures that can be employed to 
prevent VTE, known collectively as thromboprophylaxis. The American Agency for Healthcare 
Research and Quality refers to these measures as their ‘number one patient safety practice’.3 Many 
national and international bodies have released thromboprophylaxis guidelines in recent years; 
however, despite their wide promulgation, studies indicate that thromboprophylaxis is 
underutilised both in Australia and internationally.
4-11
  
This thesis reports on work that investigated thromboprophylaxis prescribing following hip 
and knee arthroplasty in Australia, as well as barriers and enablers to its widespread use.  
 
 
1.2 Research Methodology 
A mixed methods approach to the overall research methodology was utilised, gathering together 
both quantitative and qualitative data to provide new insights into what drives thromboprophylaxis 
prescribing following hip and knee arthroplasty. The quantitative data included retrospective 
reviews and surveys. The qualitative data included open ended survey data and semi-structured 
interviews. 
A mixed methods approach was utilised to overcome the potential deficiencies inherent in 
both qualitative and quantitative research methods. For example, quantitative research methods can 
sometimes produce findings of ‘little consequence’ because they tend to generalise findings rather 
than taking into account peoples’ varied experiences or the way they interpret and make sense of 
their experiences.
12
 On the other hand, the often relatively small sample sizes used in qualitative 
research methods can sometimes limit the generalisability of their findings. Regardless of the type 
of data utilised in a study, exclusive reliance on only one dataset to answer a research question can 
bias or distort one’s picture of the particular slice of reality being investigated.13  
Triangulation attempts to map out, or explain more fully, the richness and complexity of 
human behaviour by studying it from more than one standpoint.
13 
Methodological triangulation 
(the use of two or more different kinds of methods in a single line of inquiry) was employed in this 
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research to provide a more complete understanding of the slice of reality being studied.
14
 For 
example, surgeons’ perceptions of thromboprophylaxis were captured in closed and free-text 
survey questions, while semi-structured interviews with surgeons (who may or may not have 
participated in the survey) and other stakeholders (e.g. general practitioners) also contributed 
information on how thromboprophylaxis following hip and knee arthroplasty is perceived and 
prescribed. In this way a more holistic view of prescribing and factors that influence prescribing 
was obtained. 
 
 
1.3 Significance of the Research 
Passively disseminating clinical practice guidelines has been ineffective at improving 
thromboprophylaxis use in Australia.
15
 A clear understanding of the factors that influence 
thromboprophylaxis prescribing and guideline adoption is essential for the optimal use of 
thromboprophylaxis, and subsequent optimal care and outcomes for patients undergoing hip and 
knee arthroplasty in Australia. Significantly, this research explored these factors in greater depth 
than previously reported. The findings and benefits of this research will accrue indirectly and in the 
long term. 
 
 
1.4 Limitations of the Research 
This research explored thromboprophylaxis prescribing patterns and factors that influence them. 
As such the research was not designed to examine, at least as a primary outcome, the effectiveness 
of thromboprophylaxis in Australian arthroplasty patients. 
 
 
1.5 Ethics 
The research associated with this thesis abides by the international and Australian codes on human 
and animal experimentation. This research received approval from the Human Research Ethics 
Committee (Tasmania) Network (approval reference numbers: H0010881, H0011165 and 
H0011265, including amendments), the Hunter New England Research Ethics & Governance Unit 
(11/12/14/5.07), the Austin Health Research Ethics Committee (EER 04471) and the Western Health 
Ethics Committee (QA 2012.34). 
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CHAPTER TWO: THROMBOPROPHYLAXIS FOLLOWING HIP AND KNEE 
ARTHROPLASTY 
 
 
 
2.1 Thromboemboli 
A blood clot can be classified as either an arterial or venous thromboembolism depending on the 
type of blood vessel it originates from. While both are composed of platelets and fibrin, arterial 
thrombi tend to occur at sites of arterial plaque rupture where blood flow is high.
16
 They are 
usually platelet-rich and are referred to as ‘white thrombi’. In contrast, venous thromboemboli 
originate in the venous system where blood flow and shear rates are low. Furthermore, they tend to 
occur at sites where the vein wall is often healthy. Venous thromboemboli (VTE) are rich in red 
blood cells and fibrin, and are often termed ‘red thrombi’.16 This thesis specifically focuses on 
work exploring VTE prevention following hip and knee arthroplasty. 
 
2.1.1 Venous Thromboembolism 
VTE is an evolving, multi-factorial disease that can result in either partial or complete block of 
blood flow to the surrounding tissues.
17
 Deep vein thrombosis (DVT) and pulmonary embolism 
(PE) are two aspects of this one disease process. A DVT usually starts in the calf veins, from where 
it may extend to the proximal veins; it can then subsequently break free to travel to the pulmonary 
blood vessels to result in a PE.
17,18
 In general, PE occur less commonly, with approximately one 
third of symptomatic VTE manifesting as PE and two thirds manifesting as DVT alone.
19,20
  
Many VTE will occur without symptoms and are known as asymptomatic clots. VTE which 
do become symptomatic will vary in their presentation depending on both the type and severity of 
the clot. Symptoms of DVT include pain, tenderness, erythema, and swelling. Furthermore, DVTs 
can lead to chronic venous insufficiency and eventually venous ulcers. Symptoms of PE can 
include shortness of breath, bloody sputum, chest pain, faintness, and heart failure. Massive PE are 
life threatening and remain one of the most common causes of preventable death in Australia.
17
 
The manifestation of symptoms depends on a number of factors. These include: the extent of 
thrombosis, the adequacy of collateral blood vessels, and the severity of the associated vascular 
occlusion and inflammation.
18
 Additionally, the physiological capacity of the patient to tolerate the 
thrombosis plays an important role in not only the manifestation of symptoms, but also the clinical 
outcome. For example, a moderately sized PE may cause no symptoms in an otherwise healthy 
individual, but severe symptoms or even death may result from the same PE in an individual with 
severe cardiopulmonary disease.
18 
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2.1.2 Pathophysiology 
Thrombus formation and propagation depend on the presence of three interdependent factors. 
These factors are collectively named Virchow’s triad after the nineteenth century German 
pathologist Rudolph Virchow who is credited with ‘discovering’ PE.21 Virchow’s triad of factors 
are endothelial injury or dysfunction, haemostasis, and hypercoagulability. Elements that increase 
VTE risk through instigating one or more of Virchow’s triad are collectively referred to as VTE 
risk factors (Table 1). 
 
Table 1. Virchow’s triad in clinical practice.  
22
 
Factor Clinical examples 
Hypercoagulability Oestrogen therapy, thrombophilia, previous VTE, pregnancy, cancer 
Haemostasis Cancer, obesity, major surgery, hip or leg fracture, myocardial infarction 
Endothelial injury or dysfunction Trauma, major surgery, hip or leg fracture 
 
The combination of one or more of Virchow’s triad in a person greatly increases their VTE 
risk.
22
 Consequently, a patient with a suspected DVT is more likely to have their diagnosis 
confirmed by objective testing if they have one or more of these risk factors (Figure 1).  
 
 
Figure 1. Proportion of suspected 
DVT confirmed with venography. 
 
Source: Anderson et al (2003).
2
 
 
 
Although risk factors increase the risk of developing VTE, not all factors have the same 
predictive weight.
2
 One of the strongest risk factors for VTE development is surgery, and in 
particular hip and knee arthroplasty (Table 2). 
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Table 2. Risk factors for VTE based on odds ratio .
2
 
Strong Risk Factors (OR>10) Moderate Risk Factors (OR 2-9) Weak Risk Factors (OR <2) 
      Hip or knee fracture 
      Hip or knee arthroplasty 
      Major general surgery 
      Major trauma 
      Spinal cord injury 
      Arthroscopic knee surgery 
      Central venous lines 
      Chemotherapy 
      Congestive heart or respiratory failure 
      Hormone replacement therapy 
      Malignancy 
      Oral contraceptive therapy 
      Paralytic stroke 
      Pregnancy 
      Previous venous thromboembolism 
      Thrombophilia 
      Bed rest > 3 days 
      Immobility due to sitting  
      Increasing age 
      Laparoscopic surgery 
      Obesity 
      Pregnancy 
      Varicose veins 
NB: OR = odds ratio. 
 
Depending on the type of risk factors present in a person who develops VTE, their clot can be 
classified as either provoked or unprovoked. Provoked VTE are those that occur secondary to 
transient risk factors (e.g. trauma and pregnancy), whereas unprovoked VTE are defined as being 
secondary to persistent risk factors (e.g. thrombophilia).
23
 Surgery is a transient risk factor, and 
therefore a symptomatic VTE following orthopaedic surgery is usually classified as a provoked 
VTE.  
 
2.1.3 Clinical Sequelae and Consequences 
The main cost of VTE is the loss of healthy life that it entails, both acutely and chronically. 
Acutely, people with postoperative VTE are likely to remain out of work longer than anticipated.
24-
27
 This can be due to a combination of the hospital stay (or being promptly readmitted after 
presentation to outpatient clinics/emergency departments) and the substantial physical limitations 
which they often experience during the rehabilitation and recovery period.
 
Additionally, patients 
who develop postoperative VTE usually require anticoagulation for extended periods of time, 
thereby exposing them to its inherent risks, and treatment costs. Combined, these factors can easily 
result in a patient having to endure a substantial VTE associated cost burden postoperatively.
27
     
The long term morbidity associated with VTE can be as equally burdensome as the acute 
phase symptoms. Long term complications most commonly include recurrent VTE and post 
thrombotic syndrome (which can lead to ulcers and cellulitis).
27,28 
Most complications occur weeks 
to months after the initial clot, although ulceration can occur months to years later.  
In addition to the acute and chronic repercussions described above, VTE has the potential to 
be lethal. It is estimated that 1% of all patients admitted to hospital will die from it, and it accounts 
for 10% of all hospital deaths.
1,17
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2.1.3.1 Recurrent Venous Thromboemboli 
A previous history of VTE significantly increases a person’s risk of developing subsequent VTE.29 
It is estimated that a person is approximately 40 times more likely to suffer VTE within six months 
of their initial episode compared with a previously unaffected person (3.6 to 8.0% vs. 0.08%, 
respectively).
18,30-32
  
Observational data indicate that this risk is not identical for everyone and that the risk of 
recurrent VTE in an individual patient can be estimated from a variety of interacting clinical, 
laboratory and imaging findings.
33
 Although there are conflicting views as to how accurately these 
findings can predict one’s risk, one factor which is unanimously agreed to affect VTE recurrence is 
the nature of the initial VTE (provoked or unprovoked).
31,33-35
 Significantly, surgically provoked 
VTE is associated with approximately half the risk of recurrence compared to unprovoked VTE 
(Table 3).
35
 
 
Table 3. Relative cumulative risk of recurrent VTE within four years .
35
 
Surgery Group Index VTE n 
Recurrent VTE % after Difference 
in relative 
risk  p 
Provoked Index VTE 
(95%CI) 
Unprovoked Index VTE 
(95%CI) 
Multiple surgical 
procedures combined 
11,797 7.6 (7.0-8.2) 14.7 (14.2-15.1) 48% 0.001 
Knee arthroplasty 2,617 5.9 (5.0-7.1) 14.4 (13.5-15.3) 59% 0.001 
Hip arthroplasty 2,239 7.8 (6.6-9.3) 14.3 (13.5-15.3) 45% 0.001 
 
The risk of recurrent VTE continues for years after the initial episode irrespective of whether 
the initial VTE was provoked or unprovoked; however, the cumulative risk is lower for provoked 
VTE. In both settings, the risk of recurrence is highest in the first few days to weeks after an initial 
event, with a more gradual increase in the cumulative recurrence rate thereafter (Figure 2).
35  
 
 
Figure 2. Cumulative recurrent 
VTE incidence. 
 
Kaplan-Meier plot of the 
incidence of recurrent VTE in a 
knee arthroplasty provoked VTE 
group versus a matched 
unprovoked VTE group. 
 
Source: White et al (2010).
35
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It is generally accepted that the type of VTE (PE or DVT) strongly predicts the type of VTE 
manifested on recurrence.
18,32,36,37  
That is, recurrent VTE after a DVT is most likely to be in the 
form of another DVT, and the is same true of PE. Some recent data suggests there may be no 
significant bias; however, this requires further investigation.
38 
 
2.1.3.2 Post Thrombotic Syndrome 
Post thrombotic syndrome (PTS) is the most common long term complication of DVT.
39
 This 
chronic syndrome can vary significantly between patients; however, classic symptoms include 
pain, swelling, skin depigmentation, and itchiness.
39
 It has been hypothesised that PTS occurs as a 
result of valve damage and outflow obstruction following a DVT; this can lead to vein dilatation, 
fluid accumulation, venous hypertension, abnormal microcirculation, and finally tissue hypoxia.
40
 
People who experience PTS can incur significant morbidity (including decreased mobility) 
and may potentially require chronic medical and home nursing care. Accordingly, patients who 
experience PTS report decreased disease-specific quality of life scores which are, on average, 
similar or worse than those reported by patients with osteoarthritis or chronic lung disease.
41
 These 
scores worsen with increasing PTS severity.
40
 
PTS has been reported to occur with varying frequency in patients following VTE, both 
symptomatic and asymptomatic, provoked and unprovoked.
42
 It is estimated that 23% to 60% of 
people will develop PTS and up to 10% will develop venous ulcers within 2 years of an 
unprovoked VTE, with cumulative rates further increasing thereafter.
43
 PTS incidence following 
provoked VTE is less frequent; only an estimated 5% to 10% of arthroplasty patients report severe 
PTS symptoms within two to four years of surgery.
44
 
One possible explanation why PTS is less common after a surgically provoked VTE than an 
unprovoked VTE is that a person who develops an unprovoked VTE is generally more likely to 
have multiple comorbidities compared to a patient healthy enough to undergo surgery. This means 
their physiological capacity to tolerate a thrombosis will be reduced, and thus their likelihood of 
developing PTS will be increased. Additionally, the use of thromboprophylaxis postoperatively not 
only reduces the incidence of VTE, but may also reduce the size of a thrombus in those who do 
develop one; and small thrombi are less likely to cause the venous obstruction and valvular damage 
associated with PTS.
45
  
Treatment options for PTS are limited to nocturnal leg elevation, vascular surgery, pain 
management and weight loss; consequently, VTE prevention is crucial to reducing the PTS burden 
on individuals and society. 
 
2.1.3.3 Mortality 
Although DVT itself is unlikely to be lethal, if it is left untreated it can potentially dislodge and 
move into the lungs to cause PE, which can be fatal. Accurately determining how often people die 
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as a result of VTE is difficult, particularly because many patients do not die immediately. Instead, 
patients will often have nonspecific symptoms and for this reason the diagnosis of VTE associated 
death is often delayed or missed entirely without an autopsy.
18  
Postoperative VTE mortality data is even more limited than general VTE mortality data and 
many of the studies reporting post-arthroplasty complications are limited by their retrospective 
nature. Those studies choosing to only investigate in-hospital fatality fail to capture deaths 
attributable to VTE a few days or weeks out from discharge. Conversely, choosing excessively 
long study periods can artificially inflate mortality rates by including deaths due to VTE that are 
independent of the surgery itself. 
Nevertheless, it is estimated that the general mortality risk within one month of DVT is 6% 
and 12% following PE.
19,46
 Notably, a patient’s risk factors and the nature of the clot they develop 
(provoked or unprovoked) both influence their risk of dying following VTE.
47,48
 For example, 
provoked VTE are less likely to result in death than unprovoked VTE. The 90-day mortality risk 
following hip and knee arthroplasty is reported to be 0.2% to 0.3%, only one third of which is 
attributed to VTE.
49,50
 
Furthermore, observational data indicate that surgery factors can also impact on mortality risk 
following hip and knee arthroplasty. For example, the risk of dying is significantly higher 
following hip arthroplasty compared to knee arthroplasty (3.0% vs. 0.1%).
47,51
 Moreover, 
Australian data indicate first-year cumulative mortality to be higher following total conventional 
hip arthroplasty compared to total resurfacing hip arthroplasty
*
 (1.2% vs. 0.2%), and higher 
following total knee arthroplasty compared to partial knee arthroplasty (1.0% vs. 0.4%).
52
 The 
highest risk period for postoperative fatal PE appears to be 3 to 7 days after surgery.
18  
 
 
  
                                                     
*
 Unlike traditional hip replacement, hip resurfacing does not replace the ball of the femur with a metal or 
ceramic ball. Instead, the damaged hip ball is reshaped and capped with a metal prosthesis. The damaged hip 
socket is also fitted with a metal prosthesis, similar to what is used in a conventional hip replacement. 
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2.2 Hip and Knee Arthroplasty 
Hip and knee arthroplasty (HA and KA respectively) are increasingly common procedures in 
Australia. During these surgeries an arthritic or damaged joint is removed and replaced with an 
artificial joint or prosthesis. In 2011 approximately 83,000 arthroplasties were conducted in 
Australia, with 28.4% of patients requiring more than one procedure.
53,54
 There is a general trend 
towards more knee arthroplasties being conducted annually than hip arthroplasties, and although 
the data is limited (it relies on self-reporting by surgeons and hospitals), there is an upward trend in 
both procedures each year.
53
  
Hip and knee arthroplasty are particularly strong risk factors for VTE because all three aspects 
of Virchow’s triad occur during the pre-, peri- and postoperative period (Table 4).  
 
Table 4. Virchow’s triad in arthroplasty patients. 
22,55-57
 
Operative stage Example Virchow factor 
Preoperatively Limb immobility caused by fractures or breaks.
 
Haemostasis 
Hypercoagulability 
Pre- and peri- 
operatively 
Knee arthroplasties performed with a thigh tourniquet and the 
knee in a flexed and sub-luxated position can lead to venous 
stasis.  
Haemostasis 
 
Perioperatively Endothelium can be injured during positioning and 
manipulation of the extremity.  
Endothelial injury/dysfunction 
Blood vessel wall distension caused by blood pooling, 
particularly with tourniquet use, can cause endothelial damage 
and lead to clotting activation.  
Hypercoagulability 
Endothelial injury/dysfunction 
Bone cement may cause thermal injury.  Endothelial injury/dysfunction 
Damaged bone marrow activates clotting factors released 
during the operation. These factors often aggregate in regions 
of venous stasis.
  
Hypercoagulability 
Blood loss reduces endogenous anticoagulants and inhibits the 
fibrinolytic system.  
Hypercoagulability 
Postoperatively Localised postoperative swelling and immobility can lead to 
venous stasis.  
Haemostasis 
 
 
2.2.1 Postoperative Venous Thromboemboli 
Although it is difficult to determine the baseline incidence of symptomatic VTE following hip and 
knee arthroplasty, it is generally agreed that arthroplasty patients are at an increased risk of 
developing VTE compared to the population at large (Table 5). A recent study identified a 13-fold 
and 14-fold increased VTE risk in hip and knee patients (respectively) compared with a matched 
cohort. 
58
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Table 5. Symptomatic VTE in different populations. 
Population Symptomatic VTE incidence (per 100,000) References 
General population 83 – 114 
20,30,59 
Knee and hip arthroplasty patients 1,200 – 5,300 
6-8,50,60,61  
 
Studies report that up to 40% of arthroplasty patients experience VTE within a few days of 
surgery; however, most are asymptomatic.
62,63
 The clinical relevance of asymptomatic VTE is 
unknown because their association with symptomatic VTE is uncertain. The most reliable 
approach to determine the relationship between the symptomatic and asymptomatic VTE is to 
blind a cohort of patients and health care providers to the results of venography, and compare short 
and long-term outcomes in these patients. Some clinicians argue however, that it is unethical to 
conceal these results because there is a possibility of asymptomatic VTE extending or propagating 
around the body.
64,65
  
An alternative approach would be to examine the relationship between asymptomatic VTE 
and the incidence of VTE associated clinical sequelae. Although this approach can be biased by the 
use of anticoagulants to treat asymptomatic VTE, it has been studied in a variety of settings. There 
is evidence that asymptomatic DVT is associated with the development of PTS in medical patients, 
however not so in patients who undergo lower limb surgery.
42,45,66,67
 
 
This may be due to an 
inherent difference in the nature of provoked and unprovoked VTE, and the physiological capacity 
of the afflicted patients. 
While the clinical relevance of symptomatic VTE is generally accepted, it is difficult to 
ascertain its true baseline incidence. This is because there have been no large placebo controlled 
trials or well-designed cohort studies conducted in recent years. Furthermore, those placebo 
controlled trials that were conducted in previous years are not relevant to current practice as pre-, 
peri- and postoperative surgical care following hip and knee arthroplasty has changed considerably 
over the years.
68
 For example, the average length of stay in hospital following surgery has 
decreased markedly from almost 17 days in 1992 to 9 days in 1999, and more recently from 3.2 
days in 2008 to 2 days in 2009.
69-72
  
Additionally, the patients themselves have also changed; younger, healthier patients are 
having surgery, with a greater emphasis being placed on ensuring good postoperative function and 
mobility.
73,74
 Furthermore, from 2003 onwards there has been a shift in surgical techniques to less 
invasive (and therefore potentially less thrombogenic) techniques.
68,70 
 
Although it is not possible to directly determine a baseline symptomatic VTE risk for 
arthroplasty patients, it is possible to estimate it. A review of trials conducted after 2003 reported 
symptomatic VTE risk in patients using pharmacological thromboprophylaxis to be approximately 
1.2% within the first 7 to 14 days following surgery (0.8% DVT, 0.4% PE).
68
 Several reviews have 
estimated that pharmacological prophylaxis reduces relative VTE incidence (symptomatic and 
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asymptomatic) by 50% to 70%, and potentially up to 85%.
75-78 
Extrapolating these two findings, we 
can estimate that the contemporary baseline VTE risk following arthroplasty is 2.9% within the 
first 7 to 14 days following surgery.  
Data suggests that the increased risk of VTE continues for up to three months after surgery 
both with and without thromboprophylaxis.
62,68,79
  Therefore, the true cumulative baseline risk for 
symptomatic VTE following arthroplasty is likely to be higher than 2.9% (Figure 3). The reported 
three-month symptomatic VTE incidence rate in Australia is 3.8% to 5.0% following arthroplasty, 
with most occurring within the first month following surgery (Table 5).
51
 
 
Figure 3. Pharmacological 
prophylaxis and VTE incidence 
following major orthopaedic 
surgery.  
 
Observational data is 
represented for the cumulative 
incidence rate resulting from 
high use of pharmacological 
prophylaxis in the first 7 to 14 
days postoperatively.  
 
NB: The pharmacological 
prophylaxis in this instance is low 
molecular weight heparin 
(LMWH). 
 
Source: Falck-Ytter et al (2012).
68
 
 
 
Table 6. Australian incidence of symptomatic VTE following arthroplasty. 
Source n Data period Thromboprophylaxis Incidence 
O’Reilley et 
al 2005 
63 
5999  
HA / KA  
 
1995-2001 Seven days LMWH or VKA + GCS. 
Prophylaxis then changed based on VTE investigations. 
1.9% non-fatal 
inpatient PE 
Hitos et al 
2006
6 
283  
KA  
1996-2004 All patients received mechanical ± pharmacological 
prophylaxis.  
82.5-100% given anticoagulant + mechanical prophylaxis. 
3 month VTE 
incidence: 3.9%  
Hitos et al 
2009
7 
321  
HA  
1996-2004 74-100% received mechanical + pharmacological 
prophylaxis. 
3 month VTE 
incidence: 3.8% 
Eikelboom 
et al 2004
8 
157  
HA / KA  
2002 51.5% received LMWH or VKA postoperatively, most of the 
rest received mechanical prophylaxis or aspirin. 
56.6% received prophylaxis post-discharge. 
3 month VTE 
incidence: 5.3%  
 
Buchan et 
al 2008
80 
246  
HA / KA 
 
2004-2005 98% received anticoagulants in hospital.  
8.2% receiving an anticoagulant post-discharge.  
 
3 month PE 
incidence: 2.8% 
non-fatal, 0.4% 
fatal 
NB: LMWH = low molecular weight heparin (e.g. enoxaparin), VKA = vitamin K antagonist (e.g. warfarin),  
GCS = graduated compression stockings, HA = hip arthroplasty, KA = knee arthroplasty. 
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There can be significant variation in the VTE incidence reported in studies.
81,82
 Such 
variations in VTE may be in part due to thromboprophylaxis differences; however there are many 
other potential influencing factors, some of which are described briefly below. 
 
2.2.1.1 Other Influencing Factors 
In addition to patient factors (e.g. obesity, previous history of VTE) there are many other peri- and 
postoperative factors that influence VTE incidence. For example, a multivariate analysis identified 
allogenic blood transfusion as a significant risk factor for VTE (associated with a 2.5 times 
increased VTE risk).
83
 There is also evidence that knee arthroplasty for a joint damaged by 
rheumatoid arthritis results in less DVT than knee arthroplasty to replace a joint damaged by 
osteoarthritis; however, this requires further investigation.
84
 
Early postoperative mobilisation can reduce relative VTE risk by 65%.
85-87
 Conversely, an 
increased duration of anaesthesia (3.5+ hours) has been associated with an almost four times 
increased overall VTE risk in bilateral knee arthroplasty patients (7.5% vs. 30.2%).
83
 Notably, 
bilateral simultaneous knee arthroplasty itself is associated with an increased VTE risk compared 
to unilateral knee arthroplasty (up to four times increased VTE risk and 80% increased PE risk), 
irrespective of time to mobilisation.
85,88
 Interestingly, the type of anaesthesia may also infuence 
VTE risk: regional anaesthesia has been reported to carry a lower VTE risk than general 
anaesthesia; consequently it is often recommended in guidelines and commonly used in 
practice.
17,51,89,90
 
A recent study reported that East Asian patients experience very little to no symptomatic VTE 
following hip and knee arthroplasty, suggesting the value of using routine thromboprophylaxis is 
debatable in East Asia.
81
 Notably, studies in South East Asia have actually reported higher 
symptomatic VTE rates to other studies (5.1%).
82
 Such variations in VTE may be in part due to 
thromboprophylaxis differences; however there are other influencing factors, some of which are 
described briefly below. 
Patient and surgical factors are not the only elements that can influence VTE risk. The 
Australian Orthopaedic Association (AOA) has identified that patients operated on by surgeons 
who conduct a large number of  procedures (70+) each year have the best outcome 
postoperatively.
53 
The difference is influenced by prostheses choice for some, but for others there 
are other unidentified factors contributing to the observed surgeon variation.
53
 
The influence of each type of thromboprophylaxis on VTE incidence is described in the 
proceeding section; however, the timing of prophylaxis initiation in respect to an operation can 
also impact VTE risk. For example, evidence suggests thromboprophylaxis should ideally be 
commenced six to nine hours postoperatively; starting too early (two hours preoperatively, during 
the perioperative period and up to six hours postoperatively) may increase bleeding and 
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haematoma risk, and starting too late (>12 hours postoperatively) appears to increase subsequent 
thromboembolic complications.
91,92
  
Finally, as noted in 2.2.1 Postoperative Venous Thromboemboli, the incidence of VTE 
extends well beyond hospitalisation, and potentially up to three months after surgery. 
Consequently, the duration of thromboprophylaxis can influence VTE risk postoperatively. In 
particular, extending thromboprophylaxis beyond the first fourteen days after surgery can reduce 
relative VTE risk by approximately 50% to 70%, compared to employing thromboprophylaxis for 
fourteen days or less.
51,68,75-78,93
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2.3 Preventing Venous Thromboemboli 
There are many measures that can be taken to prevent VTE following surgery. These can be 
grouped by whether they include a medical intervention or not. Those that do not require medical 
intervention are simple measures such as maintaining adequate hydration; early postoperative 
mobilisation; promoting healthy postoperative food intake; and encouraging healthy preoperative 
patient weight or BMI.
17,85,86,94-101
      
Measures that involve medical intervention are mechanical prophylaxis and pharmacological 
prophylaxis; together these strategies tackle the sluggish blood flow and increased clotting factor 
levels that occur with lower limb surgery.
102
  
 
2.3.1 Mechanical Prophylaxis 
Healthy lower limb blood flow is maintained by muscle contractions throughout the leg. During 
walking, pressure on the sole of the foot forces blood to flow out of the span of large veins at the 
arch of the foot (the plantar venous plexus or PVP) up into the calf, where it is thought to ‘prime’ 
the calf muscle (Figure 4). Calf contractions then transport the blood into the deep veins of the 
thigh, and henceforth, blood flow proceeds to the pelvic veins, vena cava, and ultimately to the 
heart; all due to lower limb muscle contraction.
103,104
 
 
Figure 4. Emptying of the plantar 
venous plexus. 
 
a : venous filling of PVP. 
b : weight bearing and subsequent 
foot arch extension immediately 
empties plexus. 
c : calf contractions transport blood 
into deep veins of the thigh. 
 
Source: Bergan et al (2006), and 
Phlebology Journal.
103,105
  
 
 
Undoubtedly, a person’s regular walking and mobility is limited postoperatively, and 
therefore so is the regular use of their calf muscles; this can lead to blood stasis and pooling in the 
veins of the legs. Mechanical thromboprophylaxis aims to combat this by applying physical 
pressure or stimuli to the relevant structures of the leg. 
There are three different types of devices used for mechanical prophylaxis: graduated 
compression stockings (GCS), intermittent pneumatic compression devices (IPCD) and venous 
foot pumps (VFP). GCS apply a static circumferential pressure to the lower limb that gradually 
decreases from the ankle to the thigh. This pressure gradient discourages fluid accumulation and 
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promotes venous flow. IPCD sequentially apply varying levels of pressure to the calf by inflating 
and deflating a compression sleeve to mimic natural calf muscle contractions.
106
 Venous foot 
pumps are different once again; they apply varying pressures (and sometimes even electrical 
stimuli) to the bottom of the foot to imitate the physiological pumping action caused by weight 
bearing on the PVP.
106
 
 
2.3.1.1 Safety and Efficacy 
One of the significant advantages of mechanical prophylaxis over pharmacological means is 
their attractive lack of bleeding potential. This makes them an appealing option for high bleeding 
risk patients. Another advantage is that they can be used in the contralateral leg perioperatively and 
in the immediate postoperative period; whereas pharmacological agents are not generally 
recommended for at least six to eight hours after surgery.
68
 Their use, however, is limited by 
several logistical and/or compliance issues. For example, they require hospitals to have enough 
units in good working condition to supply all patients. Furthermore to achieve optimal results they 
need to be used virtually continuously (including when patients are mobile).
68,107-109  
In practice VFP and IPCD are often only used in hospital because their expense limits the 
ability to supply all patients with a device at discharge. GCS are significantly cheaper and can even 
be independently purchased by patients outside of hospital; however, the efficacy of GCS relies 
heavily on nursing staff selecting the right size and teaching patients to apply them correctly. 
Choosing the wrong size or incorrect application can result in a significantly increased overall VTE 
incidence (25.6% vs. 6.1%, p<0.05).
107
 
Although mechanical prophylaxis strategies have been shown to reduce the risk of VTE, they 
have been studied with significantly less intensity compared to pharmacological means. 
Furthermore, it is not always possible to generalise the findings of trials studying the efficacy of 
each approach. This is because devices are not standardised in their mode of compression, flow 
rate, or type of sleeve used.
110,111
 Another confounding factor in comparing device studies is that 
they often include varying adjunctive treatments, including pharmacological prophylaxis.
110 
Nevertheless, a meta-analysis of trials comparing the efficacy of IPCD combined with 
pharmacological prophylaxis, against either IPCD or pharmacological prophylaxis alone concluded 
that the combination was up to 80% more effective than either prophylaxis strategy alone.
112
 
Similarly, a meta-analysis of trials exploring VFP use in arthroplasty patients reported them to be 
up to 40% more effective than pharmacological prophylaxis; however, results did vary 
considerably between studies.
113
 The results of trials on GCS have been mixed, potentially due to 
the pitfalls of incorrect application; in general, however, they appear less effective than other 
mechanical prophylaxis measures.
114
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2.3.2 Pharmacological prophylaxis 
As previously mentioned, VTE tend to be rich in fibrin and red blood cells. Although the relative 
proportion of platelets is low, there is evidence to suggest platelet activity is significantly increased 
perioperatively, thereby augmenting blood coagulability and thrombus formation (Figure 5).
57,115,116
  
 
Figure 5. Clot formation. 
 
           = transformation 
           = catalysis 
TXA2 = thromboxane A2 
Roman numerals refer 
to coagulation factors 
 
Sources: Tousoulis et al 
(2010) and Bayer 
Pharma.
117
 
118
 
 
 
Consequently, there are two classes of pharmacological agents used for thromboprophylaxis 
postoperatively: anticoagulants and antiplatelets. Anticoagulants prevent blood clots by blocking 
different steps along the coagulation pathway, thereby limiting thrombin formation. Antiplatelets 
inhibit platelet activation and aggregation.  
 
2.3.2.1 Anticoagulants 
There are a range of anticoagulants recommended for orthopaedic patients, including (in 
alphabetical order): apixaban, dabigatran, fondaparinux, low molecular weight heparin (LMWH), 
rivaroxaban, unfractionated heparin (UFH) and warfarin. Each agent blocks a different step(s) in 
the coagulation pathway (Figure 6). 
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Figure 6. Anticoagulants’ mode of 
action. 
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Anticoagulants are administered either by injection (fondaparinux, LMWH and UFH) into the 
abdomen or orally (apixaban, dabigatran, rivaroxaban and warfarin). Although oral anticoagulants 
are convenient to administer, apixaban, dabigatran and rivaroxaban were only registered with the 
Therapeutic Goods Administration in recent years. Consequently, post-marketing surveillance for 
adverse events is not complete and these novel oral agents are not conventionally recommended as 
first choice agents postoperatively. 
Warfarin is a vitamin K antagonist (VKA) that has been in use since the 1950s. Despite its 
long history of use it is also generally not first choice for arthroplasty patients (unless they were 
using it preoperatively) in Australia due to its significant drug, food and disease interactions, as 
well as highly individualised and variable dosing.
17,119
 A failure to maintain the appropriate level of 
anticoagulation with warfarin exposes patients to an increased risk of thrombosis or bleeding.
17
 
Furthermore, warfarin has a delayed onset of action and actually induces a procoagulant state 
during the initiation period.
120
 
 
2.3.2.1.1 Anticoagulant Safety and Efficacy 
The ability of anticoagulants to prevent VTE is generally accepted; however, their comparative 
efficacy and safety is unclear. LMWH is the most popular group of agents used in arthroplasty 
patients in Australia, particularly enoxaparin.
121
 Extended-duration prophylaxis with LMWH can 
reduce relative VTE risk by ~60%; however, there has often been concern that their subcutaneous 
administration could potentially reduce patients’ overall satisfaction and adherence to treatment, 
and hence their ability to prevent VTE effectively.
75,76,122,123
 Recent data suggests injection of 
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treatment is not a barrier to patient compliance, particularly for injectable anticoagulants that are 
only administered once daily compared to multiple times a day.
124,125
 
Novel oral agents (NOA) on the other hand are convenient to administer and study data 
suggest they are at least as effective as LMWH against VTE, and in some cases up to 30% to 60% 
more effective.
126-129
 A significant proportion of the arthroplasty associated NOA research to date 
has been industry supported, and such support may potentially have generated bias in the 
literature.
127,128,130
 Therefore, more studies are required to confirm the relative efficacy of these 
agents to LMWH. 
In addition to potentially being more effective against VTE, NOA have also been associated 
with similar as well as statistically significant and non-significant increases in major and minor 
bleeding, and wound infection post-arthroplasty.
127,131,132
 This is of concern because although UFH, 
VKA and to some extent LMWH all have well established methods of reversal, there is no antidote 
or set treatment options for NOA-related emergency situations.
131,133,134
 
  
2.3.2.2 Antiplatelets 
Antiplatelets have traditionally been reserved for primary and secondary prevention of 
cardiovascular disease; however, their use for VTE prevention has increased in popularity in recent 
times, possibly due to their proposed potential for lower bleeding and faster postoperative 
recovery.
135,136
 Both commonly used antiplatelets, aspirin and clopidogrel, are oral agents that only 
require once daily treatment. Clopidogrel inhibits platelet aggregation by inhibiting adenosine 
diphosphate (ADP)-mediated platelet activation. It also blocks ADP-mediated amplification of 
platelet aggregation. Aspirin on the other hand blocks the production of thromboxane A2, an 
inducer of platelet aggregation and vasoconstriction. Aspirin is sometimes also used in 
combination with dipyridamole, another antiplatelet that blocks phosphodiesterase to increase 
cyclic adenosine monophosphate (Figure 7). 
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Figure 7. Mode of 
platelet activation. 
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     Although clopidogrel has been shown to be a more effective antiplatelet agent than aspirin in 
cardiovascular event prevention, its use is limited by its considerably higher cost and inter-patient 
variability.
137,138
 
 
2.3.2.2.1 Antiplatelet Safety and Efficacy 
Studies exploring the ability of aspirin to prevent VTE have reported mixed results. Although the 
use of antiplatelets for arterial thromboemboli prevention is well established, their use in venous 
thromboemboli prevention is controversial.
139
 Part of the inconsistency in study findings may be 
due to a reported variability in aspirin response between patients; however, inter-study 
methodological differences are likely to also be responsible.
140,141
  
Studies that have implemented multimodal prophylaxis post-arthroplasty, which typically 
consists of regional anaesthesia, early mobilisation, mechanical prophylaxis and aspirin, have 
reported a symptomatic VTE incidence of 1.9% to 3.1% (PE incidence: 0.24% to 2.6%) up to 3 
months after surgery.
135,142-146
 These results are encouraging when compared to the estimated three 
month unprotected VTE incidence of 5.0%.      
Instead of investigating universal aspirin use post-arthroplasty, other studies have 
implemented protocols that have stratified patients and their thromboprophylaxis according to their 
VTE risk: low risk patients received aspirin postoperatively; high risk patients received 
anticoagulants postoperatively.
50,147-151
 These studies have reported comparable VTE rates between 
the two groups, as have observational studies.
152,153
 To date these findings have been used to claim 
aspirin is as effective in VTE prevention in low risk patients as anticoagulants are effective in high 
risk patients; however one could argue that if this was the case, VTE incidence would be 
significantly lower in the aspirin group as they are inherently a lower risk patient group.  
Comparing the direct efficacy and safety of aspirin to anticoagulant agents in any statistically 
meaningful controlled trial is difficult because the absolute incidence of symptomatic VTE is 
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small; to show any statistically significant reduction in PE from 1.0% to 0.5%, or fatal PE from 
0.1% to 0.05% would require a sample group of 10,000 or 100,000 patients, respectively.
145
 
Nevertheless, Woller et al and Gesell et al have each attempted to compare the two groups head-
to-head in relatively small study groups.
154,155
  
Woller et al compared two groups of patients – those who were treated with aspirin or 
warfarin depending on their VTE risk (according to American Association of Orthopaedic 
Surgeons (AAOS) Guideline), and those who received warfarin irrespective of their VTE risk 
(Figure 8).
155,156
  
 
Figure 8. Graphic representation of 
patients screened and proportioned to 
study groups. 
 
NB: AAOS = American Association of 
Orthopaedic Surgeons; ACCP = 
American College of Chest Physicians. 
 
Source: Woller et al (2012).
155
 
 
 
Despite the relatively small numbers enrolled in the study, the AAOS standard risk aspirin 
group had a statistically significantly higher incidence of symptomatic VTE postoperatively 
(Table 7). 
 
Table 7. Primary efficacy and safety outcomes.   
155
 
Symptomatic 
incidence of 
Comparator 
Group 
(n=415) Elevated Risk Group (n=129) Standard Risk Group (n=152) 
Event Rate Event rate Odds ratio p Event rate Odds ratio p 
PE (%) 0.7 0 0 1.0000 4.6 6.6 0.030 
DVT (%) 0.7 0.8 1.1 1.0000 4.6 6.6 0.030 
VTE (%) 1.2 0.8 0.6 1.0000 7.9 7.0 0.001 
Death (%) 1.5 0.8 0.5 1.0000 0 0 0.350 
Major 
bleeding (%) 
0.2 0 0 1.0000 0.7 2.7 0.464 
NB: p values and odds ratio are compared with comparator group. All VTE were symptomatic. 
 
Conversely, Gesell et al used a similar method (Figure 9) and reported no significant 
difference in rates of VTE, bleeding or 90-day mortality between the two groups (Table 8).  
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Figure 9. Graphic representation 
of patients screened and 
proportioned to study groups. 
 
Source: Gesell et al (2011).
154
  
 
 
 
Table 8. Primary efficacy and safety outcomes .
154
 
Symptomatic incidence of Study Control p 
PE (%) 1.1 0.9 0.7 
DVT (%) 0.6 1.5 - 
VTE (%) 2.5 2.6 0.7 
Death (%) 0.1 0.1 0.5 
NB: Study group = thromboprophylaxis determined by VTE risk. 
 
It is uncertain why these two studies had such different findings; they used the same aspirin 
dose postoperatively (325mg twice daily), mobilised patients early postoperatively and employed 
extended prophylaxis in their patient groups, although Gesell et al did employ a longer duration  
(Woller et al = 1 month, Gesell et al = 6 weeks). Potentially, the significantly lower VTE incidence 
in Gesell et al’s study could be due to the universal employment of IPCD and epidural anaesthesia 
in their study (NB: there is no mention of mechanical prophylaxis by Woller et al, and both general 
and epidural anaesthesia was employed). 
The Pulmonary Embolism Prevention (PEP) trial was a prospective multicentre study that is 
commonly cited in the literature to support the use of aspirin post-arthroplasty.
157
 In this trial 
Rodgers et al randomised 4,088 patients to receive either aspirin or placebo post-elective hip or 
knee arthroplasty. The rate of symptomatic VTE was slightly lower in the aspirin group (1.1% vs. 
1.3%); however, this did not reach statistical significance. Significantly, 37% of patients received 
prophylaxis with LMWH or UFH during the study period, and a further 5% of patients received 
non-study aspirin. The authors did not complete a subgroup analysis for these patients to determine 
what effect anticoagulants had on VTE risk.  
The PEP trial also included a second arm that explored VTE risk in hip fracture patients. 
Similar to the arthroplasty arm, patients were randomised to receive either aspirin or placebo 
following hip fracture surgery. Once again, many patients received either non-study aspirin (3%), 
LMWH (26%) or UFH (18%) postoperatively. Furthermore, 8% of hip fracture trial subjects never 
started their study treatment. Subgroup analysis was conducted in this arm of the trial (Table 9) and 
is often used to support aspirin use in arthroplasty patients. 
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Table 9. PEP trial subgroup analysis for hip fracture patients .
157
 
Thromboprophylaxis n Symptomatic VTE (%) 
Nothing 3789 2.6
 a, b, c
 
Aspirin  3711 1.7
 a
 
LMWH 1663 1.8 
b
 
LMWH + aspirin  1761 1.3 
c
 
NB a, b, c indicate statistically significant difference. 
 
Notably, there are limitations and reasons why it is not sound to extrapolate these findings to 
the arthroplasty arm of the trial. Firstly, the PEP trial was not designed to compare the efficacy of 
different prophylaxis regimens to prevent VTE.
158
 Its primary aim was to identify what effect 
aspirin has on the incidence of vascular deaths, non-fatal vascular events and major bleeding 
complications.
159
 Consequently, Rodgers et al did not collect or analyse VTE risk factors (it is 
conceivable that anticoagulants were administered in high risk patients), investigate the influence 
of concomitant mechanical and pharmacological prophylaxis use, or examine the effect of 
prophylaxis timing (initiation or duration) on prophylaxis efficacy. Furthermore, damaged bone 
marrow activates the clotting cascade, and a direct positive correlation has been reported between 
the period of surgery delay after hip fracture trauma and VTE risk.
160-163
 This means that time to 
surgery and preoperative thromboprophylaxis use should also have been accounted for. Therefore, 
at best, the PEP trial data indicates that aspirin use may be effective to prevent VTE in some 
patients (characteristics undefined) undergoing hip fracture surgery. 
In summary, the data to date does not support universal aspirin use post-arthroplasty. There 
may be some merit in using aspirin in very low VTE risk patients; however, further research in this 
field is required. 
 
2.3.3 Thromboprophylaxis Recommendations 
Clinical practice guidelines (CPG) have been published by various professional bodies over the last 
three decades.
147
 Contemporary CPG include those produced by the National Health and Medical 
Research Council (NHMRC);
17
 the American College of Chest Physicians (ACCP);
68,108,164
 the 
National Institute of Clinical Excellence (NICE);
89
 the Australia and New Zealand Working Party 
(ANZWP);
1,119,165
 the American Academy of Orthopaedic Surgeons (AAOS);
156,166
 and the 
Arthroplasty Society of Australia (ASA)
167
, a subdivision of the AOA. Prior to the release of the 
NHMRC Guideline in 2009, the various ACCP guidelines held an arguably prominent spot as the 
standard of best practice in Australia, and many auditing studies compared prescribing to 
them.
1,8,80,168
 
CPG can be classified as either orthopaedic specific or multidisciplinary depending on 
whether they contain thromboprophylaxis recommendations for other procedures and conditions, 
or not. The AAOS and ASA guidelines are orthopaedic specific. The NHMRC, ACCP, NICE, and 
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ANZWP guidelines are multidisciplinary guidelines. Historically, the recommendations between 
these two types of CPG have varied widely as a result of three factors: differences in the approach 
to collecting and evaluating studies; differences in assumptions made and interpretation of the data; 
and differences in the relative importance that the panel have ascribed to different postoperative 
complications, including bleeding and VTE.
169
  
For example, in previous editions of their guideline the chest physicians assumed that 
asymptomatic DVT reductions in trial data would directly correlate to symptomatic VTE 
reduction.
108,164
 Conversely, orthopaedic surgeons have questioned whether any reductions in 
symptomatic DVT in trial data has any clinical relevance for symptomatic PE incidence.
169,170 
Furthermore, orthopaedic surgeons have typically been more concerned than the chest physicians 
have been about the possible consequences of prophylaxis on wound bleeding and joint healing. 
These differences in assumptions and relative importance ascribed to postoperative complications 
have resulted in different guideline focuses: the ACCP have generally focussed on preventing 
venographically proven DVT (the majority of which are asymptomatic), whereas the AAOS have 
focussed on minimising symptomatic PE.
147,156,164,170
  
Despite these methodological and analytical differences, most CPG have endorsed the use of 
anticoagulants post-arthroplasty, and support the addition of mechanical prophylaxis to 
anticoagulants.
169
 Furthermore, they have generally agreed on the preferential use of mechanical 
prophylaxis over anticoagulant use in patients with increased bleeding risk. Last, but not least, 
CPG generally all recommend against the use of screening techniques (e.g. Doppler or duplex 
ultrasound) at discharge to screen for asymptomatic VTE.
68,166
 
However there have also been four points on which CPG have at times disagreed: the use of 
aspirin and warfarin as routine prophylaxis agents, the value of using of mechanical prophylaxis by 
itself, and the ideal duration of postoperative prophylaxis.
79,127,139,171
 Over the years in which the 
research contained herein was completed, CPG have varied in their stance on these points. Table 
10 outlines the thromboprophylaxis recommendations current at the time this research commenced 
in late 2009. 
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Table 10. Thromboprophylaxis recommendations in late 2009.  
Recommended agents are highlighted in blue with gradings noted where applicable (e.g. A, 1B; see Appendix A). 
 Agent ANZWP 2007
1
 AAOS* 2007
156
 ACCP 2008
164
 NHMRC 2009
17
 ASA - 
H
ip
 A
rt
h
ro
p
la
st
y 
Aspirin  B   
To weigh efficacy 
against risk of 
complications 
caused by 
preventative 
measures. 
  
Mechanical 
thromboprophylaxi
s strongly 
recommended. Use 
of aspirin, warfarin,  
UFH, LWMH, 
fondaparinux and 
the melagatrans 
and duration of 
these agents to be 
carefully 
considered and 
thoroughly 
discussed with the 
patient. 
Dabigatran    B 
Fondaparinux NG B 1A B 
LMWH NG B 1A A 
Rivaroxaban    B 
UFH  
VKA / B 1A / 
Duration 28 to 35 days 7 to 42 days 
(varies dep. on 
agent) (C) 
Min. 10 days, 
up to 35 days 
Up to 35 days 
Mechanical 
Prophylaxis 
AND IPCD &/or 
GCS 
To be used until 
discharged 
home 
- GCS, IPCD, or VFP, 
until fully mobile 
K
n
e
e
 A
rt
h
ro
p
la
st
y 
Aspirin  B   
Dabigatran    B 
Fondaparinux NG B 1A B 
LMWH NG B 1A A 
Rivaroxaban    B 
UFH  
VKA / B 1A / 
Duration 5 to 10 days 7 to 42 days 
(varies dep. on 
agent) (C) 
Min. 10 days, 
up to 35 days 
Up to 14 days 
Mechanical 
Prophylaxis 
AND IPCD &/or 
GCS 
To be used until 
discharged 
home 
OR Optimal 
IPCD (1A) 
GCS, IPCD, or VFP, 
until fully mobile 
*AAOS recommendations vary based on patient risk of PE and major bleeds. 
NB: NG = no grading;  = recommendation against use; / = only recommended under certain conditions;    
       Min. = minimum. 
 
In the last three years the ASA, ACCP, NICE and AAOS each released a new edition of their 
guideline (Table 11). 
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Table 11. Updated AAOS, ACCP and ASA thromboprophylaxis recommendations. 
Recommended agents are highlighted in blue with gradings noted where applicable (e.g. A, 1B; see Appendix A). 
 Agent ASA 2010
167
 ACCP 2012
68
 NICE 2010
89
 AAOS 2011
166
 
H
ip
 A
rt
h
ro
p
la
st
y 
Apixaban  1B  
‘We suggest the use of 
pharmacologic agents and/or 
mechanical compressive devices 
for the prevention of VTE in patient 
undergoing elective hip or knee 
arthroplasty and who are not at 
elevated risk beyond that of the 
surgery itself for VTE or bleeding.  
 
Current evidence is unclear about 
which prophylactic strategy (or 
strategies) is/are optimal or 
suboptimal. Therefore, we are 
unable to recommend for or 
against specific prophylactics in 
these patients.  
 
In the absence of reliable evidence 
about how long to employ these 
prophylactic strategies, it is the 
opinion of this work group that 
patients and physicians discuss the 
duration of prophylaxis.’ 
Aspirin NG 1B  
Dabigatran  1B NG 
Fondaparinux 1B NG 
LMWH NG 1B* NG 
Rivaroxaban NG 1B NG 
UFH  1B NG 
VKA NG 1B  
Duration 3 to 6 
weeks 
Min. 10-14 
days, up to 35 
days 
28 to 35 days 
Mechanical 
Prophylaxis 
IPCD, VFP  GCS, VFP or IPCD 
until mobile 
K
n
e
e
 A
rt
h
ro
p
la
st
y 
Apixaban  1B  
Aspirin NG 1B  
Dabigatran  1B NG 
Fondaparinux 1B NG 
LMWH NG 1B* NG 
Rivaroxaban NG 1B NG 
UFH  1B NG 
VKA NG 1B  
Duration 3 to 6 
weeks 
Min. 10-14 
days, up to 35 
days 
10 to 14 days 
Mechanical 
Prophylaxis 
IPCD, VFP  GCS, VFP or IPCD 
until mobile 
*ACCP 2012 Guidelines recommend LMWH in preference to the other agents (Grade 2C/2B). 
NB: NG = recommendation is not graded. Min. = minimum. 
 
      
2.3.3.1 Other Recommendations 
In addition to recommending pharmacological and mechanical thromboprophylaxis, the NHMRC, 
ANZWP, AAOS and NICE guidelines all recommend early mobilisation to prevent VTE.
1,17,89,166
 
Furthermore, the NHMRC, ANZWP and NICE guidelines also recommend adequate hydration as a 
simple measure that should be applied as standard practice to prevent VTE. 
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2.4 Guideline Adherence 
Despite the wide promulgation of CPG, studies report that thromboprophylaxis is underutilised 
both in Australia and internationally.
4-11,172 
In 2006/7 an international audit of 32 countries 
determined that anywhere between 0% and 100% of at risk orthopaedic patients received ACCP 
approved agents postoperatively.
11
 Almost 95% of the Australian patients involved in the audit 
received ACCP approved agents. Similarly, a retrospective review conducted in a New South 
Wales hospital found that 87% of patients received ACCP approved agents at the recommended 
dose following hip and knee arthroplasty.
80  
However, not all Australian data demonstrates such high adherence to contemporary 
guidelines. A study conducted in a Western Australian hospital reported that thromboprophylaxis 
was initiated in less than 50% of patients who underwent hip arthroplasty.
9
 Similar practices were 
described in another Western Australian study, where 51.5% of at risk patients received ACCP 
recommended thromboprophylaxis; only 18.9% of patients continued to receive prophylaxis after 
discharge.
8
 These studies indicate that there is a high degree of variability in thromboprophylaxis 
prescribing in Australian hospitals.
5,8,9,80 
This has been identified by the National Institute of 
Clinical Studies in Australia (NICS) and the NHMRC as a significant evidence-practice gap.
10,173
  
Grol et al identified that guidelines with clear noncontroversial and evidence based 
recommendations are more likely to be adhered to than guidelines with recommendations that are 
not clear, are controversial, or are based on opinion.
20
 What is evident when reviewing the updated 
recommendations (Table 11) is that the AAOS and ACCP have reduced the grading strength and 
become broader in their recommendations for postoperative thromboprophylaxis. This indicates a 
level of general uncertainty as to what constitutes best practice. It is not surprising then that there is 
a high degree of variability in adherence rates to thromboprophylaxis guidelines both nationally 
and internationally.       
In 2009 when the NHMRC Guideline was released, the most recently published Australian 
guideline adherence study reported data from 2005; more recent studies have used internal 
benchmarks instead of guidelines in their audits.
174
 Excluding publications from the data contained 
in this thesis, there have not been any further Australian papers published to date describing 
thromboprophylaxis prescribing patterns and/or guideline adherence in Australia. 
 
2.4.1 Implementing Guidelines 
CPG can be limited in their ability to affect physician behaviour, and the implementation of CPG 
into practice requires more than simply publishing them.
59,175
 There are many strategies that can be 
employed to increase the uptake of a CPG into practice, and multifaceted methods are often 
recommended and implemented effectively.
176,177
 Straus et al note that an implementation strategy 
that includes an analysis of factors that influence prescribing, as well as a selection of appropriate 
Chapter 2: Thromboprophylaxis following Hip and Knee Arthroplasty 
C. Mirkazemi          27 
  
and feasible knowledge translation interventions and indicators to measure impact, increases the 
likelihood of success.
178
  
Factors that can influence adherence to CPG can do so both positively and negatively. Those 
factors that positively impact on adherence are termed enablers. Those factors that negatively 
impact on adherence are termed barriers. Barriers to the uptake of CPG can be broadly categorised 
into three types: those in which physician knowledge imposes a barrier, those in which physician 
attitude imposes a barrier and, finally, those in which external factors prevent guideline adoption 
(Figure 10). 
179,175
 
 
 
Figure 10. Barriers to physician adherence to CPG. 
Source: Cabana et al (1999).
175
 
 
It is in the best interest of both hospitals and patients for evidence-based CPG to be effectively 
implemented. In 2013 Duff et al reported that a 20% improvement in adherence to an internal 
hospital thromboprophylaxis protocol was estimated to have resulted in 13 fewer deaths, 84 fewer 
symptomatic DVTs, 19 fewer symptomatic PEs, and 512 fewer hospital-bed days.
179
 These 
improvements were associated with an overall cost saving of $245,429 over 12 months.  
Although guideline adherence has been documented to be low in Australia and overseas, 
enablers and barriers to thromboprophylaxis guideline uptake and adherence by orthopaedic 
surgeons have not been analysed in the literature.
180
 Nevertheless, in 2011 Duff et al reported that 
the following factors were identified as barriers to thromboprophylaxis guideline uptake in a 
metropolitan Sydney hospital: A lack of motivation to change, a lack of systems support, a 
knowledge or awareness deficit and disputed evidence.
177
 The following two sections summarises 
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known enablers and barriers to thromboprophylaxis prescribing (as a surrogate to guideline 
adherence) following orthopaedic surgery overseas.  
 
2.4.1.1 Enablers 
In 1992 Rodgers et al surveyed 94 New Zealand (NZ) orthopaedic surgeons to identify their 
thromboprophylaxis prescribing preferences, and factors that might increase the likelihood of them 
prescribing thromboprophylaxis.
181
 A patient history of VTE was identified as the most important 
factor that would increase likelihood of prescribing thromboprophylaxis (Figure 11). Moreover, 
gross obesity, prolonged preoperative immobility and active malignancy were also identified as 
important patient factors by approximately 50% of surveyed surgeons. 
 
Figure 11. Factors 
that increase the 
likelihood of 
prescribing 
pharmacological 
prophylaxis 
(1992). 
 
Factors of  great 
importance, and □ 
little importance, 
as indicated by 
survey participants. 
 
Source: Rodgers et 
al (1994)(n=94).
181
 
 
 
The survey was repeated seven years later in 1999 by Walker et al. At this point it was 
identified that orthopaedic surgeons had substantially changed their prescribing of pharmacological 
prophylaxis, with a significant increase in the use of anticoagulants, and in particular LMWH 
(from 55% to 76%).
182 
It was suggested by Walker et al that the increase in LMWH use was likely 
due to ‘emerging evidence for the use of pharmacological thromboprophylaxis, medical education, 
the impact of a new cohort of surgeons, awareness of thromboprophylaxis [possibly as a result of 
the Pulmonary Embolism Prevention (PEP) Trial that was conducted between 1992 and 1998 and 
involved many NZ orthopaedic surgeons], increasing concern over litigation, and intensive 
marketing by pharmaceutical companies’.182 Interestingly, the top three factors that surgeons 
identified as being of great importance in increasing the likelihood of them prescribing 
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thromboprophylaxis remained the same: previous VTE, active malignancy and gross obesity 
(Figure 12). 
      
Figure 12. Factors 
that increase the 
likelihood of 
prescribing 
pharmacological 
agents (1999). 
 
Factors of  great 
importance, and □ 
little importance, as 
indicated by survey 
participants. 
 
Source: Walker et al 
(2002)(n=123).
182
 
 
 
More recently, a survey of Malaysian orthopaedic surgeons by Zairul-Nizam et al identified 
that a surgical procedure’s risk grading was the most significant factor that influenced 
thromboprophylaxis prescribing postoperatively, followed by a patient history of previous VTE, 
the presence of concurrent illnesses and patient obesity (Figure 13).
183
 NB: It is uncertain what year 
the survey itself was conducted (corresponding author did not reply to query), however the study 
was published in 2003.
 
 
 
 
Figure 13. Indications for thromboprophylaxis use  (n=131). 
   Source: Zairul-Nizam et al (2003).
183
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2.4.1.2 Barriers 
In addition to surveying factors that would increase the likelihood of prescribing 
thromboprophylaxis, these studies explored barriers to thromboprophylaxis prescribing. Rodgers et 
al reported that NZ surgeons surveyed in 1992 identified major bleeding diathesis and active peptic 
ulcers as the top two patient factors that would stop them prescribing pharmacological agents 
postoperatively (Figure 14).
181
 
 
 
Figure 14. Factors that 
might decrease the use of 
pharmacological 
prophylaxis. 
 
Factors of  great 
importance, and  little 
importance, as indicated 
by survey participants. 
 
Source: Rodgers et al 
(1994)(n=94).
181
 
 
Furthermore, Rodgers et al reported that more than one third of surgeons cited fear of 
bleeding complications and a low perceived VTE risk as barriers to prescribing pharmacological 
thromboprophylaxis postoperatively (Figure 15).
181
 Similar findings were reported by Walker et 
al.
182
 A perception that VTE risk is too low to warrant prophylaxis is not surprising given the 
median time to a symptomatic VTE following surgery is 17 to 30 days and the vast majority of 
VTE are asymptomatic and/or occur post-discharge.
184,185
 Moreover, the length of hospital stay has 
shortened over the years. As previously mentioned, some patients stay in hospital as little as 2 days 
after surgery, and it is not uncommon for patients to be discharged before regaining full mobility, 
thereby increasing their risk of VTE.
186 
These factors can mask the true incidence of VTE and can 
accordingly become barriers to the optimal use of thromboprophylaxis. 
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Figure 15. Barriers to 
pharmacological 
thromboprophylaxis 
use. 
 
Surgeons were asked to 
indicate whether their 
prophylaxis use was 
limited by all or some 
of these factors.  
 
Source: Rodgers et al 
(1994)(n=123).
181
  
 
Zairul-Nizam et al also identified bleeding concerns as a major barrier to prescribing 
pharmacological agents, as well as a perceived low risk of VTE postoperatively (Figure 16).
183
 
Concerns about patient adherence, bleeding, adverse effects and outpatient monitoring associated 
with pharmacological agents have also been reported in other literature.
55,56
 
 
 
Figure 16. 
Reasons for not 
instituting 
pharmacological 
prophylaxis. 
  
NB: ‘Religious’ 
refers to the 
religious practice 
of the patient 
e.g. Muslim 
patients who 
decline the use 
of porcine based 
agents. 
 
Source: Zairul-
Nizam et al 
(2003)(n=131).
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At the commencement of this research in 2009 there had been no studies conducted in 
Australia analysing factors that influence thromboprophylaxis prescribing specifically post-
arthroplasty, and the data aforementioned dated back to the 1990s, and early 2000s (assuming 
Zairul-Nizam et al conducted their survey in early 2000s, just prior to publishing in 2003).  
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In February 2012 Molnar et al published their findings of a survey conducted in 2009 of 
Australian orthopaedic surgeons conducting hip and knee arthroplasties (n=581).
121
 The survey 
identified that 98% of participants regularly prescribed pharmacological thromboprophylaxis 
following arthroplasty, particularly favouring anticoagulants. Interestingly, these surgeons were 
more likely to prescribe anticoagulants in fear of litigation (19.2% vs. 10.1%), and were more 
likely to rely on protocols or guidelines (32.2% vs. 17.2%), instead of basing their decision on their 
own reading (52.4% vs. 71.3%). No further enablers or barriers to prescribing were reported, 
leaving enablers and barriers to prescribing thromboprophylaxis post-arthroplasty in Australia 
largely unknown. 
 
 
2.5 Rationale for Research 
Approximately 3% to 5% of arthroplasty patients will experience a symptomatic VTE following 
their surgery, roughly equating to 2,500 to 4,150 Australians each year. Many more will have no 
telling symptoms. The real burden of these clots is undetermined; however, they can be significant 
and at times even fatal. Although thromboprophylaxis has been reported to prevent up to 60% of 
VTE following arthroplasty, and guidelines have been published for years, anecdotal evidence 
suggested local thromboprophylaxis prescribing was persistently suboptimal at the commencement 
of this research. Therefore, the research contained herein commenced with a review of local 
thromboprophylaxis prescribing in 2009. 
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 CHAPTER THREE: LOCAL THROMBOPROPHYLAXIS PRESCRIBING 
 
 
 
3.1 Introduction 
The Royal Hobart Hospital (RHH) is Tasmania’s leading hospital, servicing a population of 
~240,000 people. As the major teaching and research hospital in the state it had approximately 550 
beds (including 90 day-only beds). The Orthopaedic Unit had 25 dedicated adult beds in the 
department. 
 
 
3.2 Aims 
The aims of this study were two-fold: 
 to identify and compare local thromboprophylaxis prescribing patterns with contemporary 
recommendations, and 
 to measure the incidence of symptomatic VTE within 90 days of surgery.  
 
 
3.3 Methods 
3.3.1 Patient Selection 
The medical records of 300 consecutive patients who underwent a hip or knee arthroplasty (150 of 
each) between June 2007 and June 2009 were retrieved and systematically reviewed. Where 
patients had multiple arthroplasty admissions within the review period only the most recent 
admission was included. 
 
3.3.2 Data Collection 
Data extraction included information on age, gender, operation, VTE risk factors, mode of 
anaesthesia, kidney function, mechanical and pharmacological prophylaxis (including duration and 
dosage), hospital length of stay and reported postoperative bleeding complications. Clinically 
symptomatic VTE, including those causing readmission or presentation to a general practitioner or 
emergency department within 90 days of surgery, were also recorded for all patients. Symptomatic 
VTE was defined as the presence of symptoms confirmed by a positive duplex ultrasonography for 
DVT and positive pulmonary CT angiography for PE. 
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3.3.3 Thromboprophylaxis Analysis 
Pharmacological agents available during the study period at the RHH were (in alphabetical order) 
aspirin ± dipyridamole, clopidogrel, fondaparinux, LMWH, unfractionated heparin and warfarin. 
GCS were the only mechanical options available. 
In this study, pharmacological prophylaxis prescribing was compared with recommendations 
made in the ACCP 7
th
 Ed. Guideline.
108
 The ANZWP 3
rd
 Ed. Guideline was also available to 
surgeons during the study period and the ACCP 8
th
 Ed. Guideline was released half-way through 
the study period; both had similar recommendations to the ACCP 7
th
 Ed. Guideline (Table 12). 
 
Table 12. Guideline recommendations during the study period. 
Recommended agents are highlighted in blue with gradings noted (e.g. A, 1B; see Appendix A). 
 Agent ANZWP 3
rd
 Ed.
1
 ACCP 7
th
 Ed.
108
 ACCP 8
th
 Ed.
164
 
H
ip
 A
rt
h
ro
p
la
st
y 
Aspirin    
Fondaparinux NG 1A 1A 
LMWH NG 1A 1A 
Rivaroxaban    
VKA  1A 1A 
Duration 28 – 35 days  Min. 10 days, and 
up to 28 to 35 days 
Min. 10 days, up to 35 
days 
Mechanical IPCD &/or GCS – – 
K
n
e
e
 A
rt
h
ro
p
la
st
y 
Aspirin    
Fondaparinux NG 1A 1A 
LMWH NG 1A 1A 
Rivaroxaban    
VKA  1A 1A 
Duration 5 – 10 days  Min. 10 days Min. 10 days, up to 35 
days 
Mechanical IPCD &/or GCS OR IPCD (1A) OR IPCD (1A) 
NB: NG = no grading;  = recommendation against agent; – = recommend against use as sole 
form of thromboprophylaxis; min = minimum. 
 
Patients were deemed as having received ACCP recommended thromboprophylaxis if the 
agent, dose and duration of therapy prescribed was in line with the ACCP 7
th
 Ed. Guideline. To 
assess the suitability of the pharmacological agents and doses prescribed for each patient, renal 
function was estimated using the Cockroft-Gault equation: 
 
 
Where  CrCl = creatinine clearance  
 IBW = ideal body weight (kg), and 
 SeCr = serum creatinine (μmol/L). 
 
NB: Ideal body weight was estimated by entering each patient’s height and gender into an electronic ideal body weight 
calculator produced by Therapeutic Guidelines Ltd.
187
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As ‘duration of therapy’ was vague for hip arthroplasty patients (up to 35 days), the parameter 
was defined as ≥ 28 days, in line with the ANZWP Guideline.1 
 
3.3.4 Exclusion criteria  
Contraindications to mechanical thromboprophylaxis included severe cellulitis, leg deformity and 
severe dermatitis. Pharmacological agents were deemed appropriate for patients unless any of the 
following relative and absolute contraindications were recorded in their medical notes: bleeding 
disorder (e.g. haemophilia), recent central nervous system bleeding, intracranial or spinal lesion, 
abnormal blood coagulation, thrombocytopenia or severe platelet dysfunction, severe hepatic 
disease (including oesophageal varices), severe renal dysfunction (creatinine clearance 
< 10 mL/min) or pregnancy. When active bleeding events reviewed by medical staff in the hospital 
were judged to be critical enough to warrant cessation of pharmacological prophylaxis the patient 
was recorded as inappropriate for receiving further pharmacological prophylaxis.  
 
3.3.5 Statistics 
All information was stored in an Access database (Microsoft® Access 2010, Washington, USA), 
and analysed using the statistical program Statistical Package for the Social Sciences (SPSS) 19.0 
(IBM® Armonk, NY USA). The differences between groups were tested using the t-test for 
independence for continuous data, and the chi square test for categorical variables. Pearson’s rank 
correlation coefficients were calculated for measuring correlations. Continuous variables were 
summarised as means with standard deviation (SD) and ranges where appropriate. Only p≤0.05 
values were considered statistically significant. 
 
 
3.4 Results 
3.4.1 Patient Demographics and Anaesthesia 
In total, 300 patients (169 females, 131 males) with a mean age of 68.7 years (SD 10.4) were 
included in the study. The mean length of stay in hospital was 6.9 days (SD 3.6) following surgery. 
General anaesthesia was employed in most patients, either alone (185, 63.3%, n=292) or in 
combination with neuraxial anaesthesia (48, 16.4%).  
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Table 13. Patient demographics (150 HA and KA each, N=300). 
 
HA KA Overall 
mean/n N % / SD mean /n N % / SD mean /n % / SD 
Age 68.9 150 10.7 68.5 150 10.0 68.7 10.4 
Female gender 84 150 56.0% 85 150 56.7% 169 56.3% 
Body mass index* 28.0 131 5.5 32.5 142 6.3 30.3 6.3 
Length of stay 7.2 150 4.3 6.6 150 2.7 6.9 3.6 
CrCl 65.4 144 2.2 62.1 145 1.9 63.7 24.5 
Anticoagulant use 
prior to admission 
10 150 6.7% 9 150 6.0% 19 6.3% 
Antiplatelet use prior 
to admission 
48 150 32.0% 53 150 35.3% 101 33.7% 
Discharged home 112 149 75.2% 120 149 80.5% 232 77.9% 
NB: Excludes patients who developed a complications postoperatively, and those with contraindications to 
pharmacological prophylaxis. 
* indicates statistically significant difference. 
 
3.4.2 Contraindications to Thromboprophylaxis 
There were no absolute or relative contraindications to mechanical or pharmacological 
thromboprophylaxis documented in patients’ histories. Therefore, for the purpose of this study all 
patients were deemed appropriate for receiving both forms of thromboprophylaxis postoperatively.  
 
3.4.3 Mechanical Thromboprophylaxis 
Only 42 patients (14.0%) had documented GCS use. The mean BMI of these patients was 
significantly lower than those not prescribed GCS (28.3 vs. 30.7 kg/m
2
, p<0.05, n=273). There was 
no significant difference in the demographics of patients who received GCS and those who did not. 
No patients received documented GCS at discharge. Obese patients (BMI ≥ 25.0) were less likely 
to be prescribed mechanical prophylaxis than non-obese patients (13.1% vs. 17.8% respectively), 
however this did not reach statistical significance. 
 
3.4.4 Pharmacological Thromboprophylaxis 
3.4.4.1 Agent 
Inpatient and discharge pharmacological thromboprophylaxis data was available for 298 patients 
(99.3%). Of these patients, most (99.0%) received pharmacological prophylaxis postoperatively 
during the inpatient phase which, in the absence of complications, was continued throughout their 
admission. Anticoagulants were most commonly prescribed, particularly LMWH (Table 14). Over 
a quarter of patients (82, 27.7%) were prescribed an anticoagulant and an antiplatelet concurrently 
during their inpatient stay (Table 14).  
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Excluding patients who developed a VTE or bleeding event during their admission (n=4), only 
108 patients (36.5%, n=296) continued to receive any pharmacological prophylaxis following 
discharge. The majority of these patients received an antiplatelet (Table 14). 
 
Table 14. Inpatient and discharge thromboprophylaxis (N=296). 
Agent 
Inpatient Discharge 
n % n % 
LMWH 173 58.4 21 7.1 
LMWH + antiplatelet 72 24.3 9 3.0 
Fondaparinux 28 9.5 2 0.7 
Fondaparinux + antiplatelet 9 3.0 2 0.7 
Warfarin 8 2.7 12 4.1 
Warfarin + antiplatelet - - 1 0.3 
No agent 3 1.0 186 62.8 
Heparin  1 0.3 - - 
Heparin + antiplatelet 1 0.3 1 0.3 
Antiplatelet only 1 0.3 60 20.3 
Unknown - - 2 0.7 
NB: Excludes patients who developed a bleed (2) or VTE (2) postoperatively whilst still in hospital. 
 
Most discharge anticoagulants were newly initiated in hospital (39, 81.2%), particularly 
LMWH (87.2%) and fondaparinux (10.2%). Patients were significantly more likely to be 
discharged with an anticoagulant if they were transferred to a rehabilitation unit compared to going 
home (63.3% vs. 5.2%, p<0.001).  
Most patients discharged on an antiplatelet (51, 85.0%) were taking their antiplatelet agent 
prior to surgery, and only 15.0% were newly initiated in hospital. Aspirin was the most commonly 
prescribed antiplatelet. 
 
3.4.4.2 Duration 
The mean duration of thromboprophylaxis prescribed was 6.0 days (SD 2.7).  There was no 
significant difference in the number of days prescribed for hip or knee arthroplasty patients (6.0 
days for both), however patients who were discharged to a rehabilitation unit were prescribed 
slightly longer thromboprophylaxis courses (6.9 days vs. 5.9 days, p=0.01), particularly in hip 
arthroplasty patients (7.1 vs. 5.8 days, p=0.03).  
Excluding patients who developed an inpatient clot (n=1) or were using an anticoagulant at 
home (n=5), one knee arthroplasty patient was discharged home on an anticoagulant agent (0.9%, 
N=114). Excluding patients who developed a bleed (n=2) or were using an anticoagulant at home 
(n=5), and patients whose discharge thromboprophylaxis was unknown (n=2), only nine patients 
were discharged home on an anticoagulant agent (8.7%, N=103). 
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3.4.5 Contemporary Guidelines 
Kidney function and thromboprophylaxis dose and duration data was not available for all patients, 
however where possible, patients’ thromboprophylaxis was compared to the contemporary 
guideline to assess suitability of prescribing. Excluding patients prescribed therapeutic 
anticoagulation for pre-existing medical conditions, and patients who experienced a bleed or VTE 
during their inpatient admission, only 8.8% of knee patients (10, n=113) and 1.0% of hip patients 
(1, n=103) discharged home received ACCP recommended prophylaxis (including agent, dose and 
duration). This equates to 5.1% overall (11, n=216). The remaining patients either received no 
pharmacological prophylaxis or received it at an inappropriate dose and/or duration (Figure 17). 
 
Figure 17. Proportion discharged home with ACCP recommended prophylaxis (N=216). 
                                       No thromboprophylaxis                             Appropriate agent only   
                                         Appropriate agent and dose only                       Appropriate agent, dose and duration 
 
Obese patients (BMI ≥ 25.0) were more likely to receive ACCP appropriate pharmacological 
prophylaxis compared to non-obese patients (5.6% vs. 2.7%); however this did not reach statistical 
significance. 
 
3.4.6 Postoperative Complications 
3.4.6.1 Bleeding 
Two inpatients (0.6%) developed a bleed postoperatively that warranted cessation of their 
pharmacological prophylaxis; both were male hip arthroplasty patients with either liver or renal 
impairment. 
 
3.4.6.2 Symptomatic VTE 
The 90-day incidence of symptomatic VTE was 2.7% (95% CI: 1.0-5.0%, Table 15).  The 
incidence in knee patients was 4.0% (95% CI: 1.0-8.0%; 4 DVTs, 1 PE and 1 DVT + PE). The 
incidence in hip patients was 1.3% (95% CI: 0-5.0%; 2 DVTs). The in-hospital VTE incidence was 
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0.7% (2, n=300) and occurred at 4 and 5 days following surgery. Both patients were prescribed 
anticoagulants at the time their clot(s) occurred.  
 
Table 15. Symptomatic postoperative VTE incidence.  
VTE 
HA KA 
n % n % 
Overall (n=300) 2 1.3 6 4.0 
In hospital (n=300) - - 2 1.3 
       DVT - - 1 0.7 
       DVT + PE - - 1 0.7 
After discharge (n=296)** 2 1.4 4 2.7 
       PE - - 1 0.7 
       DVT 2 1.4 3 2.0 
NB: **Excludes patients who developed a clot or bleed in hospital 
(i.e. HA = 148 patients, KA = 148 patients). 
 
Excluding inpatient clots and bleeds, VTE occurred in 2% of patients following discharge 
(5 DVTs, 1 PE, n=296). The median time to VTE outside of hospital was 11 days (range: 7 to 31 
days). Four patients were readmitted to the hospital for a median of 2.5 days to receive VTE 
treatment under a medical team (range 1 to 6 days). Of the patients who suffered a thromboembolic 
event following discharge, only one patient had been prescribed an anticoagulant at discharge. This 
patient had been using warfarin prior to surgery and was discharged with warfarin and LMWH to 
cover until the International Normalised Ratio (INR) was therapeutic. It is uncertain if the INR was 
therapeutic at the time of the event, six days following discharge, however sub therapeutic INR at 
the time of discharge has been associated with both a higher readmission rate, and risk of 
complications
188
. The remaining five patients who developed VTE following discharge did not 
receive ACCP recommended prophylaxis, predominantly due to a shortfall in the duration of 
therapy prescribed (average of only 5.2 days prescribed, SD 1.5). No significant risk factors were 
identified for developing VTE following surgery. 
 
 
3.5 Discussion 
In-hospital anticoagulant use was routine and despite bleeding risk concerns, over 25% of patients 
received both an antiplatelet and anticoagulant agent during their admission.
139
 Notably, this study 
determined that over 60% of patients did not receive any documented thromboprophylaxis on 
discharge from hospital. When comparing prescribing practices to the ACCP 7
th
 Ed. Guideline, 
only 5.1% of patients discharged home received complete courses of pharmacological prophylaxis 
overall. This was predominantly due to a shortfall in the duration of therapy prescribed. This has 
previously been described in a retrospective observational studies.
155,172
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There was a trend towards knee arthroplasty patients receiving full prophylaxis courses more 
often than hip arthroplasty patients (8.8% vs. 1.0%), likely because the average length of stay in 
hospital (6.9 days SD 3.6) was considerably closer to the recommended duration of therapy for 
knee patients compared to hip patients (10 vs. 28 days minimum). This meant that hip patients 
were more reliant on anticoagulant prophylaxis being prescribed for them after discharge from the 
ward. This only occurred in nine hip patients discharged home (8.7%, n=103) and typically for a 
much shorter duration than was required to complete the recommended 28 days of treatment. In the 
strictest sense, the ACCP 7
th
 Ed. Guideline recommends a minimum of 10 days 
thromboprophylaxis, with extension up to 28 to 35 days following hip arthroplasty (Table 12). 
Notably, using this parameter to define adherence (10 to 35 days) does not significantly alter the 
assessed adherence level to the ACCP 7
th
 Ed. Guideline (6.7%), because the average duration of 
anticoagulant therapy for hip patients was only 6.0 days (SD 2.7). 
This study identified an in-hospital and 90-day VTE incidence of 0.7% and 2.0%, 
respectively, comparable with other studies in the literature.
62,184
 The majority of VTE occurred 
following discharge, which has also been previously reported in the literature.
51,62,143,184,185
 As all 
readmissions to hospital for VTE treatment were under medical units, local VTE incidence 
following arthroplasty may be underestimated by surgical teams.  
As previously noted in Table 2, patient obesity increases VTE risk.
2,97-99,189,190
 It is surprising 
then that obese patients (BMI ≥ 25.0) were less likely to be prescribed mechanical prophylaxis than 
non-obese patients in this study. This may be due to difficulties that can arise from fitting stockings 
on obese patients. Interestingly, White et al reported mechanical prophylaxis to be effective in non-
obese hip arthroplasty patients, not obese patients.
87
 Sadeghi et al report that standard doses of 
pharmacological agents are effective regardless of BMI; obese patients in the present study tended 
to be more likely to receive ACCP appropriate pharmacological prophylaxis compared to non-
obese patients.
85
  
There were several limitations to this study. It was retrospective in nature and relied solely on 
documentation in hospital records to identify thromboprophylaxis use, possible contraindications, 
and thrombotic and bleeding events. The retrospective nature of the study also introduced potential 
low-prescribing bias following hospital discharge, as although there were no specific 
recommendations on discharge summaries, it is possible that general practitioners may have 
independently prescribed thromboprophylaxis for their patients after discharge. Similarly, the 
retrospective nature may have posed potential bias for a low reported VTE incidence as not all 
cases of out-of-hospital diagnosed and treated VTE may have presented to the RHH. That the RHH 
is the only public hospital within the area should have minimised this potential limitation, although 
it is feasible that some patients may have been admitted to one of several private hospitals in the 
area, or treated directly by their general practitioner with no feedback to the RHH.  
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The retrospective nature of the study did not allow exploration of potential barriers to routine 
thromboprophylaxis use, including perceived and actual risk of major bleeding associated with 
pharmacological prophylaxis. Being a retrospective study, it was not possible to determine if such 
perceived risks affected thromboprophylaxis prescribing, particularly at discharge. 
    Despite these limitations, the findings indicate that the lack of consensus as to what 
constituted appropriate thromboprophylaxis following hip and knee arthroplasty during the study 
period left most patients without guideline recommended thromboprophylaxis, potentially leaving 
many patients exposed to a higher risk of VTE.
155
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 CHAPTER FOUR: PRESCRIBING IN AUSTRALIAN PUBLIC HOSPITALS 
 
 
 
4.1 Introduction 
The retrospective review conducted at the RHH confirmed the existence of a guideline-practice 
gap. A retrospective audit of thromboprophylaxis prescribing was undertaken in several public 
hospitals to identify if this finding was representative of prescribing around Tasmania and 
interstate. All of Tasmania’s public hospitals were approached, and several extra were chosen from 
two states with relatively easy flight access from Tasmania: Victoria and New South Wales.  
 
 
4.2 Aim 
The aim of this study was to identify what thromboprophylaxis prescribing practices prevail at 
public hospitals in Tasmania, Victoria and New South Wales, and compare them with the NHMRC 
Guideline. 
 
 
4.3 Methods 
4.3.1 Hospital Selection 
Fifteen public hospitals listed on the Australian Orthopaedic Association’s National Joint Registry 
were approached to participate in this study. These hospitals included all of Tasmania’s public 
hospitals as well as hospitals chosen from the National Joint Registry list of statistics contributors 
that were relatively easy to access for a visiting researcher (in case outside data collection was 
required). Twelve hospitals agreed, however most could not complete the study: two hospitals’ 
orthopaedic departments vetoed the project due to its auditing nature; one hospital had participated 
in an intervention study to increase thromboprophylaxis prescribing during the study period (which 
would have biased the data); one hospital lost the resources needed to support the project; and two 
hospitals simply stopped responding to correspondence. Ultimately only six hospitals completed 
the audit: three in Tasmania (including the RHH), two in Victoria and one in New South Wales. 
 
4.3.2 Data Collection 
The medical records of the first 30 consecutive patients who underwent a hip or knee arthroplasty 
(15 of each) in 2011 were retrieved and systematically reviewed. This sample size allowed for a 
descriptive snapshot of prescribing at each hospital, whilst also ensuring the numbers were 
manageable enough to allow for audits at multiple hospitals. Where patients had multiple 
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arthroplasty admissions within the review period only the most recent admission was included. 
Data extraction followed the same process outlined in 3.3.2 Data Collection. Unfortunately data 
was missing from some patient files/datasets, including inpatient complications, dosages, 
creatinine clearance information and total duration of therapy prescribed. This was taken into 
account in the analysis and is a major limitation of this study. 
 
 4.3.3 Thromboprophylaxis Analysis 
The NHMRC Guideline was released nationally over 12 months prior to the study period. Patients 
were deemed as having received NHMRC recommended thromboprophylaxis if the agent, dose 
and duration of therapy prescribed was in line with the Guideline. To assess the suitability of the 
pharmacological agents and doses prescribed for each patient, renal function was estimated using 
the Cockroft-Gault equation (see page 33). 
As the ‘duration of therapy’ recommended in the NHMRC Guideline was deemed vague (up 
to 14 days for knee arthroplasty patients, and up to 35 days for hip arthroplasty patients), the 
following duration parameters were used in this study’s analysis to define adherent prophylaxis: a 
minimum of 10 to 14 days for knee patients and a minimum of 28 to 35 days for hip patients. 
These parameters are aligned with those used in the previous study (Chapter 3). 
Any VTE, bleeding (including wound ooze) or infective complications that occurred during 
the inpatient period (either on the orthopaedic or rehab unit) were recorded and included in the 
final analysis. 
 
4.3.4 Statistics 
All information was stored in an Access database (Microsoft® Access 2010), and analysed using 
the statistical program SPSS 20. The differences between groups were tested using the t-test for 
independence for continuous data, and the chi square test for categorical variables. Continuous 
variables were summarised as means with standard deviation. Only p≤0.05 values were considered 
statistically significant.  
 
4.4 Results 
4.4.1 Patient Demographics and Anaesthesia 
In total, 180 patients (108 females, 70 males) with a mean age of 68.1 years (SD 10.4) were 
included in the study (Table 16). The mean length of stay on the orthopaedic ward was 5.8 days 
(SD 4.0) following surgery. General anaesthesia was employed in most patients, either alone (39, 
38.6% n=101) or in combination with neuraxial anaesthesia (29, 28.7%); the rest received 
neuraxial anaesthesia with sedation. 
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Table 16. Patient demographics (90 HA, 90 KA; n=180) 
 
HA KA Overall 
n / mean % / SD n / mean % / SD n/mean %/SD 
Age  
(n=180) 
67.3 11.8 68.9 8.7 68.1 10.4 
Female gender  
(n=178, 88 KA) 
57 63.3 51 57.9 108 60.7 
Body mass index  
(n=167, 85 KA) 
30.2 7.2 32.3 5.3 31.3 6.3 
Length of stay  
(n=177, 87 KA) 
6.3 5.1 5.3 2.1 5.9 4.0 
Anticoagulant use prior to 
admission (n=180) 
11 12.2 3 0.1 14 7.8 
Antiplatelet use prior to 
admission (n=180) 
20 22.2 33 36.7 53 29.4 
 
4.4.2 Contraindications to Thromboprophylaxis 
One patient was confused and persistently removing her clothes during her admission; she was 
deemed to be unsuitable for any prophylaxis by staff. Another patient had a history of leg ulcers 
and was deemed unsuitable to receive mechanical prophylaxis. 
 
4.4.3 Mechanical Thromboprophylaxis 
Seventy-seven patients (43.3%) had documented mechanical prophylaxis use; all were prescribed 
GCS. There was no statistically significant difference in the BMI between patients with 
documented GCS use and those without. There was also no other significant differences in the 
demographics of patients prescribed mechanical prophylaxis. 
 
4.4.4 Pharmacological Thromboprophylaxis 
Thromboprophylaxis records were unavailable for one patient. The rest of the cohort received 
some form of pharmacological prophylaxis as an inpatient, which in the absence of complications, 
was continued throughout their admission. Anticoagulants were most commonly prescribed, 
particularly LMWH (Table 17). The most common antiplatelet agent prescribed was aspirin ± 
dipyridamole (90.0%). Fourteen patients (7.9%) were prescribed an anticoagulant and an 
antiplatelet concurrently during their inpatient stay. 
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Table 17. Inpatient and discharge thromboprophylaxis. 
Agent 
Inpatient (N=178)*
#
 Discharge (N=162)*^
#
 
n % n % 
LMWH 157 88.2 100 61.7 
Antiplatelet 10 5.6 19 11.7 
Rivaroxaban 7 3.9 4 2.5 
Warfarin 4 2.2 4 2.5 
Nothing - - 35 21.6 
NB: *Excludes patient with contraindication to pharmacological prophylaxis. ^Excludes patients 
who developed a bleed (5), wound infection (5) or VTE (6) in hospital. 
#
Excludes 1 patient with 
unknown thromboprophylaxis (both during inpatient period and at discharge). 
 
Anticoagulants were the most commonly prescribed agent at discharge, with most being 
newly initiated in hospital (95, 88.0%, n=108).  Almost two thirds of all patients prescribed an 
antiplatelet at discharge were identified as using one preadmission (11, 57.9%). There was no 
difference in thromboprophylaxis prescribing for patients discharged home and those discharged 
elsewhere.  
 
4.4.5 Hospital Comparison 
Most patients at each hospital received an anticoagulant agent during their inpatient stay 
(Table 18). 
 
Table 18. Comparing hospitals’ inpatient prescribing patterns (n=178). 
Inpatient 
prescription 
Hospital (%) 
1 2 3 4 5 6 
Aspirin 5 (16.7) 0 - 0 - 5 (17.2) 0 - 0 - 
Anticoagulant  25 (83.3) 30 (100.0) 30 (100.0) 24 (82.7) 29 (100.0) 30 (100.0) 
NB: Excludes patient with contraindication to pharmacological prophylaxis (1), and patient with unknown 
thromboprophylaxis (1). 
 
There was greater variation in thromboprophylaxis prescribing at discharge: aspirin use and 
prescribing nothing at discharge were more common at hospitals 1 and 6 respectively; and hospital 
3 was the only hospital to use anticoagulants exclusively (Table 19). 
 
Table 19. Comparing hospitals’ discharge prescribing patterns (n=162). 
Discharge 
prescription 
Hospital (%) 
1 2 3 4 5 6 
Nothing 9 (32.1) 9 (34.6) 0 - 5 (20.0) 1 (4.0) 11 (39.3) 
Aspirin 13 (46.5) 1 (3.8) 0 - 5 (20.0) 0 - 0 - 
Anticoagulant 6 (21.4) 16 (61.6) 30 (100.0) 15 (60.0) 24 (96.0) 17 (60.7) 
NB: Excludes patient with contraindication to pharmacological prophylaxis (1), patient with unknown 
thromboprophylaxis (1), and any patients who developed a complication in hospital (n=16). 
 
Chapter 4: Prescribing in Australian Public Hospitals 
 
C. Mirkazemi          46 
  
4.4.6 Contemporary Guidelines 
Unfortunately datasets were not returned complete from some hospitals, particularly in relation to 
creatinine clearance data, thromboprophylaxis doses and prescribed thromboprophylaxis course 
duration data. Consequently, assessing adherence to contemporary guidelines was not possible for 
many patient records. This has resulted in particularly low absolute numbers in this section of the 
analysis. 
Excluding patients who were prescribed an anticoagulant for a pre-existing medical condition 
and patients who developed postoperative complications, twenty-two knee patients (68.9%, N=32) 
and thirteen hip patients (39.4%, N=33) received NHMRC recommended thromboprophylaxis 
(Figure 18). Hip arthroplasty patients were less likely to receive the recommended course of 
thromboprophylaxis compared to knee arthroplasty patients (p<0.02). Patients who were prescribed 
thromboprophylaxis that was adherent with the NHMRC Guideline tended to have a higher BMI 
than those who did not (32.9 vs. 29.6, p = 0.03). There was no significant association between BMI 
and surgery type. 
 
 
Figure 18. Proportion of patients who received NHMRC recommended prophylaxis (N=65). 
                                       Nothing appropriate                                   Appropriate agent only   
                                         Appropriate agent and dose only                       Appropriate agent, dose and duration 
 
Figure 19 represents a larger set of data (n= 100, 61.7% of those eligible (N=162)) as the 
dosage data was removed from the analysis. Once more, hip arthroplasty patients were less likely 
to receive the full duration of prophylaxis compared to knee arthroplasty patients (21 vs. 29, 39.6% 
vs. 61.7%, p<0.05). 
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Figure 19. Proportion of patients who received NHMRC recommended prophylaxis (N=100). 
   Nothing appropriate          Appropriate agent only        Appropriate agent and duration 
 
 
4.4.7 Postoperative Complications 
4.4.7.1 Bleeding and Infections 
Five patients (3.5%) developed a bleeding complication, and five patients (3.5%) developed a 
wound or joint infection postoperatively (n=141). Interestingly, men were more likely to develop 
bleeding complications postoperatively than women (7.1% vs. 0.9%, p<0.05), and all infective 
complications were reported in knee arthroplasty patients. There were no other significant 
associations between bleeding and infection risk and patient demographics. 
 
4.4.7.2 Symptomatic VTE 
Six patients (4.3%, n=141) developed VTE in hospital (2 hip patients, 4 knee patients), with no 
significant difference in the characteristics of those who did and those who didn’t develop VTE. 
Five patients developed a DVT and one patient developed a PE. All patients who developed VTE 
postoperatively received an anticoagulant at some stage during their inpatient stay. Four of the 
patients who developed a DVT were being given enoxaparin 40mg daily at the time of their DVT 
diagnosis; two of these patients had a history of hypertension, and heart disease; one patient had 
dyslipidaemia; and the other only had a past medical history of osteoarthritis and associated pain. 
The other two patients who developed VTE (one PE, one DVT) were on either an 
inappropriate agent or dose of thromboprophylaxis at the time their VTE developed. The patient 
who developed a DVT had initially received rivaroxaban 10mg daily for three days. He was then 
given aspirin 100mg and developed a DVT twenty four days later on the rehab ward. The patient 
who developed a PE had a history of type 2 diabetes and peripheral vascular disease, and despite a 
healthy admission creatinine clearance (67 mL/min) initially received enoxaparin 20mg 
postoperatively instead of the recommended 40mg. Following her PE she was prescribed 
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enoxaparin 80mg twice daily for the rest of her inpatient stay (4 days); and at discharge she 
received six weeks of low dose aspirin. 
Unfortunately it was not possible to determine the median number of days to postoperative 
complication (VTE, bleeding or infection) in this study. 
 
 
4.5 Discussion 
This review identified that inpatient thromboprophylaxis prescribing was similar across the 
surveyed public hospitals, with many patients receiving anticoagulant thromboprophylaxis as 
recommended by the NHMRC Guideline. Prescribing at discharge however varied between 
hospitals, with one third (54, 33.3%) of patients receiving either an antiplatelet agent, or nothing at 
discharge. Overall, a little over half of the patients with full datasets were prescribed an NHMRC 
recommended agent, dose and thromboprophylaxis course (35, 53.8%, n=65).  
Although it was not an aim of this study, the review identified a significant complication risk 
associated with the surgeries, with 16 patients (11.3%) developing a postoperative complication 
while in hospital: five (3.5%) developed a bleed, five (3.5%) developed a wound or joint infection, 
and six patients developed a VTE (4.3%, N=141).  
Inpatient prescribing in this review was similar to that outlined in Chapter 3; most patients 
were prescribed anticoagulants following surgery, in particular LMWH. Furthermore, when RHH 
data was separated out from the rest and compared to the Chapter 3 data there was no significant 
difference in pharmacological prophylaxis prescribing. This suggests that RHH prescribing 
practices had not significantly changed in the 18 months between the two studies. Noteworthy 
however, was the drop in documented mechanical prophylaxis use (from 14.0% to 0%).  
Even though inpatient prescribing in this multicentre study was not significantly different to 
the RHH data in Chapter 3, there was a significant difference in the prescribing of 
thromboprophylaxis at discharge. In particular, significantly more patients were prescribed an 
anticoagulant at discharge across the multiple centres (66.7% vs. 16.3%); and a significantly 
greater proportion of patients went home with some form of pharmacological thromboprophylaxis 
(78.4% vs. 36.7%). Interestingly antiplatelets were less commonly prescribed at discharge in this 
cohort, and most patients prescribed an antiplatelet agent were using one prior to admission. 
The proportion of patients who developed VTE postoperatively in hospital was significantly 
higher in this study than the previous study (4.3% vs. 0.7%). As previously noted, VTE occurs 
more commonly after discharge.
 51,62,143,184,185
 It is likely then that the 90-day incidence would have 
been close to double the previous study (2.7%), however only a 90 day follow up with the cohort 
could confirm this. 
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A major limitation of this study is the significant number of patient records returned with 
missing data. This is because some data (e.g. discharge prescribing data and lab data) were not 
readily available in the paper based hospital files that were reviewed by investigators. This lack of 
data ultimately limited the adherence analysis in particular. Nevertheless, similar to the previous 
study, this study identified that patients with increased BMI tended to be more likely to receive 
guideline approved thromboprophylaxis. Remarkably, a significantly greater number of patients 
received ‘appropriate’ thromboprophylaxis in this study, compared to the study outlined in Chapter 
3 (53.8% vs. 5.1%).  
Remarkably two hospitals’ orthopaedic departments vetoed this study because of its auditing 
nature, increasing nonresponse bias risk. It is possible that these hospitals may have been less 
likely to adhere with the NHMRC Guideline recommendations than those included in the study; 
however, only a follow up with these hospitals would be able to confirm this. Whilst it is 
unfortunate that only six hospitals were able to participate, the data confirmed that the guideline-
practice gap identified in Chapter 3 was not unique to the RHH. 
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 CHAPTER FIVE: AUSTRALIAN HOSPITAL PROTOCOLS 
 
 
 
5.1 Introduction 
The studies outlined in Chapters 3 and 4 confirmed that despite the presence of national and 
international guidelines, thromboprophylaxis prescribing is variable in both Tasmania and 
interstate. Anecdotal evidence suggested some hospitals had their own thromboprophylaxis 
protocols that differed from the contemporary guidelines. A national survey of hospitals was 
conducted to identify if these protocols had any impact on prescribing. 
 
 
5.2 Aim 
The aims of this survey were four-fold: 
 to determine how many Australian hospitals have thromboprophylaxis protocols, 
 where protocols exist, to identify what they are based on and how effectively they are 
being used in practice, 
 where protocols exist but are not being extensively used, to identify potential barriers to 
their uptake, and 
 to identify strategies being effectively employed to improve adherence to protocols. 
 
 
5.3 Methods 
5.3.1 Participant Selection and Invitation 
Potential participants were identified by reviewing the list of hospitals that contribute data to the 
National Joint Replacement Registry (http://aoanjrr.dmac.adelaide.edu.au), and through reviewing 
the list of hospitals with orthopaedic services on the Australian government’s MyHospitals website 
(http://www.myhospitals.gov.au). A list of 363 hospitals was compiled using these means. These 
hospitals were then contacted via telephone to determine if they offered hip and/or knee 
arthroplasty services at the hospital (as opposed to other orthopaedic services). Finally, the 
YellowPages and MyHospitals websites were used to develop an address list for 310 hospitals (158 
private, 152 public). 
A letter was sent to the orthopaedic clinical nurse manager (CNM) at each hospital inviting 
them to participate on behalf of their hospital (Appendix B). As a strategy to encourage 
participation, each CNM who completed the survey was offered the opportunity to enter into a 
draw for a AUD250 gift voucher.  
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Despite the gift voucher incentive, the initial response rate was only ~10%. A review of the 
literature identified that other studies have found that sending an advance postal survey notice, 
using unconditional monetary incentives (e.g. gift certificates), employing handwritten notes, 
and/or sending large numbers of reminders can improve survey response rates.
191-194
 After 
reviewing all of these strategies and more, three changes were implemented to improve the 
response rate of this survey. Firstly, an ethics amendment was submitted and approved to increase 
the participation incentive to a first place prize of a third generation Apple iPad (valued at 
AUD539), with the AUD250 gift voucher subsequently becoming a second prize. Secondly, as 
some CNMs had difficulty accessing the survey online, a hard copy of the survey was included in 
each reminder letter along with a reply-paid envelope. Thirdly, each and every letter was 
personally signed by the researcher, and included a little post-it thank you note. 
 
5.3.2 The Survey 
The survey was initially created online with the LimeSurvey open source PHP web application 
software (http://limesurvey.org/) and hosted on a University of Tasmania server (Appendix B). It 
was divided into three sections: hospital details; thromboprophylaxis protocols and their evidence 
base; and barriers to the uptake of protocols (modified from data presented in Figure 10). The 
survey concluded with space for participants to share any further comments on 
thromboprophylaxis.  
The survey was available online for three months from March 2012 to June 2012. During this 
time two reminder letters (each with a hard copy of the survey enclosed) were sent. Notably, once 
the option to complete the survey on paper was implemented all of the responses received 
thereafter were in the hard copy format. 
  
5.3.3 Statistics 
All information was stored in an Access database (Microsoft® Access 2010), and analysed using 
SPSS 19.0. The differences between groups were tested using the t-test for independence for 
continuous data, and the chi square test for categorical variables. Continuous variables were 
summarised as means and standard deviation. A univariate analysis, followed by a multivariate 
analysis of variables, was performed to assess the contribution of individual hospital variables on 
the likelihood of a hospital having a formal protocol. Only p≤0.05 values were considered 
statistically significant. 
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5.4 Results 
One hundred and forty-three surveys (46.1%) were returned in total; however, thirteen respondents 
reported that their hospital did not offer hip or knee arthroplasties and a further four surveys were 
returned mostly empty. This resulted in a final response rate of 42.8% (126 surveys, N=294).  
Although this survey was addressed to clinical nurse managers, a range of other health 
professionals responded, including: hospital CEOs, theatre staff, heads of orthopaedic departments 
(HODs), clinical pharmacists, registered nurses, registrars, residents, interns, physiotherapists, 
hospital and nurse educators, haematologists, anaesthetists, surgical ward managers, nurse 
practitioners, coordinators of clinical policy and clinic managers. 
 
5.4.1 Demographics 
Hospitals responded from every state and territory in Australia; unfortunately the only one returned 
from the Northern Territory was not viable for analysis. The response rates from Victoria, New 
South Wales, and Queensland based hospitals were only 38.4%, 36.4% and 35.0% respectively; 
these states provided the bulk (70.6%) of completed responses (Figure 20). The best response rates 
were from the Australian Capital Territory (100%), Western Australia (75.0%) and Tasmania 
(66.7%). Two participants did not identify which state their hospital was in. 
 
Figure 20. Response rate from 
each state. 
 
 
Seventy-one (56.3%) responding hospitals were private hospitals, two were unmarked and the 
remaining fifty-three (42.1%) were public hospitals. The hospitals had a combined total of 20,575 
beds, averaging 171 beds per hospital (SD 159, n=120, Table 20). Public hospitals had more beds 
on average than private hospitals (216 vs. 138 respectively, p=0.01). 
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Table 20. Hospital demographics. 
 
Public Hospitals Private Hospitals Overall 
n mean SD n mean SD mean SD 
Beds* 52 215.6 187.5 68 137.6 123.8 171 158.8 
Surgeons  55 5.6 4.2 71 5.9 5.6 5.8 5.0 
Hip arthroplasties* 53 103.2 98.8 67 181.7 210.1 147.0 174.0 
Knee arthroplasties* 52 112.7 121.9 67 217.3 190.0 171.6 171.3 
Total arthroplasties* 53 213.7 214.3 67 399.0 386.9 317.2 334.1 
NB: * indicates statistically significant difference between hospital sector. 
 
A combined total of 715 orthopaedic surgeons were reported to operate at the responding 
hospitals. This averaged to 6 surgeons per hospital regardless of sector (SD 5, n=126); however, it 
is likely there was some overlap as surgeons often operate at more than one hospital. 
The annual number of arthroplasties conducted at each hospital varied considerably from 4 to 
1600 surgeries. Public hospitals reported significantly lower arthroplasty numbers than private 
hospitals (214 vs. 399 respectively, p=0.001). Reflective of the national trend, both sectors reported 
a trend towards conducting more knee arthroplasties than hip arthroplasties (172 knees vs. 147 hips 
annually); however, this did not reach statistical significance. 
 
5.4.2 Thromboprophylaxis Protocols 
Sixty three respondents (50.0%) reported having a formal thromboprophylaxis protocol at their 
hospital (26 private hospitals, 37 public hospitals). Multivariate analyses identified that the total 
number of arthroplasties conducted at a hospital was the only factor that had any statistically 
significant impact on whether a hospital reported having a formal thromboprophylaxis protocol or 
not. Hospitals that reported having a formal protocol in place conducted less arthroplasties (262 vs. 
374, p=0.07), were more likely to have more beds (202 vs. 140, p<0.05), and were almost twice 
more likely to be a public hospital than a private hospital (67.2% vs. 36.6%, p<0.001).  
 
5.4.3 Evidence Base 
Only eight respondents attached their thromboprophylaxis protocol to the survey (12.7%); 
however, most participants indicated the evidence base for their protocol. The NHMRC Guideline 
was the most common basis on which thromboprophylaxis protocols were reportedly developed or 
based on (Figure 21).  
 
Chapter 5: Australian Hospital Protocols 
 
C. Mirkazemi          54 
  
 
Figure 21. Basis of thromboprophylaxis protocols in responding hospitals   (N=63). 
     NB: Some respondents indicated multiple sources for their hospital protocol  
 
     Private hospital protocols were more likely to be based on the NHMRC Guideline (81.5% vs. 
51.3%, p<0.05), and public protocols were more likely to be based on unit consensus (40.5% vs. 
7.4%, p<0.05).  
  
5.4.4 Protocol Adherence 
Most protocols were described as mandatory (45, 72.5%, n=62), with staff reportedly familiar with 
protocols in 95.1% of hospitals. Protocol adherence was reported to be high (86.3% adherence, 
SD 19.7) and was not impacted by protocol evidence base, hospital state/territory, or hospital 
sector. HODs were more likely to report high adherence to protocols than any other health 
professionals (n=6, 95.4% vs. 85.4%, p<0.01). 
 
5.4.5 Adherence Improvement Strategies 
Approximately two thirds of hospitals with protocols reported having policies in place to 
encourage adherence (40, 63.5%). Most commonly, these policies included embedding prophylaxis 
into clinical pathways (preadmission, inpatient and at discharge), regular audits and staff education 
(Table 21).  
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Table 21. Reported hospital policies to encourage protocol adherence (N=63). 
Theme n % 
Regular prescribing audits conducted 15 24 
Embedded in inpatient processes e.g. clinical pathway, prompts, handover checks 14 22 
Staff education (new and continuing staff) 11 17 
Embedded in discharge process 10 16 
Embedded in preadmission process e.g. preadmission written education 9 14 
Thromboprophylaxis part of drug chart 6 10 
Hospital expectation all staff follow policy 5 8 
Risk assessment tools e.g. stickers in inpatient notes  4 6 
Protocol placed in visual spot 3 5 
VTE committee or expert involvement 2 3 
 
There was a trend towards increased adherence in hospitals with adherence strategies, 
particularly following hip arthroplasty (91.0% vs. 79.2%, p=0.08). This was most markedly evident 
in hospitals that had embedded thromboprophylaxis into regular practice and implemented staff 
education strategies.  
 
5.4.6 Barriers to Protocol Uptake 
One hundred and eighteen participants (93.6%) completed this component of the survey (50.8% 
from hospitals with protocols). However, many of them (43, 36.4%) did not consider any of the 
listed perceptions as barriers to the uptake of protocols. Of those that answered otherwise, the 
perception that protocols interfere with professional autonomy was the most commonly perceived 
barrier to protocol update (Figure 22).  
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Figure 22. Potential barriers to protocol uptake (N=118).           
          Yes      Maybe  
 
 
5.4.7 Hospitals without Protocols 
Of the 63 hospitals with no reported protocol, 60 (95.2%) indicated that their orthopaedic surgeons 
had their own protocol. Respondents were less likely to know what these protocols were based on 
compared to formal protocols (24.6% vs. 6.6%, p<0.01) (Figure 23). Surgeons were more likely to 
have their own protocol in private hospitals than public hospitals (100% vs. 83.3%, p<0.05). 
 
 
Figure 23. Basis of thromboprophylaxis protocols in responding hospitals  (N=123). 
       No formal protocol   Formal protocol in place. *indicates statistically significant difference (p<0.05). 
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5.5 Discussion 
This study identified that half of the hospitals surveyed had a formal thromboprophylaxis protocol 
in place. Interestingly, these hospitals tended to have more beds, but were reported to conduct 
fewer hips and knee arthroplasties each year. Where protocols existed, they were more likely to be 
based on the NHMRC Guideline than any other evidence base. Adherence to protocols was 
relatively good, with over 85% of arthroplasty patients reportedly receiving thromboprophylaxis 
according to their hospital or unit protocol, irrespective of the basis of the protocol. 
Implementation of adherence strategies have been previously  reported to improve VTE risk 
assessments and thromboprophylaxis use; and similarly, there was a trend towards hospitals with 
adherence strategies in place in this study having higher adherence rates, however this did not 
reach statistical significance.
177,195
 
Relatively few participants identified potential barriers to the uptake of protocols in their 
hospitals, potentially due to their use of thromboprophylaxis already being so high. The biggest 
perceived barrier to protocol uptake was the perception that protocols interfere with surgeon 
autonomy. This may be because clinical practice guidelines, and similarly protocols, can be 
considered a threat to clinical and professional autonomy if they are seen as too prescriptive – 
specifying how health care should be performed.
175,196
 Similar to the findings reported in 2.4.1.2 
Barriers, bleeding concern was also identified in this survey as a potential (though not significant) 
barrier to pharmacological prophylaxis use.
182,197
 Patient compliance and a lack of time to refer to 
protocols in practice were also identified as potential barriers to protocol uptake. 
Unexpectedly, public hospitals were more likely to report protocols based on unit consensus, 
and less likely to report protocols based on the NHMRC Guideline.Almost all of the hospitals 
without a hospital or unit protocol in place indicated that their orthopaedic surgeons had their own 
protocol. This suggests orthopaedic surgeons are inclined to carefully consider the postoperative 
thromboprophylaxis needs of their patients. That some surgeons base their individual protocol on 
contemporary guidelines suggests they are reviewing these guidelines as individuals, even if their 
hospital or unit are not. Although this survey was addressed to clinical nurse managers, a range of 
other health professionals responded. Interestingly, HODs were more likely to report high 
adherence to protocols than any other health professionals. This may be due to the proactive nature 
of these HODs (as exemplified in them taking the time to fill out a survey addressed to CNMs), or 
due to a desire to promote their hospital as adherent to guidelines 
Surprisingly, the response rate from private hospitals was better than from public hospitals 
(44.3% vs. 34.9%). An interesting aspect of this study was the large impact a few tweaks to its 
method made on the response rate. Providing a means to complete and return a hard copy of the 
survey, increasing the prize draw, and adding a personal touch increased the response rate by over 
450%. It is likely all of these elements assisted together as 75.4% of respondents chose to complete 
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the hard copy of the survey and many sent personal ‘good luck’ and ‘thank you’ notes back with 
their responses (as shown below). Furthermore, some participants emailed the researcher 
separately to the mail back to ensure that they were in the draw for the iPad. 
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 CHAPTER SIX: SURVEY OF AUSTRALIAN ORTHOPAEDIC SURGEONS 
 
 
 
6.1 Introduction 
The retrospective audits in Chapters 3 and 4 identified that many arthroplasty patients did not 
receive recommended thromboprophylaxis courses in Australia, in 2010 and 2011. The results of 
Chapter 5 (conducted in 2012) shed a little light on factors that influence thromboprophylaxis use 
and protocol uptake in hospitals. To further complement the retrospective data as it was collected, 
and to further explore factors that influence prescribing, a number of projects centered on 
surveying and interviewing surgeons were conducted. The first of these was an online survey of 
orthopaedic surgeons that was conducted in late 2010. 
 
 
6.2 Aim 
The aim of this survey was two-fold:  
 to identify what thromboprophylaxis trends exist in Australia for arthroplasty patients; 
 and to identify enablers and barriers to thromboprophylaxis prescribing, from the 
perspective of orthopaedic surgeons. 
 
 
6.3 Methods 
6.3.1 Participant Selection and Invitation 
An invitation to participate in the survey was distributed by the Arthroplasty Society of Australia 
(ASA) to its 103 members (Appendix C). The AOA was approached initially to seek assistance in 
recruiting orthopaedic surgeons. However, it replied that ‘many surgeons perform few or no joint 
replacements in the lower limb’ and anticipated the response rate would be poor. The Association 
suggested collaborating with the ASA whose members specialise in joint replacements (at least 
80% of the surgeries they conduct must be joint replacements). Fortunately, the ASA agreed to 
distribute electronic invitations with a link to the survey online. 
 
6.3.2 The Survey 
An electronic survey was created with the LimeSurvey open source PHP web application software 
(http://limesurvey.org/), and hosted online on a University of Tasmania server (Appendix C). It 
was divided into five sections covering: demographic and professional practising information; 
perceived thromboprophylaxis effectiveness, preferred agents and duration of use; factors that 
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influence prophylaxis prescribing during the inpatient and discharge period; four case studies 
designed to assist in the identification of factors that influence thromboprophylaxis prescribing; 
and questions concerning institution-specific guidelines and contemporary guidelines. The case 
studies were designed to assess the impact of age, weight, medications and past history of bleeding 
and VTE on thromboprophylaxis prescribing. 
The survey concluded with space for participants to share any further comments on 
thromboprophylaxis, and an invitation to participate in short interviews on thromboprophylaxis use 
postoperatively. 
The survey was open for participants to access for 6 weeks, during which the ASA sent two 
electronic reminders encouraging members to participate. Furthermore, a second generation Apple 
iPad (valued at AUD629) prize draw was used as a strategy to improve participation. 
 
6.3.3 Statistics 
Data was collected using LimeSurvey and formatted for analysis with SPSS 19.0. Continuous 
variables were summarised as medians and ranges. The differences between groups were tested 
using the Mann–Whitney test for continuous data, and the chi squared test for categorical variables. 
Spearman’s rank correlation coefficients were calculated for measuring correlations. Only p≤0.05 
values were considered statistically significant. 
 
 
6.4 Results 
In total, twenty-five surgeons completed the survey (response rate: 24%). Another surgeon started 
the survey but did not complete it.  
 
6.4.1 Demographics 
Surgeons practising in Victoria (10, 40.0%), New South Wales (7, 28.0%), South Australia (4, 
16.0%), Queensland (3, 12.0%) and Western Australia (1, 4.0%) completed the survey. All 
participants were male, with a median of 20 years practice as an orthopaedic surgeon (range: 8 to 
27 years). Most surgeons practised predominantly in the private sector (23, 92.0%), and conducted 
an average of nine hip (range: 1 to 30, total: 269) and ten knee arthroplasties (range: 1 to 30, total: 
271) monthly.  
 
6.4.2 Prescribing Practices 
All surgeons prescribed pharmacological prophylaxis following arthroplasty, choosing LMWH 
(12, 48.0%), aspirin (11, 44.0%), fondaparinux (1, 4.0%) and rivaroxaban (1, 4.0%) as their agents 
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of choice. There was no significant correlation between preferred agent and professional 
experience (years or surgeries). 
Except for one participant, all surgeons routinely prescribed pharmacological prophylaxis for 
the entire inpatient period (Table 22). There was no correlation between the number of years 
practising and duration preference. 
 
Table 22. Preferred duration of thromboprophylaxis (N=25). 
 Hip Arthroplasty (%) Knee Arthroplasty (%) 
During inpatient stay 4.0 4.0 
At discharge 24.0 24.0 
At 14 days postoperatively 24.0 36.0 
4 to 5 weeks postoperatively 48.0 36.0 
 
 
6.4.3 Thromboprophylaxis Efficacy 
When asked if pharmacological prophylaxis is effective in preventing fatal PE, 24.0% of surgeons 
did not believe so, 64.0% of surgeons thought it may potentially reduce fatal PE, and only three 
surgeons (12.0%) believed pharmacological agents definitely decreased fatal PE following surgery.  
 
6.4.4 Influencing Factors 
A patient history of VTE, hormone replacement therapy (HRT) use and prolonged preoperative 
immobility were the top three patient factors surgeons indicated would prompt them to prescribe 
pharmacological prophylaxis during the inpatient and discharge period (Table 23). High bleeding 
risk, a perception that extended thromboprophylaxis is inconvenient, belief that pharmacological 
methods are not superior to mechanical methods; and a low perceived VTE risk were the top four 
factors felt to generally limit prophylaxis prescribing postoperatively (Table 24).  
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Table 23. Patient factors that prompt pharmacological prophylaxis use  (N=25). 
 Inpatient % Discharge % Overall % 
Age < 70 years 12.0 4.0 16.0 
Age ≥ 70 years 20.0 4.0 20.0 
Current smoker 24.0 8.0 28.0 
General anaesthesia 12.0 0.0 12.0 
HRT 44.0 32.0 52.0 
Moderate obesity (BMI >30) 32.0 12.0 32.0 
Morbid obesity (BMI >40) 28.0 16.0 36.0 
None of these factors 4.0 4.0 8.0 
Preoperative infection 12.0 0.0 12.0 
Previous thrombophlebitis 24.0 16.0 28.0 
Previous vein surgery 16.0 4.0 20.0 
Previous VTE 92.0 76.0 96.0 
Prolonged preoperative immobility 44.0 4.0 44.0 
Surgery>2 hrs 24.0 4.0 24.0 
NB: BMI = body mass index, HRT = hormone replacement therapy.  
 
 
Table 24. Perceptions that limit pharmacological prophylaxis use  (N=25).  
  Inpatient % Discharge % Overall % 
It increases the risk of infection at the operation site 28.0 4.0 28.0 
It is not safe as it causes too much bleeding 68.0 36.0 76.0 
It is not superior to mechanical methods 40.0 8.0 40.0 
It is too expensive 4.0 12.0 12.0 
It is too inconvenient 0.0 48.0 48.0 
Patients will not be compliant 0.0 12.0 12.0 
Poor continuation of care from hospital to community 4.0 16.0 16.0 
Study evidence isn't applicable to real-world populations 32.0 28.0 36.0 
The risks of VTE are low 24.0 40.0 40.0 
None of the above 24.0 12.0 32.0 
 
 
6.4.5 Familiarity with Contemporary Guidelines 
All surgeons indicated they were very familiar with the ASA Guideline, followed by the AAOS 
and NHMRC guidelines (Figure 24).  Surgeons who were familiar with the NICE Guideline 
reported conducting less arthroplasties a month than those who had only come across it in passing 
(17 vs. 29, p=0.01). There was no other significant difference in demographics. 
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Figure 24. Surgeon familiarity with contemporary guidelines (N=25). 
        I have not come across it before       I have heard of it in passing      I am very familiar with it 
 
 
6.4.6 Case Studies and Thromboprophylaxis Prescribing 
The first case was designed as an older lady with no history of VTE or bleeds. Participants tended 
to prescribe the agent they had previously stated was their preferred agent; however those surgeons 
who prescribed an anticoagulant tended to prescribe a lower dose than would be recommended for 
the patient’s kidney function. 
The second case was an average aged male with no history of VTE or bleeds, but was obese 
(BMI=31), had mild kidney impairment and was diabetic. Once again, participants prescribed their 
previously stated preferred agent, however despite his kidney impairment they were more inclined 
to choose normal doses of anticoagulants (higher than would be recommended for this patient). 
The third and fourth cases were a middle aged female and a slightly older male with a 
significant and potentially life-threatening history of VTE and bleeding respectively. Participants 
deviated from their preferred agents in these cases to balance the risks associated with the cases: 
almost all participants (96.0%) prescribed an anticoagulant for the patient taking hormone 
replacement therapy with a history of VTE; and most participants either prescribed either 
mechanical prophylaxis ± aspirin for the patient with a history of haemorrhagic stroke. 
 
6.4.7 Case Studies and Guideline Adherence 
The four case studies were also used to compare adherence to the ASA and NHMRC guidelines. 
Across the cases, 68.0% and 88.0% of surgeons prescribed mechanical prophylaxis in line with 
ASA and NHMRC recommendations, respectively. Adherence to pharmacological prophylaxis 
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recommendations was considerably lower across the cases; between 56.0% and 60.0% of 
participants prescribed in line with the NHMRC Guideline across the cases. This dropped to 
between 16.0% and 56.0% across the cases when doses were reviewed (as per product 
information). Between 56.0% and 96.0% of participants prescribed an ASA recommended agent, 
and between 44.0% and 84.0% prescribed it at an appropriate dose. 
As there are no ‘duration of therapy’ recommendations in the ASA Guideline, and the 
NHMRC recommendations are vague (up to 14 days for knees, up to 35 days for hips) duration of 
therapy was not compared to guideline recommendations. In general, however, there was a trend 
towards surgeons prescribing longer anticoagulant courses for the case with a previous history of 
VTE (80.0% chose to prescribe an anticoagulant for 4 weeks or longer), and no anticoagulant agent 
for the case with a previous history of haemorrhagic stroke (56.0% chose not to prescribe anything, 
and 32.0% chose to prescribe aspirin solely). 
 
6.4.7 Thromboprophylaxis Protocols  
Most participants (19, 76.0%) indicated that their institution(s) had a thromboprophylaxis protocol, 
but only a little over half (53.0%) had any processes in place to encourage adherence. After being 
provided with a summary of the NHMRC recommendations to review, participants were asked if 
there was anything they felt was not appropriate in the recommendations; most surgeons (20, 
80.0%) responded ‘yes’. The two most common reasons cited (as described in a free-text box) 
were assertions that the recommendations were grounded on an inappropriate evidence base, and 
did not include aspirin as an option for sole thromboprophylaxis (Table 25). 
 
Table 25. Why the NHMRC recommendations were deemed inappropriate  (N=20). 
Theme n % 
Inappropriate evidence base 11 55.0 
Aspirin should be included as a sole agent 6 30.0 
Aggressive mobilisation is not included 3 15.0 
Industry funding biases literature and hence guidelines 4 20.0 
Inappropriate duration recommended 3 15.0 
Bleeding risk is an issue 3 15.0 
No orthopaedic input into developing guidelines 3 15.0 
Heavy reliance on pharmacological prophylaxis 2 10.0 
Warfarin should be included as a sole agent 1 5.0 
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6.5 Discussion 
The aim of this survey was two-fold: to identify prescribing trends and to identify enablers and 
barriers to prescribing from the perspective of the orthopaedic surgeon. The first part of the survey 
identified that prescribing preferences vary between surgeons. The cases identified however that 
almost all participants were inclined to change and tailor their prescribing according to their 
patient’s associated risk factors.  
While some participants’ preferred prophylaxis regimes were aligned with the NHMRC 
Guideline, approximately half of them were not. Prescribing was less likely to adhere with the 
guideline if participants were concerned about bleeding, perceived pharmacological prophylaxis to 
be no more superior to mechanical prophylaxis or perceived VTE risk to be too low to warrant 
prophylaxis. These concerns and perceptions can be regarded as barriers to prescribing 
pharmacological prophylaxis. Surgeon prescribing was more likely to be adherent with the 
NHMRC Guideline when they were prescribing for a patient had a history of VTE; this was also 
identified as a factor in the first part of the survey that would prompt prescription of 
pharmacological prophylaxis (Table 23). 
The results of this small survey confirm that the provision of VTE prophylaxis is variable, as 
indicated by other clinical audits, including those in the preceding chapters.
17
 Interestingly, 
whereas the results outlined in Chapters 3 and 4 were subject to being influenced by other doctors’ 
prescribing preferences (e.g. junior doctors and geriatricians), this survey confirmed that surgeons 
are responsible for at least part of the prescribing variability identified in studies. 
Despite the absence of proven strategies for CPG implementation, it is tempting to blame 
surgeons for the guideline-practice gap.
140
 One could argue, however, that guideline-practice gaps 
that persist over many years (as the thromboprophylaxis one has in Australia) are symptomatic of 
deficiencies in either the guidelines themselves or their implementation strategies, and not 
clinicians’ aptitude.10 This is evident when one considers that many CPG have not been fully 
implemented into practice, despite widespread acceptance of the value of evidence based 
recommendations by the health community.
140 
The strength of CPG lie in their ability to summarise scientific evidence that is available for 
decision making, whereby the outcomes are either black (harmful: harms far outweigh benefits) or 
white (beneficial: benefits far outweigh harms); recommendations with insufficient evidence or 
risk-benefit ratios that are very close are termed grey.
178
 As highlighted in Chapter 2, there have 
traditionally been marked differences in thromboprophylaxis recommendations between 
guidelines, particularly regarding the appropriateness of prescribing aspirin and warfarin as sole 
agents.
171
 Recommendations in these areas have in some cases been potentially influenced by 
expert opinion, and could arguably be classified as grey.
68,139,198 
 Another point of debate is the 
appropriateness of extended-duration prophylaxis, and the evidence (or the alleged lack thereof) to 
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support it. This is apparent in the 2011 AAOS Guideline which does not recommend any specific 
duration of prophylaxis therapy for arthroplasty patients, instead stating that “In the absence of 
reliable evidence about how long to employ these prophylactic strategies, it is the opinion of this 
work group that patients and physicians discuss the duration of prophylaxis.
68
 That the surgeons 
participating in this survey varied in their choice of preferred pharmacological agent and duration 
is likely a reflection of the ongoing uncertainty and debate in these areas, and it is not surprising 
then that the practice gap continues to persist. 
Although few surgeons believed pharmacological prophylaxis prevents fatal PE, and many 
responded that VTE risk is low following arthroplasty, all participants reported routinely 
prescribing pharmacological prophylaxis postoperatively, with similar inclinations for LMWH and 
aspirin as described in Chapters 3 and 4. One of the main arguments for the use of aspirin 
postoperatively is its lower bleeding potential compared to anticoagulants.
50,145 
Most of the 
surgeons who preferred aspirin in this study also believed that pharmacological prophylaxis is not 
safe as it increases bleeding risk. One of the main arguments for the use of anticoagulants is that 
they reduce VTE more effectively than aspirin. Interesting, the three surgeons who perceived 
pharmacological prophylaxis as effective in preventing fatal PE favoured an anticoagulant post-
arthroplasty. 
In addition to bleeding concerns and a perceived low VTE risk postoperatively, a strong 
barrier identified to pharmacological prophylaxis use was the belief that study evidence is not 
applicable to real-world populations. This may be because some contemporary guidelines have 
cited papers that have used asymptomatic VTE as endpoints, the clinical relevance of which is 
controversial.
139,171 
Furthermore, trials often exclude many real-life situations of patients e.g. those 
with extreme body weights, significant renal impairment or multiple comorbidities. 
As all participating surgeons were ASA members, it was anticipated many would be familiar 
with the ASA Guideline. That so many participants (30.0%) had only heard of the NHMRC 
Guideline in passing was unexpected. Also surprising was the large proportion of participants who 
deemed the NHMRC Guideline inappropriate. Interestingly, all surgeons who reported not being 
familiar with the NHMRC Guideline deemed it inappropriate once reviewed; two thirds of 
surgeons who were familiar with it agreed. Also interestingly, many surgeons (40.0%) who 
questioned the appropriateness of the evidence base of the NHMRC Guideline stated earlier in the 
survey that they believed study evidence pertaining to thromboprophylaxis is not applicable to 
real-world populations. Although all surgeons expressed familiarity with the ASA Guideline, their 
prescribing was not always consistent with its recommendations. This may be due to reservations 
regarding the ASA recommendations.  
On six of the occasions when participants ‘prescribed’ an inappropriate dose for one of the 
case studies, the dose was excessively high and perhaps due to confusion over agents’ generic and 
brand names; for example some surgeons prescribed rivaroxaban 40mg, fondaparinux 20mg (NB: 
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only generic names were used in the survey). This suggests that any interventions to improve 
guideline adherence should highlight appropriate anticoagulant dosing requirements, particularly 
for the newer anticoagulants. 
Although collaborating with the ASA did assist in targeting orthopaedic surgeons who 
regularly perform joint replacements, professional endorsement of surveys has also been reported 
to negatively affect response rates, and may be one reason why the response rate for this survey 
was so significantly lower than the reported 61% average from mailed physician surveys.
199,200
 As 
the invitation to participate in the survey was distributed electronically by the ASA, it was not 
possible to use the strategies employed in Chapter 5 to improve the response rate (namely 
personally signing each letter, adding a thank you note and including a hard copy of the survey in 
the invitation letter). An alternative approach could have been to increase the number of reminders: 
Braithwaite et al increased the response to their electronic survey of general practitioners from just 
under 30% to 52.4% following five electronic reminders (and up to 63% following a telephone 
based survey of non-responders).
193
 Unfortunately, the number of survey reminders sent for this 
study was capped by the ASA, and privacy laws prevented the ASA sharing their members’ details 
for a telephone-based survey of non-responders. 
It has been demonstrated that as response rates decrease, the risk for nonresponse bias 
increases.
201
 The response rate for this survey (25.0%) was arguably low. Nonresponse bias is 
particularly relevant when the topic is considered sensitive.
202
 Thromboprophylaxis prescribing 
following hip and knee arthroplasty is arguably a sensitive topic, with surgeons vetoing the 
multicentre study in Chapter 4 because of its auditory nature and Molnar et al describing 
prescribing practices being influenced by the fear of litigation.
121
 It is possible then, that non-
responders may have been even less likely to comply or agree with thromboprophylaxis guideline 
recommendations than responders; however, only a follow up with non-responders would be able 
to confirm this. 
Despite the limited response rate, the survey was successful in identifying many barriers 
against the smooth adoption of any thromboprophylaxis guideline including: doubt regarding 
thromboprophylaxis efficacy, a perceived low VTE risk, and belief that recommendations are 
based on inappropriate evidence. 
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 CHAPTER SEVEN: HEALTH PROFESSIONALS’ PERCEPTIONS 
 
 
 
7.1 Introduction 
The surveys in Chapters 5 and 6 explored enablers and barriers to thromboprophylaxis prescribing; 
however they did so in a limited way because surveys are by design a one way conversation with 
no opportunity to explore ideas further. To overcome these limitations, a qualitative arm was added 
to the research to more fully explore the perspectives and experiences of health professionals 
involved with the provision of thromboprophylaxis to arthroplasty patients. 
 
 
7.2 Aim 
The aim of this study was three-fold:  
 to explore factors that drive and influence thromboprophylaxis prescribing postoperatively; 
 to explore surgeons’ position and point of view; and 
 to explore what factors surgeons’ identify as important, and why. 
 
 
7.3 Methods 
The qualitative approach selected for this study was informed by grounded theory. This approach 
is inductive and allows theory to be developed through an iterative analysis of the empirical data.
203
  
An iterative method is one in which the process of data collection and analysis are both cyclic 
and occurring simultaneously so that both processes are regularly reviewed and revised.
204
 The 
grounded theory approach consists of a precise set of steps that are carefully executed in a 
particular order. For this project a modified version of grounded theory was adopted that included 
the following features: purposeful sampling; an iterative data collection and analysis process 
whereby data was analysed as it was collected and the insights gained through this process were 
used to shape the subsequent data collection and analysis; the use of coding for data analysis; and 
most importantly, the commitment to an inductive approach that allowed theories to emerge from 
the data.  
 
7.3.1 Recruitment and Sampling 
The sampling process in grounded theory research (also widely used in qualitative research more 
generally) is termed theoretical or purposeful sampling. It involves purposefully selecting 
participant groups and data sources for their ability to help the research to meet the aims of the 
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study and as the study progresses, to provide data that can confirm, challenge or expand an 
emerging theme.
204
 The primary aim of this study was to explore factors that drive and influence 
thromboprophylaxis prescribing post-arthroplasty. To gain an understanding of the decision 
making process and experiences, surgeons were approached directly. To complement these views 
and to get a better grasp of real practice, these interviews were supplemented by interviews with 
junior orthopaedic doctors, general practitioners and clinical pharmacists (orthopaedic pharmacists 
and pharmacists involved in the formulation of a Tasmanian thromboprophylaxis guideline for hip 
and knee arthroplasty patients).  
An invitation to participate in the interviews was sent to all orthopaedic surgeons practising in 
Tasmania (eighteen surgeons); two geriatric consultants (who practise in orthopaedics) and six 
junior orthopaedic doctors at the local public hospital (the RHH); five clinical pharmacists; and 
five orthopaedic surgeons practising in Victoria who expressed interest in participating in the study 
after completing the online survey outlined in Chapter 6. Additionally, invitations were sent to 186 
general practitioners (GPs) practising within a half hour driving radius to the main hospitals in 
Hobart. In order to maximise participant uptake of the interviews, participants were offered face-
to-face interviews at a time and place convenient to them, as well as a AUD200 gift voucher (GPs 
only) or an opportunity to enter a draw for a second generation Apple iPad (valued at AUD629, 
prize draw open to everyone else).  
A purposeful sample of eleven orthopaedic surgeons and two junior orthopaedic doctors who 
worked across nine hospitals was obtained, as well as interviews with four clinical pharmacists and 
five GPs. The hospitals where participants worked included five public and four private hospitals, 
predominantly in Tasmania. All interviews were conducted over a three month period from April 
to June 2011. 
 
7.3.2 Interview Style 
Semi-structured interviewing was selected for the interview style as this approach is highly suitable 
for a study informed by a grounded theory approach, and because it allowed information to be 
collected in areas of interest that were identified in the online surveys, whilst still including a 
significant degree of flexibility to adjust the order, wording and type of questions asked during the 
interview. This flexibility allowed new topics and themes to be explored as they emerged, thereby 
facilitating in-depth understanding.
205
 The interview schedules generally consisted of open ended 
questions to which participants were encouraged to respond freely (see Appendix D). 
The interviews were conducted one-on-one between the researcher and each participant. The 
use of focus groups was considered briefly; however, there were ethical challenges identified 
(related to confidentiality and anonymity) that had the potential to inhibit discussion. It was 
considered more appropriate therefore, for the participants to be interviewed separately and in 
private; this provided them with the opportunity to express their views fully, and to openly relate 
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their experiences and opinions of other peoples’ practice without being influenced by other 
participants in a large focus group. One-on-one interviews are also usually readily accepted by 
people.
203
 
With the exception of one interview, participants were interviewed in their work spaces, 
thereby allowing the researcher to observe them in their working environment. Before each 
interview commenced, each participant’s permission was sought to allow the interview to be 
recorded on two digital voice recorders. Once full consent was confirmed a few background details 
were noted and the interviews commenced. At the end of each interview, participants were 
provided with the opportunity to clarify any comments made, to speak on any other topics and/or 
to ask any questions of the researcher. Each participant’s permission was obtained to contact them 
after the interview so that any necessary clarifications could be made and any pertinent topics that 
emerged in subsequent interviews could be explored. 
Throughout the interview, the researcher took steps to build rapport through active and 
empathic listening. Directly following each interview these observations were audio recorded, 
along with initial reflections of the interview (these were later transcribed and hereafter referred to 
as field notes). 
 
7.3.3 Data Analysis 
In line with the iterative study design, the principle of constant comparison was adopted in the data 
analysis. This involves comparing each piece of data with every other piece of relevant data and is 
important in developing theories that are grounded in the data.
52
 By employing this process, cycles 
of data analysis were intertwined closely with the data collection phase, and the result of the 
ongoing data analysis informed subsequent data collection.
52,204
 The cycle of comparison and 
reflection on ‘old’ and ‘new’ data was repeated several times. 
All interviews were transcribed verbatim by the researcher into text. Transcription, the first 
‘official’ step of data analysis, was always combined with reflection and review of field notes. 
Questions arising during the initial transcribing process were noted and explored in subsequent 
interviews and in limited email correspondence with the participants. In this way it was possible to 
answer questions that arose from the analysis of and reflection on previous data.  
The coding process was conducted using an iterative thematic analysis approach, informed by 
grounded theory and constant comparison. As interviews were transcribed they were coded, 
meaning that interesting and important sections such as concepts, observations, reasons given for 
prescribing practices, comments on guidelines etc. (anything relevant to the research questions) 
were marked and labelled. As the research progressed, new codes were developed and earlier 
interviews were reread and compared to the newer interviews.  
Subsequently, ‘axiel coding’ was performed where these initial codes were grouped into 
thematic categories. A simple ‘copy and paste’ technique was used to group coded sections from 
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the transcripts together under relevant thematic categories (which grew and broadened with each 
transcript review).      
The thematic categories were then reviewed, reduced and expanded through a process of 
constant comparison and then revised and refined into broader themes until they appeared to be 
saturated. Finally, after these preliminary findings had been established, all the interview 
transcripts were reread to fine tune the analysis, and ensure nothing had been missed. Eighty-two 
categories and themes were identified in the data in total. These themes are summarised under 
twenty-two subheadings in the following sections. 
Another researcher from a different background (sociology) read through the analysis several 
times to offer a second opinion and promote reflexivity. They agreed that the final thematic 
categories described in the following pages reflected the source data. 
 
 
7.4 Results 
7.4.1 Participants 
The surgeon participants (S) were all Anglo-Saxon males, with varying degrees of orthopaedic 
surgery experience between them (6 to 23 years, average 13 years). The surgeons estimated that 
they conducted between 12 and 16 joint replacements a month each, with a slight predominance for 
knee arthroplasties, reflective of the national trend, and data previously described. 
The GPs were all Anglo-Saxon; two were females, three were males. Between them they had 
6 to 35 years of practice as a GP (average 21 years). The GPs were unable to estimate how many of 
their patients underwent hip and knee arthroplasties each year, but described them as ‘coming in 
groups’. One GP said she had not had any patients undergo the surgeries for many years, but had 
patients on waiting lists for joint replacement(s). 
The junior doctors (JD) were both young Middle Eastern males and had practised medicine 
for less than one year, and on average only 5 weeks in orthopaedic surgery (10 weeks is the normal 
intern placement). The clinical pharmacists (CP) were of Anglo-Saxon background; one was a 
female, three were males. Between them they had 6 months to 22 years of practice as a registered 
pharmacist practising in clinical pharmacy. 
 
7.4.2 Surgical and Postoperative Changes 
When asked if the surgical procedure had changed significantly over the years, one surgeon stated 
that ‘the operation is basically the same’, while another said he had been using a more minimally 
invasive approach in recent years that allowed quicker, less painful procedures with a potentially 
lower complication rate. Surgeons generally remarked that there was a trend to ‘operate on 
younger individuals than before’, ‘fitter patients’ and not ‘elderly patients with multiple 
Chapter 7: Health Professionals’ Perceptions 
C. Mirkazemi          72 
  
comorbidities’. Other factors that surgeons noted had changed over the years included the length of 
stay in hospital (trending downwards), an increase in the use of mechanical thromboprophylaxis, 
the introduction of bedding exercises and, importantly, the elimination of any preoperative 
anticoagulant doses. Finally, many surgeons spoke of early mobilisation as being the ‘biggest 
factor’ that had changed over the years. 
The patients used to be admitted the day before, lie around all day, sometimes rest in bed for 
three or four days, plus after surgery. Now it’s ‘get the patient out of bed and get them mobile’. 
Quicker operations, shorter hospitalisation times. S5 
One surgeon noted that as a trainee, VTE ‘was quite a common thing’; however, he felt that 
the increased attention given to VTE prevention in recent years had led to many different care 
changes (including thromboprophylaxis use) which had reduced VTE incidence overall.  
 
7.4.3 Prescribing Patterns 
Junior orthopaedic doctors said their prescribing was directed by more senior doctors.  
In terms of postoperative orders, there’s normally a kind of protocol to follow. In terms of 
anything outside of those orders then there is flexibility of prescribing. But generally your 
prescribing is led by the, the geri[atric] consultants. … There’s no protocol. It’s more actually 
determined by the surgeon. JD1 
The junior doctors described most surgeons as prescribing identically; however, when the 
surgeons were interviewed they described a different picture. This is likely because both junior 
doctors practised at one public hospital, whereas the surgeons practised across many different 
hospitals and sectors.  
Despite the relatively small number of surgeons interviewed, their prescribing patterns 
differed considerably, both in agent and duration. Some surgeons prescribed anticoagulants during 
the inpatient stay and an antiplatelet (aspirin) at home for up to 6 weeks. One participant prescribed 
aspirin solely for 6 weeks postoperatively. Others prescribed anticoagulants (LMWH and 
rivaroxaban) for up to 6 weeks postoperatively. Notably, rivaroxaban was only being used in the 
context of a study being conducted at one of the public hospitals; that is, none of the surgeons were 
voluntarily prescribing it.  
General practitioners said they did not independently prescribe anything for their patients 
post-arthroplasty unless directed to by the operating surgeon. Although pharmacists do not 
prescribe thromboprophylaxis themselves they said they encouraged doctors to use guidelines in 
practice, (particularly the ACCP Guideline) as part of their role as clinical pharmacists. 
I think some, some doctors are very receptive. I think it generally depends on the intern and how 
much they’re, how happy they are to prescribe, because again the registrars don’t generally mind 
too much what happens after the surgery, um so they sort of will go, you know, if the intern’s 
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happy to do it, they’ll do it. Sometimes the consultants have strict views, and that determines 
what’s done. But yeah. Most of the time’s not too bad. CP3 
 
7.4.4 Factors that Influenced Prescribing Patterns 
There were many factors that were found to influence prescribing patterns amongst participants 
(described in detail in proceeding sections). Although prescribing patterns were different between 
surgeons, they agreed that first and foremost each patient should be treated as a whole person, 
balancing the risks and benefits associated with pharmacological prophylaxis, and taking 
advantage of non-pharmacological means of VTE prevention.  
Basically you’ve gotta treat more than just the heart, or more than just the lungs, or more than 
just the clots, or more than just.. You know you have to stop yourself from being too tunnel 
visioned about what you’re trying to do. S6 
Well I think it’s more than just a prescribing pattern. There are things which we do at the time of 
the operation; so it’s my preference to have a spinal anaesthetic which reduces the risk. I use calf 
compression on the leg which is not being operated on. I use foot pumps postoperatively. And 
then the routine prophylaxis is to use clexane afterwards for both hips and knees. S4 
This sentiment was echoed by GPs. 
We’ve got to remember that we’re treating the patient. We’re not treating ourselves. We’re not 
blindly doing what we’re supposed to be doing. We’re doing things because it makes a difference 
to that individual patient. And we’ve got to know [that] what we’re doing is relevant to that 
patient, and provides some benefit. GP1 
I mean, I think probably that’s probably a better guideline [AAOS Guideline] in some ways 
because you’re actually.. rather than one size fits all it’s a case of assessing the patient that’s 
sitting in front of you. Because every patient that sits in front of you is going to be different. And 
that probably is a bit more I suppose, Um. You know, gonna, gonna suit the patient’s individual 
circumstances better. Rather than just, just saying well it says here to give clexane. So that would 
probably be, yeah, I think that would be ok. GP2 
 
7.4.4.1 Patient History 
Most surgeons spoke of stratifying their patients to some degree before prescribing 
pharmacological prophylaxis, particularly anticoagulants. For example, five surgeons noted that if 
a patient had a personal or family history of VTE (particularly unprovoked VTE) they would 
‘investigate them further for thrombotic risk’, ‘tend to be more aggressive’ and ‘talk to them about 
the possibility of long term Clexane [LMWH]’. The duration of therapy prescribed for 
anticoagulants was described as varying ‘according to clinical scenario’, whereby the decision to 
extend anticoagulant cover is weighed up against other patient-centric concerns such as their 
‘frailty’ and ‘their ability to self-administer’ injections. 
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One surgeon said he altered his prescribing if he got ‘the feeling’ that a patient would bleed. 
Likewise, surgeons spoke of altering their prescribing for patients with a history of bleeding by 
withholding the first dose of prophylaxis until one day after surgery and/or using a smaller dose; 
however, this was described as ‘rarely’ being an issue.  
 
7.4.4.2 Training 
Surgeons said that their surgical training influenced their prescribing patterns, but only in 
combination with other influencing factors.  
Look, some of it’s training, some of it’s my interpretation of the current literature.  Some of it’s 
discussion with peers at conference. S4 
Yeah a little bit of what’s just been handed down. Uh there’s a little bit of discussion with my 
colleagues, um and a little of the sort of, the review papers and things like that as well. All sorts 
of [things] put together. S1 
 
7.4.4.3 Outside Input 
Although the decision to prescribe thromboprophylaxis and the type of thromboprophylaxis was 
universally agreed to ultimately be the operating surgeon’s decision, reference was also made by 
three surgeons to anaesthetists having input and involvement in decision making. Occasionally, 
patients and their families also have input into prophylaxis postoperatively. 
…his daughter was a GP, he’s a retired surgeon - did an ankle arthrodesis on him. I was happy to 
just have him on aspirin. His daughter insisted, as did another daughter who was a pathologist.. 
no a microbiologist, insisted that he go on to clexane. And so I said fine. S2 
GPs stated that they did not instigate thromboprophylaxis for their patients after discharge, 
unless directed to by the operating surgeon. 
So if they come out of hospital not on thromboprophylaxis, I don’t usually start it because I 
presume they didn’t think it was necessary. I defer to their expertise in that area. GP5 
One GP said that he would prescribe thromboprophylaxis for any patients that were ‘very high 
risk, such as diabetic, overweight and pretty well immobilised after their knee replacement’; 
however, it ‘hasn’t happened because those people are always on something’. Although GPs and 
surgeons stated GPs were not involved in thromboprophylaxis decision making, surgeons 
expressed openness for more GP input. Furthermore, both GPs and surgeons noted that GPs are the 
ones to treat clots that arise following discharge. 
My specific involvement in anticoagulation afterwards [after surgery] has been sort of pretty 
minimal. Actually I’m just trying to think of anyone. I haven’t been involved except with those 
which the surgeons give DVTs to. GP1 
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7.4.4.4 Literature and Study Data 
At different points during their interview each surgeon cited research papers to lend credit to their 
point. Some surgeons said they attended a ‘journal club’ to discuss relevant literature, and others 
spoke of discussing literature with colleagues in general or at conferences. Interestingly, 
participants expressed hesitation and scepticism in accepting study evidence at face value. 
I’ve been in research long enough to know you can tailormake your result a bit as well. S7 
So my colleague who’s you know, keen on aspirin, he’s always flashing these papers that prove, 
yet again that aspirin’s just as effective as uh, low molecular weight heparin. …if you wanna 
search far enough you can find some sort of study that’ll support your argument. S8 
Uh and as I’m sure you’re aware the evidence, you know, for that [extended therapy 
thromboprophylaxis] is pretty soft. You know to actually say that they’ve prevented a pulmonary 
embolus is um [a] pretty hard thing to prove. S1 
In general, GPs and surgeons remarked that papers that used asymptomatic VTE as endpoints 
had little clinical relevance or impact on their prescribing.  
No. [laughs] … They’re using asymptomatic clots as a surrogate measure for risk of PE. And there 
is no relationship. There is no established relationship. So I think it’s a waste of time to try and 
prevent those asymptomatic clots anyway. S2 
Yeah it’s just bullshit. Exactly what’s the point to that? ... To me, the important thing is 
pulmonary embolism and you know, symptomatic DVT, maybe, as a sort of lesser worry. And only 
above knee DVT is the concern, rather than below knee. S1 
It has zero relevance because I believe if I look hard enough I will find a clot in every one of my 
knee replacements and every one of my hip replacement patients. S3 
Although, you know, in discussing this with the haematologists you know, an asymptomatic deep 
vein thrombosis, unless you’re thinking it’s a totally different animal to, to a, to a, you know, a 
symptomatic DVT, is probably just this early stage of something bigger. Whether it progresses or 
whatever. It’s probably just one end of the extreme. But um. I’m less inclined um, to look 
favourably on a study if the end point is asymptomatic DVTs. S10 
Pharmacists tended to be more conservative in their remarks. 
Oh I think it’s part of an overall picture. ... But I, I would think, I would personally put value in, in 
something that can be shown to, to reduce overall clot burden. But clearly, clearly, it is clinical 
endpoints that are important and so, you know, two drugs, one prevents asymptomatic or sub 
therapeutic clot better than other, yet hard clinical outcomes are the same. Well you’ve then 
gotta think about what that means and think about, think very seriously about, you know, other 
aspects, other components of the triad of, of, um, therapeutic, measure of therapeutic success. 
Clinical outcome, safety and cost. CP1 
From other reading I’ve seen, it talks about not only the complications of PE, but long term, I 
think it’s called, the post, post thrombotic syndrome, which some of the vascular. Some vascular 
doctors have sort of said, yeah long term you get like obviously decreased like, um, um, increased 
risk of getting ulcers in the long term, which those sort of things, um, um, if we can prevent those, 
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they say that it’s probably likely to improve their, their long term outcomes, and their vascular 
system. So I think they definitely should be looked at. So I wouldn’t just say because the patient’s 
not aware, it’s not important. CP2 
 
7.4.4.5 Thromboprophylaxis Aim 
As described above, surgeons expressed little clinical concern for below knee DVT; similar 
remarks were made by GPs. In contrast, PE and symptomatic above knee DVT did pose a concern 
for many participants, and they described their prescribing as being geared to preventing them 
while balancing the risks associated with prophylaxis. Three participants spoke distinctly of trying 
to reduce fatal PEs, not simply PEs in general. Participants who spoke about trying to reduce 
overall mortality, instead of just VTE, spoke particularly favourably about prescribing antiplatelets. 
And I defend aspirin on the basis of um, when I was training, then there were a couple of meta-
analyses that looked at thromboprophylaxis. And what they did find was that there was a lower 
all-cause mortality in the patient group that received aspirin alone, compared to um those that 
received other thromboprophylaxis. So while my patients might not die of a PE, I’m lowering the 
risk for um stroke and heart attack. So that’s my rationale for using aspirin. S2 
 
7.4.4.6 Local Protocols and Hospital Sectors 
Surgeons operating at hospitals with unit or hospital thromboprophylaxis protocols commented 
that their prescribing patterns were influenced by the existence of these protocols. All participants 
performed surgeries in both the public and private sector; however, unit protocols were only 
discussed in relation to the public sector.  
Overall, surgeons were mixed on whether their prescribing practices differed between their 
private and public practice. Some surgeons said they prescribed identically in both sectors in order 
to keep it simple and to avoid ‘a system that’s so confusing that it’s likely to lead to errors’, 
whereas other surgeons practised differently between the sectors. 
All participants who had practices that differed between private and public worked at public 
hospitals with unit thromboprophylaxis protocols in place which were adhered to by junior doctors. 
Participants who worked at a public hospital without a unit protocol spoke of liaising with 
registrars regarding their prescribing preferences early in the registrar’s year of training. 
Interestingly four surgeons noted that they ‘tend to be relatively ignorant of what’s actually 
happening’ in practice.  
 
7.4.4.7 Thromboprophylaxis Efficacy 
Doubt was often expressed regarding the effectiveness of pharmacological agents to prevent VTE.  
And I think that generally surgeons are divided into two camps like that. Those who really think 
it’s [LMWH] a good thing, and those who think it’s a waste of time. And then there’s probably a 
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smaller group who do it just because it’s maybe medico-legally seen to be doing the right thing. 
S2 
I’m not convinced that taking clexane [LMWH], warfarin or any other agent decreases the 
incidence of significant fatal PE. I’m not convinced that there’s any agent that would reduce that 
risk. S5 
I’m just not convinced the science is good enough to support its [aspirin] use. It seems that it’s a 
gentler thing to do than to use heparin based treatments. … But it might not be effective. S4 
All surgeons who doubted the effectiveness of antiplatelets to prevent VTE did not prescribe 
them regularly. Notably, some of the surgeons who doubted the effectiveness of anticoagulants did 
prescribe them during the inpatient phase and chose to switch to aspirin on discharge. Interestingly, 
these surgeons were not always obliged by the presence of any unit or hospital protocol to 
prescribe anticoagulants during the inpatient stay. 
Conversely some of the surgeons who spoke positively about aspirin’s ability to reduce ‘all-
cause mortality’ did not prescribe it during the inpatient phase, potentially due to the presence of 
unit protocols that recommended against it. 
 
7.4.4.8 Patient Compliance and Satisfaction 
As described in Chapter 2, many longstanding anticoagulants require subcutaneous injections that 
are self-administered (or administered by a family member) if required after discharge; which can 
be inconvenient. Surgeons who did not prescribe anticoagulants cited this as one reason why they 
didn’t.  
Ah, well one is, I’m not convinced that a lot of patients are compliant with injections because they 
don’t like injections. S5 
They like not having to give themselves injections when they go home. And even having injections 
while they’re in hospital. S8 
Conversely, participants who did prescribe them, although mindful that patients may not like 
self-administering injections, did not consider it to be an insurmountable obstacle. 
Uh yeah, the patients do as they’re told. Some of them don’t like it. Some of them don’t like 
injecting themselves. But it’s not so big a problem that they say I’m just not going to do this. It’s 
not that much of an issue. S6 
I’m a little bit of a naïve believer of the, the good so to speak. I think that they [patients], they 
care for themselves. It’s better. You have a better night sleep if you, you believe in the good I 
think. So I think they want to! S7 
 
7.4.4.9 Simplicity 
The desire to keep things simple and uncomplicated came up during the interviews on multiple 
levels. As described previously, some surgeons prescribed identically between their private and 
public practice for simplicity and to avoid confusion; however, there are many other examples of 
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this desire for simplicity influencing practice. Contemporary guidelines typically recommend 
shorter courses of prophylaxis for knee patients than hip patients. Two participants acknowledged 
this but said they prescribed the same duration of therapy for both types of patients for ease and to 
reduce confusion.  
Likewise, three participants spoke of prescribing medications either now and/or in the past 
that specifically did not require phoning up for authority, which ‘takes five or ten minutes’ and 
requires the surgeon ‘to fill out these forms’, which is ‘a real pain’.  
Participants who worked at public hospitals with multiple orthopaedic surgeons spoke of unit 
protocols being in place to be more practical and make things simpler, because if all surgeons 
‘insisted on having our own kind of foibles, then it’s [sic] just make it too difficult for everyone to 
remember who does what’, and it becomes ‘too unwieldy’. 
One participant noted that his actual practice ‘differs slightly’ from what he considered best 
practice for simplicity’s sake. 
I give clexane whilst the patient is an inpatient. And I give all patients information that when 
they go home they go on to thirty five days of aspirin. … My best practice idea would be to have a 
fixed duration of clexane [LMWH] for all patients but it would probably be no more than 10 days 
and then maybe an oral agent after that. S3 
 
7.4.4.10 Contemporary Guidelines 
Although guidelines did influence prescribing, their use was usually discussed in combination with 
other influences, in particular clinical judgement. 
The same rule doesn’t apply to every patient. Like again, you’ve got a skinny old lady who bleeds 
like a stuffed pig when you cut her open; you have to adapt. You can’t just ‘the guideline says this, 
I have to do that. …Look I think a recommendation is fine. And a guideline, but I think you have 
to taper your treatment protocol to the individual. So you can’t – the same rule doesn’t apply to 
every patient. S5 
GPs expressed similar sentiments. 
It’s all very well having a protocol but you’ve actually got to think critically in following that 
protocol and make sure that it’s relevant to your individual patient. GP1 
In some instances participants expressed concern that guidelines in general created medico-
legal concerns, particularly if they make blanket recommendations. 
I’m shocked. The guideline states that any patient being immobilised, for example with ankle 
fracture, should have prophylaxis for the whole immobilisation time, which is at least 6 weeks - 
and maybe more. And I don’t understand what you’re going to do about this. It’s very clearly 
written down. And, and I don’t know. I tried to bring this up, a couple of times: what I was 
officially supposed to do about it, because it’s sort of written down. …So that, that is [a] medico-
legal concern…the state would have to pay a lot more money, and maybe that should be a 
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concern too, but that doesn’t come to my heart so much as if I would be legally bashed up or 
something. S7 
Other participants found guidelines useful and reassuring. 
I think that for the medico-legal reasons most of us want to know what’s the middle of the road 
standard care. I mean over anticoagulating people and having increased bleeding risk, and 
under coagulating people and having increased exposure risk to death from PE. S4 
One participant expressed a strong sentiment that the literature and guidelines are not well 
balanced, feeling that guidelines are being ‘driven by the drug companies’ because there are 
professors sponsored by drug companies on some guideline boards. The participant also remarked 
that there’s a ‘vested interest for a lot of these drug companies to get their drugs on the market.’ 
Remarkably, the only surgeon who described having successful experience with 
thromboprophylaxis guideline formulation was the only one who noted that the NHMRC Guideline 
incorporates a step-by-step guide that encourages the surgeon to consider ‘the patient’s clotting 
risk, the patient’s bleeding profile’, their surgery, and that it requires the surgeon to ‘make a 
conscious decision’ on thromboprophylaxis requirements for each individual patient.  
 
7.4.4.11 Medico-legal Concerns 
Although surgeons and GPs were mindful of medico-legal considerations, they were never 
described as the foremost concern when prescribing thromboprophylaxis; priority instead was 
given to clinical grounds in the decision making process. It was noted that this may be because 
medico-legal exposure in Tasmania ‘is not as bad’ as it is in other states and territories. 
I like to think that my primary concern is to do what I think is best for the patient rather than 
what some lawyer might pick me up on, or if I’d have to you know, argue my case in court. Uh so, 
for me, it’s, it’s not a strong consideration. S8 
I never let it worry me too much. Yeah, we have medico-legal you know, coverage, you know, pay 
your insurance, and if you have a problem you hope that they sort it out for you. S1 
I’m just interested in preventing complications for the patient really. Medico-legal doesn’t really 
come into it I think, not for me anyway. GP3 
Nonetheless, one surgeon did note that ‘there’s a vast spectrum of [different] individual 
[patients], and most of us are trying to say we want to sail that line without exposing ourselves to 
medico-legal threats as well’. Furthermore, as expressed in 7.4.4.10 Contemporary Guidelines 
there was some concern expressed that rules and regulations in Guidelines could impose a medico-
legal concern. 
 
7.4.4.12 Culture 
One participant noted that the culture and systems in Australia are different from those experienced 
overseas, describing Australia as being a country with a great ‘listening ear for the individual 
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opinion’. In other countries the surgeons were described collectively as ‘more of a public work 
force where the individual opinion was probably less listened to than here – here, each consultant 
is more an individual with his or her needs or interests’. In other countries ‘there were no questions 
about it’, you do what the guidelines recommend; ‘but here, you can see all [degrees of] variance’. 
 
7.4.4.13 Complications 
Both VTE and bleeding complications were cited by surgeons and GPs as major factors that have 
influenced their practice. In a few instances either personal or anecdotal experience of increased 
wound ooze and bleeding with anticoagulant use was enough to deter surgeons from prescribing 
them. A GP said her opinion and practice changed after one of her patients was left a paraplegic 
following a postoperative spinal bleed; however, she described later on in the interview feeling ‘a 
bit conflicted at the moment’ about what to do with thromboprophylaxis following surgery. When 
asked what had changed in her opinion and practice she described taking greater initiative in 
liaising with the surgeon and anaesthetist, in addition to changes she had made to her prescribing 
which expressly oppose all current recommendations for warfarin (re-)initiation. 
And perhaps I’m a bit slower in getting the warfarin back on. So I give them a little bit longer so 
they actually, probably when they get home, I don’t, I don’t continue them on the clexane 
[LMWH], I just, unless they’ve got a really good reason. … what I have done is I don’t continue the 
clexane [LMWH], I just start the warfarin slowly and build it up. Rather than put them on the 
clexane [LMWH]. …before then I was continuing the clexane [LMWH] until they reached the 
therapeutic INR. GP2 
Conversely, a surgeon spoke of being ‘pretty much a doubter’ when it came to 
thromboprophylaxis, until one of his patients experienced a fatal VTE.  
You know, I’ve had one patient many, many, many, MANY years ago die of a [PE], after a hip 
replacement. I was actually on the ward at the time. It was two days after, I remember that. I 
operated on Thursday and it happened on Saturday morning. I was doing a ward round. I 
couldn’t believe it. I’d just seen her, and she looked fantastic. And then a little bit later you know, 
they were calling the code blue and um, and um, I walked around and then, all these intensive 
care people trying to resuscitate her. It was dreadful. S10 
When asked how this experience had affected his prescribing, the participant spoke of it being 
a trigger to become more concerned about VTE prophylaxis, and becoming ‘involved with it for a 
while’. Interestingly he noted that his subsequent involvement with thromboprophylaxis guidelines 
had led him to become ‘totally convinced’ of the ‘benefit of extended prophylaxis’, and ‘a firm 
believer’ that the benefits of using ‘mechanical prophylaxis is additive to that’. 
In order for VTE complications to influence practice, however, operating surgeons must be 
aware of their (and their colleagues’) complication rate. Interestingly, surgeons said that even 
though they ‘like to think’ they are well informed of all postoperative complications, there’s 
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‘probably quite a few that slip under the radar’; which means they ‘don’t see a huge number [of 
VTE] in practice’. 
You know, I think the patients would tell me [about a DVT or PE out of hospital]. And I don’t hear 
about it. S1 
Now I don’t see a lot of the DVTs, PEs. I know quite a few are managed by GPs and physicians 
[which] we don’t find out about it [sic]. S5 
And often, I shouldn’t say often because it doesn’t happen very often. But not infrequently if a 
patient does present with a symptomatic DVT or a PE, there is actually no notification given to 
the operating surgeon, or even the operating team. So in other words, we will occasionally find 
out via the grapevine, or at a 6 week check when our patient comes back in that they’re on 
warfarin for a PE. S3 
 
7.4.5 A Statewide Guideline 
In recent years the creation of a statewide thromboprophylaxis guideline for Tasmania has been 
proposed. There was a mixed response to this topic in the Tasmanian interviews with some 
participants feeling that it’s not ‘going to add a lot more – really there’s recommendations from a 
lot of very well qualified committees already’, and others conceding that such a guideline ‘is fine’ 
so long as surgeons are able to ‘taper the treatment protocol to the individual’, or you’re ‘kind of 
leaving yourselves open a bit to, you know, people saying get stuffed!’. One participant spoke of 
the push for a statewide guideline as ‘typical DHHS’ behaviour, wanting something that ‘would be 
seen as the due standard of care’ and that any surgeon that deviated from it ‘would have to explain 
why’ (NB: DHHS = Department of Health and Human Services). He described the statewide 
proposal as ‘a push for a policy’, but that it was not ‘a push from the orthopaedic surgeons 
themselves’. He went on to comment that ‘it would have no formal impact on private surgeons’ 
approaches’.  
Having said that, I know myself and other surgeons would probably read it once, ignore most of 
it, and if there was seen to be any support for our own practice or own preference, it would be 
quoted as that. … So again, it’s one of those things where you’d take what you want out of it. And 
ignore the rest. S3 
There were two participants who specifically commented that they felt orthopaedic surgeons 
must be part of the development committee of such a statewide guideline, as they are the ‘people 
who are on the ground, working that space’, whereas ‘a lot of the time the panel will be you know, 
physicians, and, and pharmacists, and people who are not at the coalface so to speak’.  
GPs on the whole spoke positively about a statewide guideline, noting that it protects both the 
patient and the doctor, but that they must have a ‘tier of assessment’ incorporated into them, rather 
than being ‘just a one size fits all’. 
I think the sticky thing is they probably won’t all agree. I think that maybe it may be better to say 
well look this is it, if you have any specific variations that you’d like to follow through, then you 
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can make those sort of slight changes and sort of indicate on the sheet that that’s your amended 
preferred protocol. So that covers the people that feel very strongly about something. GP1 
 
7.4.6 Novel Oral Agents 
Uptake of NOA was mixed and surgeons spoke of many reasons why, including: lack of 
knowledge about the new agent(s), concern and hesitation to start using a medication with little 
post-marketing surveillance data, and finally bleeding concerns arising from study data as well as 
personal and collective experience. 
Um and then I guess it’s a little bit of you know, fear of the unknown. …there is obviously quite a 
bit of information about it [rivaroxaban]. And uh, you know quite a few studies, but obviously 
nowhere near the experience that we’ve had with uh, you know the sort of more standard ones. 
And uh, so people are still a little bit anxious about uh, how it’s going to work out. S8 
I think that [if] possible, it [rivaroxaban] needs some real-world use before I’m comfortable to 
use it. S4 
When I was there 6, 7, 8 years ago, there was an introduction of an oral anticoagulant that went 
through the system and started to be used, and it was drawn back due to liver affections [sic]. So 
a bit of conservatism. S7 
I was using it [rivaroxaban] and I had a couple of patients that bled, so I’ve stopped using it. S5 
I’ve heard anecdotally that there’s increased risk of bleeding [with rivaroxaban]. S6 
Interestingly three participants said government authority requirements put them off 
prescribing the new agents, describing the process of getting approval as ‘a real nuisance’, ‘a real 
pain’ and ‘a deterrent’ to using the new agents. Lastly, one participant commented that changing 
his practice to prescribe one of the new agents would mean changing the written documentation he 
gives to patients, and so it is ‘partly apathy’ why he doesn’t trial them. Feeling apathetic was not 
limited to prescribing new agents or to this one participant: although many surgeons operate at the 
hospital this participant works at, he said between them ‘they probably wouldn’t do one ward 
round a fortnight’. 
Lastly, surgeons were resistant to change because they felt generally content with current 
thromboprophylaxis options. 
And also, sort of, to my knowledge, there hasn’t been any real, sort of, problems to the clexane 
regime that we have. S7 
I guess we’re all a bit conservative in, in that regard and you know, if something’s working ok 
with what we’re doing it’s sort of, hard to change. ... So you need, you need a good reason to 
change I guess to, to take, take a, take a small risk that you know, the new thing is not going to 
be as good as it’s cracked up to be. S8 
Interestingly, one of the GPs stated that one of the big benefits of warfarin therapy is that the 
regular blood tests involves ‘monitoring this higher risk group a bit more closely’, and that ‘other 
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things crop up’ during the reviews. Nevertheless, it was noted by a surgeon that the new oral 
agents ‘would make life a lot easier’, so long as ‘the benefit is higher than the risk’. 
      
7.4.7 Aspirin 
As noted in 7.4.4 Factors that Influenced Prescribing Patterns, participants were divided into two 
camps when it came to prescribing anticoagulants. When discussing aspirin use for VTE 
prophylaxis, surgeons were equally divided. Comments against aspirin use included ‘that it’s not 
appropriate’, that not all surgeons were ‘convinced the science is good enough to support its use’, 
that it has ‘dubious literature support’, is ‘less effective’ than the mechanical options on their own, 
and that ‘it seems to be a case of doing something to be seen to be doing something’. One 
participant who stated that aspirin is not appropriate conceded that aspirin might be somewhat 
effective in preventing VTE. 
My background is that aspirin is good for the arterial side of the, the vascular tree, and, and uh, 
not much to do with clots. On the other hand it’s a circle isn’t it, so if you affect one end of it you 
might have an effect on the other end. S7 
Conversely, participants who used aspirin commented that aspirin has good evidence to 
support it, citing ‘equally low rates of DVTs’, and frequently made reference to bleeding 
complications associated with anticoagulants. These participants also cited lower all-cause 
mortality in patients prescribed aspirin compared to other agents, with one surgeon stating that he 
is not using aspirin ‘just to be seen to be doing something’.  
As noted in 7.4.3 Prescribing Patterns, some participants made use of both anticoagulants and 
antiplatelets; typically anticoagulant cover in hospital and aspirin on discharge. Two of these 
participants said they prescribed aspirin after discharge because ‘patients don’t like giving 
themselves injections’, with one conceding he would prescribe an oral anticoagulant (such as 
rivaroxaban) at discharge if he was convinced it would not cause more bleeding than his current 
inpatient preference, LMWH. 
GPs were also divided on the efficacy of aspirin to prevent VTE. Some felt that it had no 
significant role to play while others felt it was better than nothing; or that it is an effective agent in 
patients who are mobile, but not those who are bedbound and have other comorbidities. One GP 
said that he did not use aspirin very often as ‘it’s not that effective, and also it’s got the risks of 
gastric irritation’.   
 
7.4.8 Bleeding and Infections 
Concern was expressed by all participants regarding the potential of anticoagulants to cause 
excessive bleeding. 
By definition it’s an anticoagulant, so uh, um, you know it’s got a good effect in that it decreases 
the risk of clotting where we don’t want it. But it also decreases the clotting where we do want 
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the clot. So you’ve gotta find that balance between not over anticoagulating versus you know 
having some effect and reducing the uh risk of venous thrombosis. S8 
Notably blood loss was not in itself the main concern for most participants, but rather its 
perceived propensity to cultivate infections which were described as being ‘disastrous’ by two 
surgeons and ‘an absolute nightmare’ by a third. A fourth told his patients that if they have an 
infected joint replacement ‘they’ve lost a year of any productive time.’ Another participant spoke 
of blood as an ‘irritating thing in the tissues’ that increased swelling and pain for the patient. 
Uh, infection is another, very potentially serious complication … if patients do get a haematoma, 
uh you know wound haematoma, then that definitely increase the risk of  infection because 
haematomas are like the perfect blood clot, culture medium for bacteria. Uh and even with a 
discharging wound, you know if from a haematoma, the stuff that’s trickling out you know that’s 
sort of keeping the wound open, so the bugs on the surface can sort of sneak in and infect the 
whole thing. S8 
In this context, it was acknowledged by only one participant that medications are simply one 
factor that increases bleeding risk postoperatively. Other factors identified include: how big and 
long the operation is; the surgeon’s skill; the invasiveness of the approach made; patient risk 
factors; and anything that happens perioperatively that may inadvertently increase bleeding. This 
same surgeon also noted that there are many factors that affect infection risk including patient 
factors (e.g. ability to fight infection), perioperative factors (e.g. skill of surgeon, sterile techniques 
of surgeon and scrub nurse, theatre sterility and filtration flow) and postoperative factors (e.g. 
patient nutrition and wound care).  
 
7.4.9 Mechanical Thromboprophylaxis 
Most participants commented on the importance of mechanical thromboprophylaxis in clot 
prevention, one stating he thought ‘everyone should be on it’. However these positive comments 
were almost completely reserved for IPCD, and not GCS. Many participants (surgeons and GPs) 
commented that GCS were not effective, and/or were not tolerated very well by patients. A junior 
doctor added that he’d had patients slip and fall because of them; a fall can be potentially 
disastrous for any patient. 
I receive phone calls occasionally from patients saying ‘look how long do I have to keep these 
things going. I find them difficult to put on, or they annoy me, or they’re hot.’ And I say ‘forget 
about them, don’t worry about them’. S2 
…of course the big problem’s getting them [GCS] on, getting them off; or getting someone to help 
them take them off.  So that’s uh, that’s the problem with it. GP1 
They’re hard to put on. Especially in that age group. You know because they’re elderly and 
they’ve already got osteoarthritis. GP2 
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Some patients hate them [GCS], some don’t find them too difficult. It depends a lot on how frail 
they are and how much problem [sic] they have putting them on or off. Whether they have 
someone in the house who can help them. There’s a whole lot of issues. GP3 
Two participants said they used GCS ‘for swelling control if there’s a problem, rather than 
prophylaxis’. Another participant noted he used mechanical thromboprophylaxis ‘more so because 
of hospital expectations and hospital policy’, and that he is ‘recently questioning it’. 
Stockings I think are a waste of .. not a waste of time, but I think they’re probably more problem 
than what you get from them. Whenever you use things you’ve gotta weigh up the risks versus 
the benefits. And I think the problem with stockings is that they are hard to get on and off. They 
tend to roll down and act as a tourniquet. S6 
One surgeon who did speak positively about GCS (referred to in the interview as 
thromboembolic deterrent stockings or TEDs) expressed frustration that they were not always 
provided in a timely fashion to his patients. 
Most of my patients who I’ve asked for longer length TED stockings didn’t seem to have them two 
or three days later because they’ve had to be ordered from stores or that sort of thing. So I’ve 
almost given up on, on specifically prescribing TED stockings because it didn’t matter what I 
wrote, or what I prescribed, even if 24 hours later I ask ‘where is the patient’s TED stockings?’ I 
was told “oh we’re on to it”. And the next day they still wouldn’t be fitted. So by day three or day 
four I’m .. it’s just not worth it. S3 
This same participant was the only one to mention any negative effects to using IPCD 
(referred to by the surgeon sequential compression devices or SCD). 
But SCDs themselves have their own risks. I’ve recently had a nerve injury occur possibly as a 
result of the tubing on an SCD. So at what benefit in terms of DVT risk reduction or more 
importantly symptomatic DVT / PE risk reduction, at what cost do I then have complications 
with the device? S3 
 
7.4.10 Care Flow from Hospital to Community 
Although many surgeons described the care flow from hospital as being ‘reasonable’ or ‘generally 
very good’, GPs did not agree. They described it as being ‘variable’ with waiting periods of up to 
three years between the first referral and actual surgery, during which time many patient factors 
can change. GPs also said they were often unaware their patient had undergone surgery until the 
patient came in a week or so later. 
Usually the patient is the one who fronts up and says I’ve had this done, and it’s like you’re 
working backwards sort of thing. And often, often it’s the patient that’s giving you the 
information as to what happened to them, and you have to then go chase up and find out if that’s 
really the case. GP2 
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Occasionally you might get a phone call saying ‘Can you do this?’ but just the quality of the 
process is, is, mostly abysmal. Occasionally we get something that’s done well, but very 
occasionally and I think our expectations of the Royal are very low. GP1 
When a patient is discharged from hospital, a discharge summary is sent to GPs to update 
them on a patient’s wellbeing and discharge plan. GPs stated that discharge summaries took 
anywhere between 5 days to 6 months (if ever) to arrive.  
And it’s just, it just seems very primitive – seems like the Napoleonic era. Of course they didn’t 
have faxes then, but they had fast horses. Maybe not much difference. GP5 
Sometimes the patient arrives back before the discharge summary is received. Sometimes you 
just have summaries that are illegible. … I think it really depends on the individual resident or 
intern and whether they get around to doing discharges in a timely fashion. GP3 
In addition to this delay in receiving discharge summaries, GPs expressed dissatisfaction with 
their quality, describing them as being ‘written squashed’ and containing ‘limited information’ that 
‘50% of the time I can’t read’; and that while ‘some of them are not bad, others are just a complete 
waste of time’.  
Oh I had one recently where we had to keep calling them and telling them to redo it because it 
was hieroglyphics. I mean, you couldn’t see it at all! GP2 
On the one hand, discharge summaries from the Royal are usually inadequate, indecipherable, 
and you know, pretty useless; and there are medico-legal aspects – they’re horrendous! … GP1 
One participant described the care flow from hospital to community being better in the private 
sector, but others did not notice any difference. When asked what areas could be improved, GPs 
stated that a ‘good type written legible summary’ with ‘good clear written instructions’ and ‘a 
phone call from the discharging residents’ would be ‘ideal’ so that there is ‘open communication 
with the hospital’. One GP noted that in general practice, they’re ‘responsible for that patients care 
from then on, and if a therapy is started in hospital, we’re committed to keeping that therapy’; 
however, the decision to institute therapy is often made without taking into account the GP’s 
experience and long working knowledge of the patient.  
Because it seems to be that we look after patients in general practice and then they go into this 
hospital - which is a bit like a spare parts body shop - and things happen to them, and they come 
back. It would be great if this system was more integrated. I mean, I know there’s a move for 
patients to be discharged postoperatively a lot earlier for surgical conditions. And I think the 
success of that would really depend on an integrated community approach rather than just 
someone being sent out. … general practice is not just a nebulous world, but we have a lot to 
offer, a lot of tacit knowledge that they can benefit from, and basically the patient [can benefit]. 
GP4 
Following surgery two GPs said that they like to make goals with their patients to help them 
get back to their previous level of function (so long as it is realistic), and to instigate services that 
are necessary for the patient to achieve their best quality of life ‘self-caring’. One of these 
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participants noted however that it is ‘often too late by the time I see them – they might come in 
three or four weeks after they’ve been discharged’. 
All of the GPs said they were not privy to surgeons’ postoperative care plans or preferences 
(including thromboprophylaxis). One GP described sometimes looking ‘like a bit of a fool’ when 
patients fronted up after a surgery with questions about the postoperative plan. Another GP 
expressed adamantly that it is ‘important that we know when the patients are going in’. She 
suggested that one strategy to keep the GP involved would be for them to start the pre-anaesthetic 
paperwork in primary care; this way they could also update surgeons on any changes since their 
original referral letter. 
While GPs on the whole stated that they were not familiar with thromboprophylaxis 
guidelines, they all agreed that being provided information and postoperative management advice 
by specialists ‘would be very helpful’.  
We just need clear, concise, accurate, straightforward, you know, information. I’m quite sure that 
one could deliver most of that on, on a single sheet, that’s succinct and relevant, it doesn’t need to 
have a load of junk attached to it. GP1 
Another GP said guidelines imbued her with the ‘confidence’ to speak to patients about their 
options so that they can make an ‘informed decision’, because ‘ultimately it is the patient’s 
decision’.  
 
 
7.5 Discussion 
Significantly, all of the participants in this study agreed that the provision of thromboprophylaxis 
to arthroplasty patients is ultimately the operating surgeon’s decision. Although all participating 
surgeons reported routinely prescribing thromboprophylaxis postoperatively, they differed 
significantly in their prescribing preferences. Many interrelated factors influenced these 
preferences; however, none more so than a surgeon’s opinion: those who believed strongly in 
aspirin’s safety and ability to prevent VTE were more likely to prefer it, and the same was true of 
anticoagulants.  
Interestingly, a surgeon’s opinion was greatly shaped by their training and collective 
experience, and not by contemporary guidelines. Surgeons described regularly debating 
postoperative thromboprophylaxis requirements amongst themselves, and subsequently, they were 
often aware of their colleagues’ prescribing preferences and associated complication rates. This 
knowledge influenced participants’ opinions about different pharmacological agents and hence, 
also ultimately influenced their prescribing preference.  
Notably, not all postoperative complications had the same bearing on practice; both the 
severity and the type of complication affected its degree of influence. For example, serious isolated 
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incidents such as the spinal bleed and fatal PE incidents significantly impacted participants’ 
anticoagulant use thereafter. However, of the more commonly occurring less devastating 
postoperative complications (DVTs & bleeding/wound ooze), only postoperative bleeding 
complications and infections were found to influence prescribing. This may be because DVTs were 
often described as being an accepted complication of surgery – ‘if I look hard enough I will find a 
clot in every one of my knee replacements and every one of my hip replacement patients’ – 
whereas bleeding complications (and consequently infections) were generally perceived to be 
preventable complications, predominantly associated with anticoagulant use rather than the surgery 
itself. Remarkably, participants described bleeding and infection complications as disastrous and 
nightmarish; however, no such adjectives were used to describe the consequences of non-fatal 
postoperative VTE.  
Despite the potential for postoperative complications to play a role in shaping surgeons’ 
prescribing, the surgeons in this study acknowledged that they were probably unaware of the true 
incidence of these complications in their patients. This is a classic example wherein a practice gap 
reflects a system issue and not solely provider performance.
178 
The sentiment expressed by multiple surgeons that you can find literature to support any 
argument was particularly noteworthy, and indicates that study data does not influence a surgeon’s 
opinion on the safety and efficacy of pharmacological agents to the same extent that personal real-
life experiences do. In particular, studies that use asymptomatic VTE reduction as a marker for 
symptomatic VTE reduction were described as having little (if any) clinical relevance. 
Interestingly, participants in the study outlined in Chapter 6 described the inclusion of this type of 
data in the NHMRC Guideline as being one reason why the Guideline was deemed inappropriate: 
‘The guidelines are based on inappropriate surrogates for thromboembolism which significantly 
detracts from their scientific validity.’  
‘End points of research do NOT include fatal PE or post thrombotic syndrome, so relevance is 
questionable.’ 
Furthermore, surgeons in this study described industry sponsorship of a study as a factor that 
immediately biased them against accepting the study’s findings as true. Similar sentiments were 
also described by surgeons who completed the survey outlined in Chapter 6.
206
 
Although surgeons differed in their thromboprophylaxis preferences, they all agreed on the 
importance of tailoring their decision to the individual patient. Some patient factors encouraged 
certain prescribing behaviours (positive factors); while others discouraged them (negative factors). 
For example, similar to the findings presented in Chapter 6, anticoagulant use was positively 
influenced by a previous history of VTE, and negatively impacted by a previous history of 
bleeding and, to some extent, advanced age. Heavy perioperative bleeding negatively impacted 
some surgeons’ thromboprophylaxis use postoperatively; however, others regarded it as an 
accepted surgical risk that is routinely remedied with blood replacement. Ensuring patient 
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satisfaction and compliance were described as factors that positively influenced some surgeons’ 
antiplatelet use; however, whether this was a factor that influenced their practice, or was a means 
of justifying their practice is uncertain.   
In addition to the patient factors listed above, the presence of unit protocols positively 
influenced prescribing of anticoagulants; this is particularly noteworthy when reflecting on the 
findings of Chapter 5. However, the sphere of a protocol’s impact was generally limited to the 
hospital in which the protocol existed. This indicates that surgeons generally favour prescribing 
autonomously, a practice that was described as being particularly encouraged by the working 
environment and culture in Australia. It is possible however that this may change in the coming 
years as surgeons’ professional autonomy is increasingly impacted negatively by the expansion of 
legal regulation in Australia.
141
 
Unlike the findings reported by Molnar et al, medico-legal concerns were not found to be a 
dominating influence for participants.
121
 This may be because medico-legal exposure in Tasmania 
‘is not as bad’ as it is in other states and territories, and the bulk of surgeons who participated in 
Molnar et al’s study were from other states and territories.  
Four barriers reported by Duff et al in the uptake of thromboprophylaxis guidelines were a 
lack of motivation to change, a lack of systems support, disputed evidence and a knowledge or 
awareness deficit; elements of these were also identified in this study.
177
 For example, although all 
surgeons expressed familiarity with at least one contemporary guideline, GPs generally did not. 
This lack of knowledge and familiarity naturally impairs their ability to contribute to postoperative 
care, even though they are ideally positioned to play a prominent role in preventing VTE after 
discharge. That GPs have chosen to step back (consciously or unconsciously) and defer to 
directives from hospital staff is of concern, as the communication between the hospital and 
community was frequently described as being poor and slow. Such communication delays would 
inevitably impact negatively on the speed and ability of GPs to provide primary care post-
discharge, and in the end leaves the patient at a significant disadvantage. 
A quick ready-reference protocol could assist greatly in overcoming both communication and 
knowledge obstacles. Rather than awaiting the formulation of a Tasmanian based protocol, another 
option would be to instigate a statewide strategy to increase the uptake of the NHMRC Guideline. 
One of the biggest barriers identified in this study (and the study outlined in Chapter 6) to the 
adoption of guidelines such as the NHMRC Guideline is the perception that they impose a ‘one 
size fits all’ approach to thromboprophylaxis by making ‘carte blanche recommendations’. In 
reality, the NHMRC Guideline takes a comprehensive approach to VTE prophylaxis and 
unbeknown to most of the participants in this study, actually addresses the many concerns they 
expressed in the interviews: 
‘The Committee acknowledges the continuing debate on the clinical relevance of asymptomatic 
distal DVT as an indicator of the efficacy of VTE prophylaxis. Some experts have argued that 
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guideline committees should consider evidence relating only to symptomatic VTE or to 
symptomatic PE. This Committee’s decision to consider all thrombosis or embolism events as 
relevant outcomes was based on the fact that VTE encompasses a spectrum of disease, from 
asymptomatic distal DVT to fatal PE, and that most events are initially asymptomatic. 
Notwithstanding this, data on symptomatic DVT and PE were weighted more highly in the 
Committee’s decision making process, and no recommendations were based on asymptomatic 
outcomes alone. 
…The risk of VTE in hospitalised patients must be balanced against the actual and perceived 
risks of pharmacological thromboprophylaxis and patients’ tolerance of pharmacological 
(especially injectable) or mechanical prophylaxis.  
... By nature of its mechanism of action, pharmacological prophylaxis may increase the risk of 
surgical bleeding.  
…As the evidence presented throughout this Guideline is mostly from randomised controlled 
trials, this may not be an accurate reflection of the incidence of bleeding outside the controlled 
trial context. .. An assessment of bleeding risk is an essential step in deciding on appropriate 
thromboprophylaxis for individual patients. 
…In particular, surgeons may be understandably reluctant to expose patients to the risk of 
excessive intra- or post-operative bleeding and the subsequent complications, especially in 
procedures such as joint replacement where bleeding can lead to severe infections and a need to 
explant prostheses. 
…It is essential to perform and record a VTE risk assessment in each patient before deciding 
whether or not to use preventive measures and on the most appropriate measures to use. .. The 
final decision to provide thromboprophylaxis is a clinical decision based on number and type of 
risk factors balanced against risk of bleeding. 
… The recommendations are intended to encapsulate the available evidence on the prevention of 
VTE. However, they should only be followed subject to the judgement of clinicians caring for 
individual patients and patients’ own preferences. 
… Patient compliance is an important consideration in choice of thromboprophylactic agent. It is 
advised that this decision about the most appropriate type of thromboprophylaxis is made in 
consultation with the patient to increase acceptability and improve compliance.17 
Significantly, only one participant was aware that the NHMRC Guideline presents data on 
both the benefits and harms of different prophylaxis options, or that it provides a step-by-step tool 
to assist doctors in making thromboprophylaxis a clinical decision that is individualised to each 
patient. This may be because the NHMRC Guideline is a multidisciplinary guideline which 
includes thromboprophylaxis recommendations for eighteen patient groups over the span of 160 
pages. Most doctors do not have the time (or desire) to read such a large document in its entirety 
and will understandably move straight to skimming the one or two pages they deem relevant to 
their specialty. Potentially producing a separate one or two page summary document for surgeons 
that expresses all of the relevant points above, coupled with the Guideline’s recommendations, 
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may result in greater acceptance and adoption of the national guideline (see Appendix E for an 
example). 
Many of the health professionals interviewed in this project were practising in Tasmania, 
which in itself has an interesting reality. It is an island state with a relatively small population. 
Being an island, ‘you have a bit of an island mentality that we should cover for our little island’. 
With only three public hospitals in the state that offer major orthopaedic surgery, and only eighteen 
orthopaedic surgeons practising in the state, there is potential for implementing statewide changes 
relatively easily.  
In Tasmania we have the chance to do things really well. We’re small enough, we can get on - we 
can do things; whereas in larger populations it can be a bit more difficult. But that depends on 
leaderships [sic], and depends on having standards. And relies on people doing things well. GP1 
A simple education strategy to inform relevant health professionals of the content and 
evidence base of the NHMRC Guideline and a strategy to improve two-way communication 
between hospital and community spheres (both to improve GP knowledge of each individual’s 
postoperative surgical care plan and to improve surgeons’ awareness of their postoperative 
complication rate) are two simple methods that could go a long way in reducing practice gaps in 
Tasmania; both should be relatively easy to implement in our island state.  
Although there are many health professionals involved in the care of a patient from admission 
to discharge, the decision to prescribe thromboprophylaxis is ultimately the operating surgeon’s to 
make. There were many factors that influenced surgeons’ perception regarding the efficacy and 
safety of thromboprophylaxis agents, and therefore their prescribing preferences. Any strategies to 
optimise and streamline prescribing must address their concerns, or else the strategies risk 
complete failure. 
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 THE NEW ACCP GUIDELINE 
 
 
 
Introduction 
The retrospective review discussed in Chapter 3 was undertaken in 2010, reviewing data from 
2007 to 2009. After comparing local prescribing practices with the 7
th
 edition of the ACCP 
Guideline it was determined that only 5.0% of patients (8.0% of hips, 1.0% of knees) received 
recommended courses of thromboprophylaxis, predominantly due to a reluctance to prescribe 
anticoagulants following discharge. The audit of several hospitals in Australia (Chapter 4) 
indicated prescribing was considerably different to guideline recommendations. These findings 
suggested that there was a nationwide guideline-practice gap.  
The studies outlined in Chapters 5, 6 and 7 identified many barriers to guideline adoption and 
thromboprophylaxis use; in particular, concerns over both bleeding complications, and the threat of 
guidelines being too prescriptive. Furthermore, 80.0% of surgeons who completed the survey in 
Chapter 6 were dissatisfied with the NHMRC Guideline because it does not include aspirin as a 
means of sole prophylaxis, recommends an apparently excessive long duration of prophylaxis and 
was perceived to rely heavily on pharmacological prophylaxis (which again was associated with 
surgeons’ bleeding concerns). Significantly, the biggest reason why surgeons felt the Guideline 
was inappropriate was that they believed it was based on an inappropriate evidence base (Table 
25). As the NHMRC recommendations are similar to the previous ACCP guidelines (Table 26), the 
findings of the study outlined in Chapter 6 could be extrapolated to indicate that the 7
th
 and 8
th
 
edition ACCP guidelines were also deemed inappropriate. This is likely why prescribing differed 
considerably when compared to the ACCP 7
th
 and 8
th
 edition guidelines in Chapter 3. 
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Table 26. Comparing the NHMRC and ACCP guidelines. 
Recommended agents are highlighted in blue with gradings noted where applicable (e.g. A, 1B, see Appendix A). 
 Agent ACCP 7
th
 Ed.
108
 ACCP 8
th
 Ed.
164
 NHMRC
17
 
H
ip
 A
rt
h
ro
p
la
st
y 
Aspirin    
Dabigatran   B 
Fondaparinux 1A 1A B 
LMWH 1A 1A A 
Rivaroxaban   B 
VKA 1A 1A  
Duration Min. 10 days, up to 35 
days 
Min. 10 days, up to 35 
days 
Up to 35 days 
Mechanical   GCS, IPCD, or VFP, until fully mobile 
K
n
e
e
 A
rt
h
ro
p
la
st
y 
Aspirin    
Dabigatran   B 
Fondaparinux 1A 1A B 
LMWH 1A 1A A 
Rivaroxaban   B 
VKA 1A 1A / 
Duration Min. 10 days Min. 10 days, up to 35 
days 
Up to 14 days 
Mechanical OR IPCD (1A) OR IPCD (1A) GCS, IPCD, or VFP, until fully mobile 
NB:  = recommendation against agent use; /= only recommended under special conditions. 
See Appendix A for more details on recommendation gradings. 
      
In January 2012 the ACCP released the ninth edition of their thromboprophylaxis guideline.
68
 
Unlike previous editions, each section of the Guideline was written by clinicians expert in 
methodology and interpretation of the evidence, rather than by world experts in the field of 
thromboprophylaxis.
207
 Furthermore, in contrast to previous editions, the new Guideline 
acknowledges the limitations of using asymptomatic DVT as a surrogate outcome, and 
incorporates strategies to estimate reductions in symptomatic DVT and PE with 
thromboprophylaxis.
207 
This has resulted in significant changes to the thromboprophylaxis 
recommendations (Table 27). 
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Table 27. Changes in ACCP Guideline. 
 ACCP 8
th
 Edition
164
 ACCP 9
th
 Edition
68
 
Topic Recommendation Grading Recommendation Grading 
Aspirin as a sole agent  1A  1B 
Mechanical 
prophylaxis as sole 
prophylaxis 
 1A  1C 
Duration of 
prophylaxis for hip 
patients 
10 – 35 days 1A 10 – 35 days 2B 
NB:  = recommendation against;  = recommendation for. 
Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh risks, burden, and costs. 
Grade 2 suggestions imply the individual patient values may lead to different choices. See Appendix A for more details 
To identify how surgeons’ prescribing compared to current recommendations, the original 
retrospective data presented in Chapters 3 and 4 were reanalysed against the new recommendations 
(Chapter 8). To determine if the changes to the recommendations were generally agreeable to the 
orthopaedic community a second online survey of surgeons was conducted (Chapter 9). 
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 CHAPTER EIGHT: GUIDELINE PRACTICE REANALYSIS 
 
 
 
8.1 Aim 
To compare the prescribing presented data in Chapters 3 and 4 with the ACCP 9
th
 Ed. Guideline.  
 
8.2 Methods 
The data pertaining to pharmacological thromboprophylaxis prescribing presented in Chapters 3 
and 4 were revisited and the findings compared to the ACCP 9
th
 Ed. Guideline. 
 
8.3 Results 
8.3.1 RHH Retrospective Data (from Chapter 3) 
In total, 39.8% of knee arthroplasty patients and 22.3% of hip arthroplasty patients who underwent 
a hip and/or knee arthroplasty between June 2007 to 2009 received thromboprophylaxis consistent 
with the new ACCP recommendations (Figure 25). This equates to 31.5% overall. 
 
 
Figure 25. Comparison of RHH prescribing practices with the ACCP 9
th
 Ed. Guideline (N=216) 
   Appropriate agent only                Appropriate agent and dose only                           Appropriate agent, dose and 
durations 
NB: Excludes patients prescribed therapeutic anticoagulation for pre-existing medical conditions, and patients who 
experienced a bleed or VTE during their inpatient admission. 
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8.3.2 Collaborative Hospital Data (from Chapter 4) 
In total, 75.0% of knee arthroplasty patients and 72.7% of hip arthroplasty patients received 
thromboprophylaxis consistent with the new ACCP recommendations (Figure 26). This equates to 
73.8% overall. This did not significantly change when the appropriateness of doses prescribed was 
not included in the analysis (Figure 27).  
 
 
Figure 26. Comparison of multicentre prescribing practices with the ACCP 9
th
 Ed. Guideline (N=65). 
   Appropriate agent only                Appropriate agent and dose only                           Appropriate agent, dose and 
duration 
NB: Excludes patients prescribed therapeutic anticoagulation for pre-existing medical conditions, and patients who 
experienced a postoperative complication during their inpatient admission. 
 
 
Figure 27. Comparison of multicentre prescribing practices with the ACCP 9
th
 Ed. Guideline (N=100). 
           Appropriate agent only                                          Appropriate agent, dose and duration 
NB: Excludes patients prescribed therapeutic anticoagulation for pre-existing medical conditions, and patients who 
experienced a postoperative complication during their inpatient admission. 
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8.4 Discussion 
The findings in this short reanalysis reveal a significantly greater compatibility between practice 
and the new ACCP Guideline. Whereas previously only 5.1% of patients on average undergoing a 
hip or knee arthroplasty at the RHH were prescribed complete courses of thromboprophylaxis 
according to the ACCP 7
th
 Ed. Guideline, almost 32% were prescribed complete courses according 
to the ACCP 9
th
 Ed. Guideline. Similarly, whereas only 53.8% of patients at the six hospitals 
surveyed in 2011 were prescribed NHMRC recommended thromboprophylaxis, 73.8% were 
prescribed thromboprophylaxis as recommended in the ACCP 9
th
 Ed. Guideline. In both cases, the 
decrease in the guideline-practice gap was predominantly due to the adoption of aspirin as an 
appropriate option for pharmacological thromboprophylaxis in the ACCP 9
th
 Ed. Guideline. 
This reanalysis suggests prescribing patterns in previous years were generally more aligned 
with contemporary recommendations than recommendations existent at the time of prescribing; i.e. 
that practice preceded guidelines. This occurrence is likely due to a combination of factors; 
however two interconnected ones stand prominent. The methodology used to produce the ACCP 
9
th
 Ed. Guideline was reported to be more rigorous than previous editions, resulting in a guideline 
that is less based on opinion, and more on research data.
207
 Clear noncontroversial and evidence 
based recommendations are more likely to be employed than guidelines with recommendations that 
are unclear, controversial, or are based on opinion.
20
 This change in methodology may in part 
explain the increase in compatibility between practice and the updated ACCP Guideline.  
Turner et al report that although there has been a significant rise in the number of CPG produced 
worldwide, few of these CPG meet quality criteria; ‘the link between research and 
recommendations is an area of particular weakness’.20 Guideline production is a lengthy and often 
time-consuming process, thereby negatively impacting on the ability of a professional body to 
make recommendations based on the most up to date evidence. This limitation is likely to be 
augmented for professional bodies such as the NHMRC and ACCP, as they produce multi-
disciplinary guidelines. As noted in Chapter 7, surgeons review and discuss the latest research 
amongst themselves. They are able to implement changes immediately, and this may be why the 
results of this reanalysis suggest that practice preceded the guidelines. This limitation in guideline 
formulation must be addressed in order to prevent guidelines lagging behind the evidence.  
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 CHAPTER NINE: SURGEONS AND THE ACCP 9TH ED. GUIDELINE 
 
 
 
9.1 Introduction 
The data reanalysis outlined in Chapter 8 determined surgeons had been prescribing more in line 
with the ACCP 9
th
 Ed. Guideline than the ACCP 7
th
 Ed. Guideline for up to four years prior to its’ 
release. This suggested that the changes made to the Guideline were agreeable to surgeons in 
Australia. A second national survey of surgeons was conducted in order to explore surgeons’ 
opinions of the AACP 9
th
 Ed. Guideline to determine if this was the case, and to identify if there 
had been any change in surgeons’ opinions since the previous survey conducted two years earlier.  
The previous survey (outlined in Chapter 6) had been targeted at ASA members and had 
resulted in a small survey sample group. In an attempt to increase absolute numbers, and thus 
reliability and generalisability of the study findings, this survey was sent to all hip and knee 
orthopaedic surgeons identified in Australia (see 9.3 Methods for details). This different survey 
pool also allowed for comparison between ASA members and non-members to determine if there 
was any inherent difference in their opinions and preferences; and to determine if ASA 
membership had any influence on guideline familiarity and acceptability. Lastly, the larger sample 
size also allowed for more reliable comparisons between aspirin and anticoagulant users, thereby 
adding more data to the investigation into enablers and barriers to prescribing different 
pharmacological prophylaxis. 
 
9.2 Aim 
The aim of this study was three-fold: 
 to explore Australian surgeons’ opinion of the ACCP 9th Ed. Guideline; 
 to compare the opinions of ASA members and non-members;  
 to determine if ASA members’ opinions had changed since the previous survey, conducted 
two years earlier; and 
 to identify any differentiating characteristics between aspirin and anticoagulant users. 
 
9.3 Methods 
The absolute number of respondents to the survey outlined in Chapter 6 was small (25 surgeons), 
thereby limiting the generalisability of the findings and increasing the risk of nonresponse bias. 
Consequently, a number of strategies were employed to increase the absolute number of responses 
to this survey, many consistent with those trialled in Chapter 5. These strategies included: 
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 opening the survey to all surgeons in Australia, irrespective of whether they were ASA 
members or not,  
 shortening the survey considerably from the template used in Chapter 6, 
 making the survey available in both a soft and hard copy format, 
 including a hard copy of the survey in every reminder letter so that surgeons could see 
how short and quick it was to complete, 
 personally signing and including a personal ‘thank you’ note in each invitation and 
reminder letter, 
 distributing the survey directly from the university, thereby excluding any potential bias 
which may have been introduced by the professional endorsement of the previous survey, 
and lastly, 
 using a 3rd generation Apple iPad draw (valued at AUD539) as an incentive to elicit 
participation. 
 
9.3.1 Participant Selection and Invitation 
The names and addresses of hip and knee surgeons were identified by searching through telephone 
listings and orthopaedic practice websites, and through general internet searches. An invitation to 
participate in the survey was sent to 485 surgeons in total. Some invitations were returned 
unopened because the surgeon was no longer at the said-practice. In these instances, follow-on 
practice details (where available) were identified and invitations (and follow-on reminders) were 
sent to the new practice. 
 
9.3.2 The Survey 
The survey was created with LimeSurvey and hosted on a University of Tasmania server. It 
contained a mixture of quantitative and qualitative questions that were divided into three sections 
covering: demographics and professional practising information; prophylaxis effectiveness and 
preferences; and lastly questions concerning familiarity with and opinion of contemporary 
guidelines (Appendix F). The quantitative styled questions were similar to those used in the study 
outlined in Chapter 6, however the qualitative open ended questions were focused on the ACCP 9
th
 
Ed. Guideline instead of the NHMRC Guideline.
68
 To ensure all participants had equal opportunity 
to provide an informed opinion on the ACCP Guideline the survey included a summary of its 
recommendations. Participants were asked to indicate whether they were ASA members or not in 
order to allow comparison of responses between this and the previous surgeon survey (and between 
ASA and non-ASA members’ responses). 
The qualitative styled section included a space for participants to share their opinion on 
appropriate and inappropriate aspects of the ACCP 9
th
 Ed. Guideline, as well as general comments 
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on thromboprophylaxis. This approach allowed exploration of their opinions in a way that check-
box styled questions could not achieve; and minimised responses being influenced by the 
researchers’ presumptions. 
The survey was open for participants to access for eight weeks in early 2012; during this time 
two reminder letters were sent encouraging surgeons to participate.  
 
9.3.3 Data Analysis and Statistics 
All data was entered into an Access database (Microsoft® Access 2010) and then transferred into 
SPSS 19.0 and NVivo 10 (QSR International® Doncaster, Victoria, Australia) for analysis of the 
quantitative and qualitative data respectively. The data was analysed only after the data collection 
phase had been completed. The methods of data analysis are described below for each style. 
 
9.3.3.1 Quantitative Data 
The differences between groups were tested using the t-test for independence for continuous data, 
and the chi square test for categorical variables. Pearson’s rank correlation coefficients were 
calculated for measuring correlations. Continuous variables were summarized as means with 
standard deviation. A univariate analysis, followed by a multivariate analysis of variables, was 
performed to assess the contribution of surgeon variables on their prescribing preferences and 
opinions. Only p≤0.05 values were considered statistically significant. 
 
9.3.3.2 Qualitative Data 
The transcription of comments made in the survey into the Access database was combined with 
reflective review. The data was then transferred into NVivo, and each surgeon’s comments were 
separated into different documents identified by their survey ID number. Each document was 
visited sequentially and open coding was performed to group comments into thematic categories. 
Documents were revisited when new nodes were introduced that resonated with documents already 
coded.  
 
 
9.4 Quantitative Results 
9.4.1 Response Rate 
In total, two hundred and fifty-eight surgeons responded to the invitation letters, however some 
responses could not be included in the analysis (Table 28). The final response rate was 49.2% (221, 
N=449). Most completed responses were submitted as hard copies; however 9 respondents (4.1%) 
completed the survey online. 
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Table 28. Break down of responses (N=258). 
 n % 
Uncertain if respondent conducted hip or knee arthroplasty 4 1.6 
Respondent did not conduct hip or knee arthroplasty 7 2.7 
Invitation letter returned because surgeon left country, no longer practising, 
terminally ill or deceased 
25 9.6 
Responded 8 months after the close of the survey 1 0.4 
Responded with completed survey 221 85.7 
 
9.4.2 Demographics 
Most respondents were males (217, 98.2%, N=220), with an average of 17.8 years practising as 
orthopaedic surgeons (SD 9.0). Most participants practised in Queensland, New South Wales and 
Victoria (Table 29) and predominantly in the private sector (155, 70.7%), followed by both sectors 
equally (55, 25.1%, N=220). 
 
Table 29. Break up of responses from each state and territory  (N=221). 
 n Overall % 
Australian Capital Territory 1 0.5 
New South Wales 59 26.7 
Northern Territory 3 1.4 
Queensland 49 22.2 
South Australia 21 9.5 
Tasmania 12 5.4 
Victoria 61 27.6 
Western Australia 15 6.8 
 
Participants conducted an average of 14.6 arthroplasties each month; with a slight 
preponderance for knee arthroplasties (6.0 hips vs. 8.9 knees, SD 14.6), which is reflective of the 
national trend. There was no correlation between the number of years practising and the number of 
arthroplasties participants conducted monthly. 
Forty-eight participants (23.0%, n=209) identified themselves as ASA members. There was no 
significant demographic difference between members and non-members, however ASA members 
reported conducting significantly more arthroplasties each month (21 vs. 13, p<0.001). 
 
9.4.3 Prescribing Practices 
9.4.3.1 Agent Preference 
Most surgeons (213, 95.9%) reported routinely prescribing pharmacological prophylaxis for their 
patients following surgery, and most (210) shared their preferred prescribing regimen. The 
regimens described included the following: 
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 LMWH 
 LMWH / rivaroxaban 
 Aspirin if one knee, LMWH if two knees 
 Apixaban 
 Rivaroxaban 
 Warfarin  
 LMWH during inpatient stay, rivaroxaban at home 
 Unfractionated heparin during inpatient stay, 
LMWH at home 
 LMWH during inpatient stay, apixaban at home 
 LMWH during the inpatient stay, aspirin at home 
 Aspirin if low risk, LMWH if high risk 
 Aspirin if low risk, rivaroxaban if high risk 
 
Anticoagulants were the most popular choice (154, 75.1%), followed by a combination of an 
anticoagulant + aspirin (28, 13.7%, Table 30). LMWH was the most popular anticoagulant; 
however as noted above, a range of anticoagulants were regularly used by respondents. 
 
Table 30. Primary pharmacological preferences (%) between ASA and non-ASA members   (N=205).  
 Overall ASA member Non-ASA member p 
Aspirin 11.2 17.0 9.5 
0.12 Anticoagulant 75.1 63.8 78.5 
Aspirin + anticoagulant 13.7 19.2 12.0 
NB: Eleven people did not indicate if they were an ASA member or not, and a further five people did not indicate 
their prescribing preference. 
 
There was no statistically significant difference in agent choice between ASA members and 
non-members; however there was a trend towards more members favouring aspirin (± an 
anticoagulant) compared to non-members. There was no significant correlation between agent 
preference and surgeon demographics. 
 
9.4.3.2 Duration Preference   
Most participants preferred continuing pharmacological prophylaxis post-discharge; and knee 
arthroplasty patients were more likely to receive shorter courses of thromboprophylaxis than hip 
arthroplasty patients (p<0.001, Table 31). 
 
Table 31. Preferred duration of thromboprophylaxis (%). 
 Hip Arthroplasty (n=176) Knee Arthroplasty (n=190) 
3-4 days 1.7 1.6 
5-7 days 8.5 10.5 
8-14 days 9.7 32.1 
15-21 days 10.2 18.4 
22-28 days 21.0 11.1 
29-35 days 25.6 7.9 
36-42 days 21.6 16.8 
90 days 1.7 1.6 
Median 
number of days 
28.0 (SD 14.1) 15.0 (SD 14.7) 
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Surgeons who preferred anticoagulants prescribed significantly shorter courses of 
thromboprophylaxis than surgeons who preferred aspirin ± an anticoagulant (-14 days for hip 
arthroplasties and -21 days for knee arthroplasties, p<0.05). There was no correlation between 
duration preference and ASA membership or surgeon demographics. 
 
9.4.4 Thromboprophylaxis Efficacy 
Almost one third of surgeons (29.1%) indicated that they did not believe pharmacological 
prophylaxis prevented fatal PE, 44.1% indicated it may potentially reduce fatal PE, and 26.8% 
responded that it definitely decreased fatal PE. There was a trend towards non-members being 
more confident in the ability of pharmacological agents to prevent fatal PE than ASA members; 
however this did not reach statistical significance (Table 32). 
 
Table 32. Opinions on efficacy of pharmacological prophylaxis (%, N=208). 
Pharmacological agents… 
ASA member 
(n=48) 
Non-ASA member 
(n=160) p 
Do not decrease fatal PE 27.1 29.4 
0.08 Potentially decrease fatal PE 56.2 40.0 
Definitely decrease fatal PE 16.7 30.6 
 
 
9.4.5 Factors that Influence Thromboprophylaxis Prescribing 
Previous VTE, prolonged preoperative immobility and morbid obesity were the top three factors 
surgeons indicated would prompt them to prescribe pharmacological prophylaxis following surgery 
(Table 33). The only statistically significant difference between ASA members and non-members 
was that ASA members were more likely to select prolonged surgery as a factor that would prompt 
them to prescribe pharmacological agents (55.1% vs. 36.1% p<0.05). In addition to the factors laid 
out in the original question, 6 surgeons (2.7%) indicated malignancy and/or family history of VTE 
would also prompt them to prescribe prophylaxis. 
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Table 33. Patient factors that prompt surgeons to prescribe pharmacological prophylaxis  (n=170). 
 %  
Previous VTE 96.5 
Prolonged preoperative immobility 78.2 
Morbid obesity (BMI >40) 75.3 
HRT 65.3 
Previous thrombophlebitis 57.1 
Moderate obesity (BMI >30) 54.7 
Current smoker 53.5 
Surgery > 2 hours 50.6 
Previous vein surgery 40.6 
Age ≥ 70 years 35.9 
Age < 70 years 32.9 
General anaesthesia 30.0 
Preoperative Infection 17.6 
None of these factors 17.1 
None of the above (I routinely prescribe chemoprophylaxis for all of my patients) 1.8 
 
The top two factors reported to limit participants’ prescribing of pharmacological prophylaxis 
for arthroplasty patients were the conviction that it increases the risk of infection at the operation 
site, and the belief that patients would not be compliant (Table 34). Furthermore, bleeding risk was 
a concern for almost half of the respondents (44.3%), particularly during the inpatient period. 
Aspirin users were more likely be concerned with bleeding complications than anticoagulant users 
(88.0% vs. 37.7%, p<0.001).  
 
Table 34. Factors that limit pharmacological prophylaxis use  ((n=221). 
  Inpatient (%) Discharge (%) 
It increases the risk of infection at the operation site 40.3 22.2 
It is not safe as it causes too much bleeding 39.8 22.2 
It is not superior to mechanical methods 24.0 13.6 
It is too expensive 1.8 4.1 
It is too inconvenient 4.1 18.1 
Patients will not be compliant 2.3 17.2 
Poor continuation of care from hospital to community 3.2 9.0 
Study evidence isn't applicable to real-world populations 14.5 15.4 
The risks of VTE are low 11.3 14.0 
None of the above 28.1 23.1 
 
A further 18.1% of participants felt that the inconvenience associated with 
thromboprophylaxis limited its prescribing at discharge. Notably, these participants prescribed 
significantly shorter courses of prophylaxis for their patients on average. This reached statistical 
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significance following knee arthroplasty (17 days vs. 23 days, p=0.04). There were no significant 
differences between any of the ASA members’ and non-members’ responses.      
 
9.4.6 Familiarity with Contemporary Guidelines 
Between 169 and 191 surgeons answered different parts of the question regarding contemporary 
guideline familiarity. Those participants who did respond indicated greatest familiarity with the 
ASA, AAOS and NHMRC guidelines (Figure 28).  
 
 
Figure 28. Surgeon familiarity with contemporary guidelines. 
        I have not come across it before       I have heard of it in passing      I am very familiar with it 
 
ASA members were significantly more likely to be familiar with the ASA Guideline than non-
members (92.8% vs. 53.6%, p<0.001). Furthermore, there was a trend towards those who had 
practised longer as orthopaedic surgeons being more familiar with the contemporary guidelines. 
This finding reached statistical significance with the ANZWP, AAOS and ASA guidelines; 
surgeons who were very familiar with these guidelines had been practising for 5 to 8 years longer 
than surgeons who had only heard of them in passing (p<0.05).  
 
9.5 Qualitative Results 
This section included three open ended questions asking surgeons what they thought was 
appropriate and inappropriate about the ACCP 9
th
 Ed. Guideline, with space for further comments 
on thromboprophylaxis in general. Many comments directly addressed recommendations in the 
Guideline, however many respondents also commented generally on thromboprophylaxis and 
postoperative VTE prevention. These reflections are all included in the analysis below.  
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9.5.1 General Response 
One hundred and sixty nine surgeons (76.5%) completed this section. Responses varied greatly 
from general ‘I agree’ statements to comments on specific recommendations that participants felt 
were appropriate and/or inappropriate, as well as suggestions on how to improve the Guideline. 
Forty-eight surgeons (28.4%) generally agreed with the Guideline, however only two proclaimed 
to follow it. Another surgeon said he was considering aligning his practice with the Guideline after 
reviewing the summary of recommendations in the survey.  
Surgeons who preferred prescribing an anticoagulant ± aspirin were significantly more likely 
to agree with the Guideline than surgeons who preferred to routinely prescribe aspirin only 
(32.2% vs. 0%, p=0.003). There was no other significant difference between surgeons who agreed 
with the recommendations and those who did not, including demographics, reported familiarity 
with the ACCP Guideline and ASA membership. 
 
9.5.2 Anything is Better than Nothing 
The ACCP 9
th
 Ed. Guideline recommends the use of some form of pharmacological prophylaxis 
over nothing. Fourteen (8.3%) surgeons highlighted this as an appropriate recommendation. 
The use of something rather than nothing is appropriate. S103 
All patients should receive prophylaxis unless contraindicated. S148 
VTE prophylaxis probably saves lives and decreases morbidity, and [its] advantages outweigh 
disadvantages. S214 
Conversely, eight participants (4.7%) questioned the validity of recommending 
pharmacological prophylaxis at all, saying it lacks efficacy and is associated with an increased risk 
of postoperative complications.  
[There is] no diff[erence] in fatal PE rate with chemoprophylaxis. S22 
There is no definitive evidence that chemoprophylaxis decreases the risk of PE. S225 
Any of the above (except mechanical) all result in weeping wounds and worrisome low grade 
fevers at various times. S2 
I don't think any thromboprophylaxis has shown a definite decrease in fatal PE. I think we are 
over treating a huge number of patients with minor below knee thrombus. S39 
These comments were in agreement with their responses earlier on in the survey with five 
having answered that pharmacological prophylaxis is not effective at all in preventing VTE, and 
the other three unsure as to its effectiveness. Despite this lack of confidence in its efficacy, all eight 
surgeons prescribed prophylaxis following surgery, most (62.5%) choosing a sole anticoagulant as 
their preferred agent of choice.  
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9.5.3 Pharmacological Prophylaxis 
The new Guideline recommends the use of any one of the following prophylactic agents: LMWH; 
fondaparinux; dabigatran, apixaban, rivaroxaban; low dose unfractionated heparin; adjusted dose 
vitamin K antagonist; aspirin (all Grade 1B). LMWH is recommended in preference to the other 
agents (Grade 2C/2B).  
This recommendation was received with mixed reactions (Table 35). There was no association 
between a participant’s opinion and their demographics. 
  
Table 35. Appropriateness of agent recommendations (N=169). 
  n %  
Aspirin is appropriate 22 13.0 
Aspirin is inappropriate 8 4.7 
LMWH is appropriate 27 16.0 
LMWH is inappropriate 5 3.0 
New Oral Agents are appropriate 11 6.5 
New Oral Agents are inappropriate 7 4.1 
Warfarin is appropriate 6 3.6 
Warfarin is inappropriate 2 1.2 
 
 
9.5.3.1 Aspirin 
Surgeons who commented positively on the recommendation to give aspirin as a sole agent were 
significantly more likely to prescribe it in practice (7/17 vs. 8/127, 41.2% vs. 6.3%, p<0.001). In 
contrast, only eight surgeons (4.7%) questioned the recommendation, all of whom preferred an 
anticoagulant as their sole therapy.  
Inappropriate: using aspirin as a viable VTE prophylaxis! No evidence. S59 
Aspirin is clearly ineffective, how does it get grouped with the others? S214 
One surgeon stated that he didn’t use aspirin to prevent VTE, but ‘mainly for decreased 
morbidity and mortality’. 
 
9.5.3.2 Anticoagulants 
Twenty six surgeons (15.4%) agreed anticoagulants are appropriate choices for prophylaxis, most 
of whom (92.3%) preferred to prescribe an anticoagulant ± aspirin following surgery. Surgeons 
who agreed with the recommendation to use injectable anticoagulants following arthroplasty did 
not elaborate why, simply stating the recommendation was appropriate. 
Appropriate: LMWH. S60 
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Conversely, surgeons who supported the recommendation to use oral anticoagulant agents 
expounded further, describing them as ‘preferable’ because they are ‘easier to administer in 
community, with equivalent efficacy’ to injectable anticoagulants.  
Oral agents are much more appropriate as injected compliance after discharge is v[ery] poor. We 
live in the real world. S92 
I am not convinced of [the] need to use injectables post-discharge - I don't feel they achieve much 
and are a little difficult for the patient - oral agents would be better when freely available. S175 
Additionally, the regular monitoring required with warfarin use was described as an 
advantage. 
Warfarin is monitored. Therefore, better control. If DVT [is] noted, the patient is already on the 
correct medication. As the only surgeon in a large hospital (15 active ortho[paedic] surgeons) 
using warfarin, the nursing staff [have] noted my complications are the lowest by far. S151 
Surgeons who commented against the use of oral agents did so because of bleeding concerns. 
Rivaroxaban is new and probably dangerous. Our physicians have had TWO intrathecal bleeds 
from this protocol and find it is dangerous.  S106 
Inappropriate: recommendations for apixaban/dabigatran/rivaroxaban because of bleeding 
risk. S121 
The problem with warfarin is with bleeding, especially with knee replacement surgery, which 
sometimes by quite major. S119 
Side effects, risks i.e. mortality from warfarin > risk fatal PE. S174 
There was no significant association between preferred agent and bleeding concerns. 
 
9.5.3.3 Low Molecular Weight Heparin in Preference to other Agents 
As noted earlier, the ACCP Guideline gives preference to LMWH over other agents. Eleven 
surgeons (6.5%) disagreed with this recommendation, with only one surgeon explaining why: 
No evidence to say this (2nd paragraph: we suggest the use of LMWH…). S36 
Other participants did not outright disagree with the preference given to LMWH, however did 
comment that ‘compliance with injections [is] difficult’ and ‘bad’, that patients ‘find it 
inconvenient’ and that ‘most won’t self-inject’.  
 
9.5.4 Mechanical Thromboprophylaxis 
The Guideline recommends mechanical prophylaxis in the form of IPCD only. Four surgeons 
(2.4%) commented that it ‘should include foot pumps as an alternative to IPCD’. Another four 
commented against the use of IPCD altogether, stating that ‘IPCD have NOT been shown to 
decrease PE’ and are ‘impractical for hip and knee replacements’. A further four surgeons 
commented that IPCD can irritate patients. 
IPCD 10 to 14 days - impractical, not appropriate once patients are mobile. S29 
IPCD impractical for prolonged period 10 to 14 days. I use first 48 hours when in bed. S57 
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Calf compression devices frequently irritate patients and keep them bed/chairbound. (I use them 
[on] all patients hip/knee). S107 
The Guideline recommends an IPCD in two scenarios: as a sole agent in patients with 
increased bleeding risk, and in combination with pharmacological means in all other patients. 
Thirty-seven surgeons (21.9%) commented that recommending mechanical prophylaxis in either 
setting is appropriate. These comments are explored in more detail in the following two sections. 
There was no significant association between surgeon demographics, and opinion on mechanical 
prophylaxis; however a greater proportion of aspirin users commented positively on their use 
(47.0% vs. 17.3%, p=0.03)  
 
9.5.4.1 Mechanical Thromboprophylaxis as a Sole Agent 
Six surgeons (3.5%) specifically agreed with the recommendation to use mechanical 
thromboprophylaxis as a sole agent in patients with increased risk of bleeding, however one did 
note that ‘patients at increased bleeding risk [are] not defined’ and ‘cannot [be] predict[ed]’. Most 
of these surgeons (75.0%, N=4) reported prescribing aspirin as a sole agent postoperatively. 
Five surgeons (2.9%) commented that mechanical thromboprophylaxis as a sole agent was 
inappropriate. Most (80.0%) of these surgeons reported prescribing anticoagulants as sole agents 
postoperatively, however often preferred to use a combination of methods. 
I will use chemoprophylaxis in patients with increased bleeding risk. I can contain bleeding at 
surgery; I can't retrieve a fatal PE. I prefer combined mechanical, chemical and physiological 
(hydration & movement) [prophylaxis]. S198 
 
9.5.4.2 Combining Mechanical and Pharmacological Prophylaxis 
Twenty four surgeons (14.2%) specifically commented that the recommendation to use a 
combination of mechanical and pharmacological thromboprophylaxis is appropriate.  
I agree with the first paragraph (and adding IPCD to chemoprophylaxis). S155 
Appropriate: combining chemical prophylaxis with mechanical prophylaxis. S59 
Only one surgeon questioned the evidence to support the recommendation. 
I am unaware of evidence which state[s] that IPCD in addition to LMWH is of any benefit. S60 
 
9.5.5 No Thromboprophylaxis 
As an alternative to IPCD, the Guideline also recommends using no prophylaxis in patients at 
increased bleeding risk. The general reaction was to this mixed: four surgeons agreed, and four 
disagreed. 
Appropriate: no prophylaxis in patients at increased risk of bleeding. S51 
No prophylaxis advice, in the context, seems inappropriate. S168 
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All eight surgeons reported prescribing anticoagulants as sole agents following hip and knee 
arthroplasty. 
 
9.5.6 Duration 
The Guideline recommends using pharmacological and mechanical thromboprophylaxis for a 
minimum of 10 to 14 days, and up to 35 days postoperatively. Participants commented that this 
range ‘makes little sense’ and leaves the ‘length of time uncertain’. 
'for up to 35 days' <-- give a better answer. S14 
Specific comments on extended-duration mechanical and pharmacological prophylaxis are 
explored in the succeeding sections below. 
 
9.5.6.1 Duration of Mechanical Prophylaxis 
There were no positive comments about the recommendations to use IPCD for an extended period 
of time. Furthermore several surgeons (6, 3.5%) questioned the practicality and value of the 
recommendation. 
How many patients have IPCD available to them after DC [discharge]? S33 
Most patients following major joint arthroplasty are home by 7 to 10 days post op. Compression 
devices therefore only available as inpatient. S68 
 Extend IPCD only until patient mobile. S146 
One day mechanical will be enough. S45 
 
9.5.6.2 Duration of Pharmacological Prophylaxis 
Opinions on the suitability of extended-duration pharmacological prophylaxis were significantly 
more varied. Six surgeons (3.5%) commented positively on the recommendation, most of whom 
(83.3%) preferred to prescribe anticoagulants postoperatively. 
It is better to treat all patients as a potential risk and therefore [use] extended prophylaxis. S209 
Three surgeons (1.8%) commented that the minimum duration recommended was too short.  
Length of chemoprophylaxis too short. Should be at least 4 weeks. S176 
Conversely, thirty-one surgeons (18.3%) commented that extended-duration therapy was 
inappropriately long and many questioned the motive and evidence to support the 
recommendation.  
How good is [the] evidence for 35 days? S214 
I don't think there is enough literature to support 35 days prophylaxis. I am aware of so called 
2nd peak. S39 
5 weeks of so called prophylaxis is too long. … My view is that prophylaxis is appropriate for 2 to 
3 weeks. S49 
Extended LMWH - good evidence till discharge date. No cost benefit analysis beyond this. S146 
Inappropriate: extending thromboprophylaxis for 35 days. Seems like a drug pusher. S65  
Chapter 9: Surgeons and the ACCP 9
th
 Ed. Guideline 
 
C. Mirkazemi          111 
  
There is no point continuing chemoprophylaxis if routine ultrasound is normal post op in a 
mobile patient. S188 
Thromboprophylaxis for 35 days is very excessive - only appropriate for very high risk patients 
(e.g. previous DVT/PE, known thrombophilia). S199 
These surgeons generally prescribed shorter courses of thromboprophylaxis compared to 
surgeons who did not comment negatively on extended-duration therapy (average of 18 days vs. 29 
days for hip arthroplasty patients, 14 days vs. 23 days for knee arthroplasty patients, p<0.001). 
Other surgeons did not necessarily disagree with the recommendation to use prolonged 
thromboprophylaxis, however they commented that there are ‘compliance’ and convenience issues 
with using injectable agents at home. 
Most of my arthroplasty patients leave hospital at day 3 or 4 post op, most won't self-inject. The 
use of district nurses for injections or INR tests is a considerable work load and expense. S176 
Subcutaneous injections out of hospital – p[atien]t compliance is bad, except for patients I can 
convince that have high risk for DVT + PE. S10 
      
9.5.7 Other Comments 
In addition to the above, many surgeons commented more generally on the Guideline itself, as well 
as postoperative complications that had impacted on their prescribing over the years. These 
comments are summarised in the proceeding sections, 9.5.7.1 General Comments on the Guideline 
and 9.5.7.2 General Comments on Postoperative Complications, respectively. 
 
9.5.7.1 General Comments on the Guideline 
9.5.7.1.1 The Evidence Base 
Many surgeons questioned whether there was any evidence to support the Guideline’s 
recommendations. 
These are based on low level evidence. S188 
… they are vague , which reflects the scarcity of good clinical research in this area. S158 It is 
expert opinion, not based on scientific studies in orthopaedics. S70 
There is no hard evidence there - just use something. S215 
I am not aware of any evidence that thromboprophylaxis changes mortality from PE. S33 
No evidence that any agent reduces P.E. S3 
There is no definitive evidence that chemoprophylaxis decreases the risk of PE. S225 
In summary, evidence is inconclusive… S214 
Evidence for efficacy is inconclusive. S212 
There is no convincing evidence for a lowering of mortality. S211 
Lacks evidence (NO EVIDENCE) for the efficacy to prevent fatal PE. S116 
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Some accused the Guideline of being ‘largely driven by pharmaceutical companies, NOT 
evidence’, noting ‘there is a lot of pressure from the drug companies to use their drug’. They 
further alleged that industry supported studies biased the literature. 
The late complications of antithrombotic usage have been greatly UNDER estimated in literature 
driven by pharmaceutical companies. S13 
The outcome/recommendation is weighted towards chemoprophylaxis which relies heavily upon 
sponsored work in which there are possible conflicts of interest. S142 
In addition to being described as ‘inconclusive’, the evidence to support recommendations 
was described as being out-dated and swayed by inappropriate surrogates for symptomatic VTE. 
All studies use historical rates of DVT/PE and bleeds, and DVT as a marker for fatal PE. S131 
Data on which study is based is out-dated, surgical protocols have evolved. S30 
35 days [is] too long - driven by old papers and pharmaceutical companies. S46 
My biggest issue is in the literature, the use of symptomatic and asymptomatic VTE - THIS 
perpetuates bias. S144 
Data is not placebo controlled - therefore study in total is compromised. S30 
Overemphasised [level] I and II evidence. Ignore existing studies including Austria/Norway + 
Kaiser group. S41 
Extrapolations of VTE evidence to PE are of dubious scientific validity. S214 
Duration recommendations are limited by government cost cutting & doubtful scientific 
evidence. S193 
Furthermore, participants alleged that the Guideline was ‘defensive more than anything 
scientific’. 
It is driven more by medico-legal concerns than by evidence of effectiveness. S94 
We are driven by medico-legal fears, NOT patient outcome. S21 
It probably makes little or no different to PE risk, but it is a MEDICO-LEGAL requirement. S4 
Several surgeons described feeling pushed into prescribing ‘thromboprophylaxis as a routine’ 
‘for medical insurance reasons’, ‘irrespective of what surgeons think’. They noted that this was 
‘dangerous’ and projected that ‘inappropriate prescribing’ and ‘overprescribing’ ‘due to poorly 
formulated and overly prescriptive recommendations’ would eventually cause problems. 
I feel blackmailed into using Clexane [enoxaparin] because of QHealth policies. S219 
We will soon be dealing with litigation due to USE of these agents. S13 
Amongst all of the concerns about the strength of the Guideline’s evidence base, some 
surgeons conceded that it is difficult to produce and/or find good methodologically sound trials. 
The amount of data required for statistical significant level 1 evidence is not obtainable. S215 
No study will ever approach reliability with PTE because sample size required ideally for one 
surgeons technique. S2 
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9.5.7.1.2 Missing Early Mobilisation 
Several surgeons commented that early mobilisation was missing from the Guideline, despite its 
perceived ability to effectively prevent VTE. 
There is no mention of early mobilisation as an effective means of thromboprophylaxis. S104 
No mention of early mobilisation - probably most important. S216 
Early mobilisation & short operative time [are] probably most effective to protect against DVT. 
S208 
I use early mobilisation as best prophylaxis for VTE…S225 
Early mobilisation makes chemoprophylaxis unnecessary. S30 
Compliance with injections [is] difficult. Early mobilisation more important. S146 
 
9.5.7.1.3 Variety of Options and Risk Stratification 
There are many thromboprophylaxis options available to orthopaedic surgeons in the new ACCP 
Guideline; and there were mixed reactions to the large variety. Those that welcomed the range 
generally did so whilst simultaneously commenting positively on the Guideline only making 
recommendations and not dictating practice to surgeons. 
Appropriate: Consideration of choice of wide array of Rx. S98 
Best aspect is leaving choice to the doctor. S175 
Appropriate: Leaves choice of chemoprophylaxis (including aspirin) to surgeon. S184 
Appropriate: RECOMMENDATION of several different options (including aspirin) for the treating 
doctor to choose from, based on the individual patients needs and relative risk of PE. S79 
Concept of stratification of risk of DVT or PE is crucial. To subject ALL patients to risky 
prophylaxis makes no sense. S30 
Those surgeons who did not welcome the broad range of options described them as being ‘too 
broad’, ‘a bit confusing’, self-contradictory, and ‘not answer[ing] the problem’. 
Extremely frustrated [that] no consensus [was] achieved - especially as have had 2 PEs with calf 
compression / clexane / early mobilisation. S107 
The wide range of options suggest[s] none is particularly effective. S35 
'adding IPCD' contradicts 'or IPCD'. S63 
I also feel [the guidelines are] too aggressive if recommended for standard, but major 
orthopaedic operations. Basically nothing helps other than early mobilisation! The rest is 
defensive, more than anything scientific! S165 
None are inappropriate, but they are vague… S158 
 
9.5.7.1.4 Authorship 
Seven surgeons questioned the appropriateness of cardiothoracic physicians making 
recommendations for orthopaedic patients. 
Inappropriate: The fact that PHYSICANS are trying to understand + Rx surgical patients. S165 
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They are a group of arrogant dumb physicians who caused all the problems in the beginning by 
telling the American orthopods [orthopaedic surgeons] what they 'should' do. The Mayo tried 
their foolish protocol which caused [a] large number of bleeding issues. The 9th edition, are 
better, but why would[n’t] I follow AAOS instead? S47 
One participant commented that ‘bitter experiences’ had taught them ‘not to trust physicians’, 
while others generally commented that physicians are ill-positioned to appreciate postoperative 
complications in orthopaedic patients. 
They don't see the wound complications, stiffness, thickening of soft tissues and scarring. S220 
Physicians don't realise the morbidity of p[ost]o[perative] bleed / bruise -> stiffness of joint, 
painful scars, increased sepsis. S222 
Many of us have had colleagues sued by so called experts who have never had to care for joint 
replacement patients and don't understand the complications of chemoprophylaxis and the 
subsequent effect on patient outcomes. S224 
DVT prophylaxis for surgery is NOT understood by physicians and we have started using our own 
guidelines and tell the physicians to… S46 
Evidence of outcomes of complications tends to be overlooked if assumption by CHEST etc. is only 
thrombotic complications are life threatening. S85 
In addition to the negative comments made about the pharmaceutical industry biasing study 
outcomes, similar assertions were made about authors of the ACCP Guideline being ‘sponsored’ 
and having ‘gross conflict[s] of interest’.  
Do they have alternative motives to make this suggestion?  Who is funding them? S213 
The consultants who make the recommendations are recipients of research funding and I don't 
believe their opinions are without bias. S220 
I think these people are compromised. S3 
A lingering suspicion that physicians making these recommendations are not completely 
unbiased in their recommendations. S52 
Concern over funding links of pharmaceutical industry to almost all senior medical advisers in 
this area. S214 
Similar allegations were also made about the ANZWP Guideline, and by inference, to the 
NHMRC Guideline; both participants below reported being very familiar with both of these 
guidelines. 
ANZWP nominated themselves and are heavily sponsored by Sanofi - something they did not 
declare until edition 4. [The] only source document for [the] NHMRC [guideline] is the ANZ 
working Party. S8 
ANZWP - Funded by Clexane [enoxaparin] manufacturer! (Sanofi Aventis). S131 
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9.5.7.2 General Comments on Postoperative Complications 
9.5.7.2.1 Venous Thromboembolism 
One participant commented that ‘most orthopaedic surgeons don’t care about DVT and/or non-
fatal PE’. Potentially this may be because ‘orthopaedic surgeons in general underestimate the risk 
as they do not necessarily hear about patients with PE or death’, or maybe because they feel that 
‘surgical VTE is VERY different to non-surgical’ VTE, and ‘argue that fatal PE is not affected 
[by] leg prophylaxis’. Alternatively, some may find that the risk / benefit ratio for pharmacological 
agents is unacceptable. 
My biggest concerns is that while chemoprophylaxis may/ may not reduce the risk of fatal PE, 
[and] fatality from other causes while using chemoprophylaxis is actually more likely i.e. fatal 
GIT [gastrointestinal] bleed from Warfarin etc. S174 
Prophylaxis extended to 35 days increases the risk of complications proportional to time, but 
does not decrease the risk of significant PE correspondingly. S176 
Fatal PE was different altogether; experiencing a patient die of PE made surgeons ‘want to 
pull out all [the] stops’. Subsequent adverse experiences also impacted on how effectively they 
believed pharmacological agents prevent VTE, but did not dissuade them from prescribing it. 
Before thromboprophylaxis I saw several patients die from PE. NIL since. S75 
I have had 2 PEs with calf compression / clexane [enoxaparin] / early mobilisation. S107  
I've anticoagulated all joint replacement patients. Generally if they are fit for operation, there is 
no contraindication to thromboprophylaxis. Even with this protocol, small number of patients   
a VT[E]. Not had a fatal PE. But have had PE. S86 
 
9.5.7.2.3 Bleeding 
While bleeding is a natural complication of any surgery, it was acknowledged that the risk will 
logically be increased by the use of pharmacological agents.  
All chemoprophylaxis have potential for significant bleeding. S130 
Concern was expressed that the true incidence of thromboprophylaxis associated 
postoperative bleeding is much higher than reported in the literature, with some participants 
commenting that it is ‘never reported’ and is ‘underestimated’; conversely others commented that 
‘bleeding risk is overstated’. Nevertheless, surgeons commented that blood loss in itself was not 
their primary concern with postoperative bleeding, but rather they were concerned about its 
perceived tendency to delay wound and joint healing.  
…the morbidity of p[ost]o[perative] bleed / bruise -> stiffness of joint, painful scars, increased 
sepsis. S222 
I have found the use of LMWH in all arthroplasty patients to be associated with a disturbingly 
high incidence of bruising, persistent wound ooze, greater post op[erative] Hb [haemoglobin] 
drop & an increased incidence of stiffness & infection. S176 
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I've tried many other chemicals [other than warfarin] and noted higher incidence of 
haemorrhage, bruising etc. joint stiffness increased, sepsis increased. S151 
Although there are bleeding risks associated with thromboprophylaxis use, several surgeons 
commented that the benefits of using it outweighed these risks.  
While I do not believe there is conclusive evidence for the prevention of fatal PE, the balance is 
for routine prophylaxis. S196 
Chemical thromboprophylaxis WORSENS [the] outcome of total join arthroplasty, but reduces 
death – BALANCE. S202 
Rarely does it [bleeding] lead to significant wound issues. PE can be fatal! S162 
It is a balance between safety for patients: to prevent clots vs. danger of bleeding. S175 
While several participants noted that every pharmacological agent’s risk profile is different, 
one commented that ‘despite all of the literature, studies, etc. we still do not have a safe 
thromboprophylaxis agent’. 
 
9.6 Survey Comparison 
As noted previously, guidelines have decreased the strength of their recommendations over the 
years. When comparing ASA members’ responses between the two surveys conducted two years 
apart (2010 and 2012), members were slightly more polarised in their answers, with a trend 
towards members becoming more confident regarding the ability of thromboprophylaxis to 
effectively prevent or not prevent fatal PE (Table 36). 
 
Table 36. ASA members’ opinions on efficacy of pharmacological prophylaxis. (%) (n=25 and 48 respectively). 
Pharmacological agents… Chapter 6  Chapter 9 p 
Do not decrease fatal PE 24.0 27.0 
0.8 Potentially decrease fatal PE 64.0 56.3 
Definitely decrease fatal PE 12.0 16.7 
 
The top three factors that surgeons reported would prompt them to prescribe 
thromboprophylaxis were identical between both studies (Table 37). Surgeons in both surveys 
almost universally agreed that a history of VTE would prompt them to prescribe 
thromboprophylaxis. There were, however, significant differences between the proportion of 
surgeons who would be prompted to prescribe thromboprophylaxis for patients who were obese, 
had a history of thrombophlebitis or vein surgery, or whose arthroplasty surgery took more than 2 
hours.  
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Table 37. Patient factors that prompt surgeons to prescribe pharmacological prophylaxis (%). 
 
Chapter 6 
(n=25) 
Chapter 9 
(n=170) 
p 
Age < 70 years 16.0 32.9 0.09 
Age ≥ 70 years 20.0 35.9 0.12 
Current smoker 28.0 53.5 <0.05 
General anaesthesia 12.0 30.0 0.06 
HRT 52.0 * 65.3 * 0.20 
Moderate obesity (BMI >30) 32.0 54.7 <0.05 
Morbid obesity (BMI >40) 36.0 75.3 <0.05 
Preoperative Infection 12.0 17.6 0.48 
Previous thrombophlebitis 28.0 57.1 <0.05 
Previous vein surgery 20.0 40.6 0.05 
Previous VTE 96.0 * 96.5 * 0.90 
Prolonged preoperative immobility 44.0 * 78.2 * <0.05 
Surgery > 2 hours 24.0 50.6 <0.05 
NB: * indicates one of the top three factors. 
 
Two of the top three factors that surgeons indicated would prevent them from prescribing 
thromboprophylaxis for their patients were identical in the two studies, namely the perception that 
pharmacological prophylaxis is not superior to mechanical prophylaxis and bleeding concerns 
(Table 38). 
 
Table 38. Factors that limit pharmacological prophylaxis use ((%). 
  
Chapter 6 
(n=25) 
Chapter 9 
(n=221) 
p 
It increases the risk of infection at the operation site 28.0 41.6 * 0.18 
It is not safe as it causes too much bleeding 76.0 * 44.3 * <0.05 
It is not superior to mechanical methods 40.0 * 25.8 * 0.13 
It is too expensive 12.0 4.1 0.08 
It is too inconvenient 48.0 * 19.9 <0.05 
Patients will not be compliant 12.0 17.6 0.47 
Poor continuation of care from hospital to community 16.0 10.4 0.40 
Study evidence isn't applicable to real-world populations 36.0 19.5 <0.05 
The risks of VTE are low 40.0 * 16.7 <0.05 
NB: * indicates one of the top three factors. 
 
Guideline familiarity between the two surveys was noticeably different. Of note, all surgeons 
in the first survey were familiar with the ASA Guideline. In contrast, only 62.3% were familiar 
with the ASA Guideline in the second survey (p<0.001). This is likely because all participants in 
the first survey were ASA members, whereas only 42 participants (18.6%) in the second survey 
were ASA members. Of these respondents, 92.8% were familiar with the ASA Guideline – similar 
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to the first survey. This is evident in Figure 29 below; however, it is important to note that although 
the ACCP is the only guideline to have been revised in the years between both surveys, surgeon 
familiarity with the contemporary guidelines was generally lower across the board.  
 
 
Figure 29. Proportion of surgeons very familiar with contemporary guidelines. 
 Chapter 6 data        Chapter 9 data, combined       Chapter 9 ASA members      Chapter 9 non-ASA members 
*indicates statistically significant difference between   and  (p<0.05). 
 
 
 
9.7 Discussion 
This survey demonstrated a lack of agreement amongst surgeons as to the appropriateness of the 
ACCP 9
th
 Ed. Guideline, and similar to the findings reported in Chapter 6, to the general use of 
thromboprophylaxis following arthroplasty.
206
  
As noted in 9.3 Methods the survey template used in this study was a shortened version of the 
survey used in the study outlined in Chapter 6. While some questions differed between the two 
surveys, a number were identical, allowing direct comparison between the findings of each survey. 
For example, in both surveys LMWH was the most popular agent of choice for surgeons, however 
the number of surgeons who preferred to use aspirin postoperatively in the current study was 75% 
lower than the previous survey (11.7% vs. 44.0% respectively).
206
 This may be because only ASA 
members (who had a tendency to prefer aspirin) were included in the previous survey and they 
only made up 23.0% of the response rate in this survey.  
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Respondents described using a variety of thromboprophylaxis regimes in this survey, with 
many surgeons favouring a combination of different agents, instead of just one. Almost 15% of 
respondents said they preferred to use an anticoagulant during their patients’ admission, and then 
switch to aspirin at discharge. Anderson et al reported this type of regime to be non-inferior to 
standard extended-therapy dalteparin use.
209
 
Interestingly, surgeons who preferred to prescribe aspirin in this study tended to prescribe 
longer courses of prophylaxis than those who preferred to prescribe an anticoagulant ± aspirin. 
These surgeons were also the ones most concerned about thromboprophylaxis associated bleeding; 
however it is likely one of the reasons they chose to prescribe aspirin over anticoagulants is the 
perceived lower bleeding risk. 
Surgeons in both surveys generally preferred to prescribe thromboprophylaxis past the initial 
inpatient period and up to 2 to 6 weeks following surgery. There was a trend in both surveys to 
surgeons preferring to prescribe longer courses of thromboprophylaxis for hip arthroplasty patients 
compared to knee arthroplasty patients.  
Despite their lack of original familiarity with them, surgeons in both surveys alleged that the 
evidence behind the guidelines (NHMRC Guideline in the previous study, the ACCP 9
th
 Ed. 
Guideline in this study) were founded on an inappropriate evidence base or were inappropriately 
broad. Significantly, of all the themes identified in the qualitative data of the present study, this 
was the only one which had a significant number of surgeons (n=54, 32.0%, N=169) in agreement 
with one another. This suggests the need for significant research in this field targeting the efficacy 
and dangers of thromboprophylaxis in the real world, taking into account patients’ comorbidities, 
surgical differences and multi-modal strategies implemented to reduce VTE. Until this type of data 
is available (and it may never be), it is likely there will be little general consensus as to what 
constitutes appropriate thromboprophylaxis for arthroplasty patients. 
Response rates to postal surveys are low and probably declining, almost certainly leading to 
unknown levels of bias.
210
 Health professionals, in particular doctors, are considered to be a 
problematic population from which to collect survey data, with average response rates from 
doctors reported to be around 60%.
210
 It has been demonstrated that as response rates decrease, the 
risk for nonresponse bias increases, which is particularly relevant with a topic as sensitive as 
thromboprophylaxis following hip and knee arthroplasty.
202
 It is possible then, that non-responders 
would have been even less likely to agree with the ACCP Guideline than responders; however, 
only a follow up with non-responders would be able to confirm this. 
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 CHAPTER TEN: CONCLUDING DISCUSSION 
 
 
 
Clinical practice guidelines are regularly disseminated by professional bodies, each designed to 
improve and optimise thromboprophylaxis use in hospitalised patients. Despite the ready 
availability of these guidelines, the National Institute of Clinical Studies has described ‘appropriate 
prophylaxis’ as ‘often underused’ in Australian patients, potentially leaving them exposed to a 
higher risk of VTE.
10
 The studies outlined in this thesis were conducted to describe and explore 
thromboprophylaxis prescribing practices and the factors that influence them. In total, six 
individual studies and one data reanalysis were conducted to achieve this aim.  
The interviews identified that prescribers prefer to tailor therapy to individual patients – a 
practice known as personalised prescribing. The reviews identified that prophylaxis is routinely 
(and optimally) used in the immediate inpatient period, and anticoagulants (particularly LMWH) 
are prescribed preferentially over antiplatelets. On average, arthroplasty patients stay in hospital for 
five to six days postoperatively, and typically receive as many days of prophylaxis. Whilst 
prescribing is routine in hospital, the reviews identified that the provision of thromboprophylaxis at 
discharge is not. 
There are many factors that influence whether a surgeon prescribes thromboprophylaxis for 
their patient at discharge or not. The surveys identified that surgeons were more likely to prescribe 
thromboprophylaxis for patients with a previous history of VTE; for smokers; for obese patients 
(BMI>30); for patients who were immobile for a prolonged period of time preoperatively; and for 
patients who had an operation time over two hours. Surgeons were less likely to prescribe 
thromboprophylaxis at discharge if they perceived it to be inconvenient for patients; perceived 
VTE risk as too low to warrant it; or perceived thromboprophylaxis to be unsafe due to bleeding 
risk. The interviews confirmed that instead of basing their opinion on study data and guidelines, 
surgeons’ prescribing was greatly shaped by their training and collective experience of 
postoperative complications. Notably, some surgeons described being ‘relatively ignorant of 
what’s actually happening’ in practice; this could result in a falsely high or low perception of their 
respective complication rates, thereby significantly influencing their prescribing practices.  
Although surgeons reported good familiarity with the relevant literature, there was a general 
sense of mistrust, and the perception amongst some surgeons that study data does not correlate well 
with real-world populations. In particular, the use of asymptomatic clots as a surrogate measure for 
symptomatic VTE, and industry funding of studies and/or study authors negatively influenced 
surgeons’ opinion of study data. Furthermore, some surgeons commented that there had been 
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significant changes in the pre-, peri- and postoperative care of arthroplasty patients over the years, 
thereby making old studies out-dated and their findings seemingly obsolete.  
In 2012 Molnar et al reported that orthopaedic surgeons’ thromboprophylaxis prescribing was 
influenced by medico-legal concerns; that is, that surgeons were prescribing defensively.
121
 
Surgeons in the interviews and surveys included in this thesis commented that guidelines can 
create a medico-legal dichotomy: on the one hand they can assist in guarding against medico-legal 
concerns by outlining what is ‘middle of the road standard care’; on the other, they hold the 
potential to impose a medico-legal risk to surgeons who disagree (and practise in discordance) with 
their recommendations.  
That guidelines have changed considerably over the years in their recommendations is the 
result of both methodology changes and an increase in the amount of study data available. Such 
changes in established evidence based recommendations are common, and occur across all classes 
of medical practice; the term coined for these changes is ‘medical reversal’.211 One of the most 
commonly cited examples of medical reversal can be seen in the recommended care of cardiac 
patients. Percutaneous coronoary interventions (PCI) are procedures conducted to revascularise 
areas of the heart that have been starved of blood flow due to coronary artery occlusions. The use 
of PCI on stable occlusions (i.e. not in the emergency setting) has been an established practice 
internationally, as it was perceived to improve patient survival and quality of life.  However, recent 
studies have determined that reperfusion with PCI does not reduce the occurrence of death or 
disease progression in these patients, and may actually increase the risk of adverse events.
211-215
 
The most common reason for medical reversal is that practice recommendations are often 
based on premature, inadequate, biased or conflicted evidence.
216
 ‘Another challenge is that 
conflicts of interest are common in medical research, leading many to question the validity and 
integrity of results from industry-sponsored trials’.217 Larger, more robust studies that are 
conducted independent of industry funding and sponsorship are required to overcome this barrier. 
Notably, one reason why surgeons said they were hesitant to start prescribing novel oral agents was 
the concern that there is insufficient independent post-marketing surveillance data available to 
confirm their efficacy and safety in the real-world setting. 
That guidelines have decreased in the strength of their recommendations suggests 
inconsistencies in study data, resulting in professional bodies becoming ‘unclear about which 
prophylactic strategy (or strategies) is/are optimal or suboptimal’.166 Disputed or unclear evidence 
have been identified as barriers to guideline adoption.
175,177
 Significantly, the uncertainty influences 
the definition of what is appropriate, and therefore the degree to which evidence-practice gaps are 
perceived to exist. This is evident in the reanalysis outlined in Chapter 8, wherein a simple change 
in yardstick from the ACCP 7
th
 Ed. Guideline to the 9
th
 Ed. Guideline resulted in a six-fold 
perceived ‘improvement’ in thromboprophylaxis use. 
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In summary, there are many factors that influence thromboprophylaxis prescribing. Of all of 
these factors, knowledge and communication are the most significant. To date there is no clear 
consensus on what constitutes appropriate thromboprophylaxis, and surgeons are not fully 
informed of their postoperative complication rates. Furthermore, many health professionals are 
unfamiliar with guideline recommendations and GPs said they were often ignorant of 
hospital/surgeon preferences for the post-discharge care of arthroplasty patients, when 
thromboprophylaxis is least likely to be prescribed. The recent advent of electronic discharge 
summaries that are emailed to GPs within 24 hours of patient discharge will likely assist greatly in 
keeping Tasmanian-based GPs informed about post-discharge care plans; however, in order for 
thromboprophylaxis to be optimised, all knowledge and communication barriers must be 
addressed.  
Based on my findings, I recommend the formation of a local (or preferably national) database 
to collect and report back postoperative complication rates for arthroplasty patients to surgeons and 
hospitals. The collection of patient factors, operation factors and thromboprophylaxis use in such a 
database would assist to clarify how thromboprophylaxis influences postoperative complications in 
different patient groups, in the real-world setting. This information would also elucidate what 
constitutes appropriate thromboprophylaxis in different patient groups, and would naturally inform 
forthcoming national guideline editions, making recommendations more acceptable for surgeons. 
Lastly, guideline dissemination strategies need to be developed (or enhanced where they exist) to 
ensure all health professionals have ready knowledge and access to national guideline 
recommendations as they are developed. Simple strategies could include the dissemination of one 
to two page summaries from large guidelines such as the NHMRC Guideline. Such summaries 
would ideally include a decision aid tool, and relevant introduction or discussion to address 
surgeons’ concerns, as suggested in Appendix E. Together these strategies will improve guideline 
recommendations, ensure optimal uptake of these recommendations and, most importantly, secure 
the best outcomes for arthroplasty patients. 
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APPENDIX A 
GUIDELINE RECOMMENDATION GRADINGS 
 
 
 
This appendix contains grading recommendations for the following guidelines: 
 the AAOS Guideline (2007), 
 the ACCP 8th Guideline (2008), 
 the ACCP 9th Ed. Guideline (2012), and 
 the NHMRC Guideline (2009). 
  
  
 
AAOS Grading Recommendations (2007) 
 
 
 
“Each guideline recommendation was graded using the following system:  
A: Good evidence (Level I Studies with consistent finding) for or against recommending 
intervention.  
B: Fair evidence (Level II or III Studies with consistent findings) for or against recommending 
intervention.  
C: Poor quality evidence (Level IV or V) for or against recommending intervention.  
 
 
Level I evidence is from high quality randomized clinical trials (e.g. a randomized trial comparing 
revision rates in patients treated with cemented and uncemented total hip arthroplasty).  
Level II evidence is from cohort studies (e.g. revision rates in patients treated with uncemented 
total hip arthroplasty compared with a control group of patients treated with cemented total hip 
arthroplasty at the same time and institution).  
Level III evidence is from case-control studies (e.g. the rates of cemented and uncemented total hip 
arthroplasty in patients with a particular outcome called "cases"; i.e. revised total hip arthroplasty, 
are compared to those who did not have outcome, called "controls"; i.e. non-revised total hip 
arthroplasty).  
Level IV evidence is from an uncontrolled case series (e.g. a case series of patients treated with 
uncemented total hip arthroplasty).   
Level V evidence is from expert opinion. The table is relatively simple with four types of studies 
and five levels. The actual criteria for assignment is a little more complicated, and for interested 
readers, are contained in the cells of the table.”156 
 
 
 
 
 
 
 
 
 
 
  
 
ACCP 8
th
 Ed. Recommendations (2008) 
 
 
 
Grade 
Grade of 
Recommendation
*
 
Benefit vs Risk 
and Burdens 
Methodologic Quality of 
Supporting Evidence Implications 
1A Strong 
recommendation; 
high-quality 
evidence. 
Desirable effects 
clearly outweigh 
undesirable 
effects, or vice 
versa 
Consistent evidence from RCTs 
without important limitations 
or exceptionally strong 
evidence from observational 
studies 
Recommendation can apply to most 
patients in most circumstances; 
further research is very unlikely to 
change our confidence in the estimate 
of effect  
1B Strong 
recommendation; 
moderate-quality 
evidence. 
Desirable effects 
clearly outweigh 
undesirable 
effects, or vice 
versa 
Evidence from RCTs with 
important limitations 
(inconsistent results, 
methodological flaws, indirect 
or imprecise), or very strong 
evidence from observational 
studies  
Recommendation can apply to most 
patients in most circumstances; higher 
quality research may well have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate  
1C Strong 
recommendation; 
low or very low-
quality evidence. 
Desirable effects 
clearly outweigh 
undesirable 
effects, or vice 
versa 
Evidence for at least one 
critical outcome from 
observational studies, case 
series, or from RCTs with 
serious flaws or indirect 
evidence  
Recommendation can apply to most 
patients in many circumstances; 
higher-quality research is likely to 
have an important impact on our 
confidence in the estimate of effect 
and may well change the estimate  
2A Weak 
recommendation; 
high-quality 
evidence. 
Desirable effects 
closely balanced 
with undesirable 
effects 
Consistent evidence from RCTs 
without important limitations 
or exceptionally strong 
evidence from observational 
studies 
The best action may differ depending 
on circumstances or patient or society 
values; further research is very 
unlikely to change our confidence in 
the estimate of effect  
2B Weak 
recommendation; 
moderate-quality 
evidence. 
Desirable effects 
closely balanced 
with undesirable 
effects 
Evidence from RCTs with 
important limitations 
(inconsistent results, 
methodological flaws, indirect 
or imprecise), or very strong 
evidence from observational 
studies  
Best action may differ depending on 
circumstances or patient or society 
values; higher-quality research may 
well have an important impact on our 
confidence in the estimate of effect 
and may change the estimate  
2C Weak 
recommendation;  
low or very low-
quality evidence. 
Desirable effects 
closely balanced 
with undesirable 
effects 
Evidence for at least one 
critical outcome from 
observational studies, case 
series, or from RCTs with 
serious flaws or indirect 
evidence  
Other alternatives may be equally 
reasonable; higher-quality research is 
likely to have an important impact on 
our confidence in the estimate of 
effect and may well change the 
estimate  
* “We use the wording we recommend for strong (Grade 1) recommendations and we suggest for weak (Grade 2) 
recommendations.”
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ACCP 9
th
 Ed. Recommendations (2012) 
 
 
 
Grade 
Grade of 
Recommendation 
Benefit vs Risk 
and Burdens 
Methodologic Strength of 
Supporting Evidence Implications 
1A Strong 
recommendation; 
high-quality 
evidence. 
Benefits clearly 
outweigh risk 
and burdens or 
vice versa. 
Consistent evidence from 
randomized controlled trials 
without important limitations 
or exceptionally strong 
evidence from observational 
studies. 
Recommendation can apply to most 
patients in most circumstances. Further 
research is very unlikely to change our 
confidence in the estimate of effect. 
1B Strong 
recommendation; 
moderate-quality 
evidence. 
Benefits clearly 
outweigh risk 
and burdens or 
vice versa. 
Evidence from randomized 
controlled trials with 
important limitations 
(inconsistent results, 
methodologic flaws, indirect 
or imprecise) or very strong 
evidence from observational 
studies. 
Recommendation can apply to most 
patients in most circumstances. Higher-
quality research may well have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate. 
1C Strong 
recommendation; 
low-or very-low-
quality evidence. 
Benefits clearly 
outweigh risk 
and burdens or 
vice versa. 
Evidence for at least one 
critical outcome from 
observational studies, case 
series, or randomized 
controlled trials, with serious 
flaws or indirect evidence. 
Recommendation can apply to most 
patients in many circumstances. 
Higher-quality research is likely to have 
an important impact on our confidence 
in the estimate of effect and may well 
change the estimate. 
2A Weak 
recommendation; 
high-quality 
evidence. 
Benefits closely 
balanced with 
risks and burden. 
Consistent evidence from 
randomized controlled trials 
without important limitations 
or exceptionally strong 
evidence from observational 
studies. 
The best action may differ depending 
on circumstances or patient or societal 
values. Further research is very unlikely 
to change our confidence in the 
estimate of effect. 
2B Weak 
recommendation; 
moderate-quality 
evidence. 
Benefits closely 
balanced with 
risks and burden. 
Evidence from randomized 
controlled trials with 
important limitations 
(inconsistent results, 
methodologic flaws, indirect 
or imprecise) or very strong 
evidence from observational 
studies. 
Best action may differ depending on 
circumstances or patient or societal 
values. Higher-quality research may 
well have an important impact on our 
confidence in the estimate of effect 
and may change the estimate. 
  
  
 
NHMRC Recommendations (2009) 
 
 
 
“Each recommendation is assigned a grade from ‘A’ to ‘D’.  
 ‘A’ refers to a recommendation based on a body of evidence that can be trusted to guide 
practice.  
 ‘B’ refers to a recommendation based on a body of evidence that can be trusted to guide 
practice in most situations.  
 Grade ‘C’ means that the body of evidence provides some support for the 
recommendation, but care should be taken in its application.  
 Grade ‘D’ means that the body of evidence is weak and the recommendation should be 
applied only if considered appropriate after consideration of the clinical context.  
Where no good-quality evidence was available but there was consensus among Committee 
members, consensus-based recommendations are given. Such recommendations are called Good 
Practice Points (GPPs).”17 
 
 
 
 
 
 
  
 
 
APPENDIX B 
AUSTRALIAN HOSPITAL PROTOCOLS: 
 
 
 
This appendix includes the invitation letter sent to CNMs, as well as the survey itself.  
 
  
 
  
 
 
  
 
  
 
   
  
 
APPENDIX C 
SURVEY OF AUSTRALIAN ORTHOPAEDIC SURGEONS 
 
 
 
This appendix includes the invitation letter sent to orthopaedic surgeons through the Arthroplasty 
Society of Australia, as well as the survey itself.  
 
   
  
 
 
   
  
   
  
   
  
   
  
   
  
   
  
  
  
 
APPENDIX D 
SEMI-STRUCTURED INTERVIEWS 
 
 
 
This appendix includes an example of the invitation letter and consent form sent to prospective 
participants, as well as an example of one of the early interview guides. NB: The interview guides 
were changed in an iterative approach after each interview. 
  
  
  
  
  
 
  
  
 
APPENDIX E 
SUMMARY OF NHMRC THROMBOPROPHYLAXIS RECOMMENDATIONS 
 
  
  
NHMRC Thromboprophylaxis Recommendations for 
Hip and Knee Replacement patients 
 
 
Adequate hydration and early mobilisation are simple measures that should be applied as standard 
practice to prevent VTE. Other important options for VTE prophylaxis include pharmacological or 
mechanical methods.  
 
The risk of VTE in patients must be balanced against the actual and perceived risks of 
pharmacological thromboprophylaxis and patients’ tolerance of pharmacological (especially 
injectable) or mechanical prophylaxis. In particular, surgeons may be understandably reluctant to 
expose patients to the risk of excessive intra- or postoperative bleeding and the subsequent 
complications, especially in procedures such as joint replacement where bleeding can lead to severe 
infections and a need to explant prostheses.  
 
By nature of its mechanism of action, pharmacological prophylaxis may increase the risk of 
surgical bleeding. As the evidence presented throughout this Guideline is mostly from randomised 
controlled trials, this may not be an accurate reflection of the incidence of bleeding outside the 
controlled trial context. 
 
An assessment of bleeding risk is an essential step in deciding on appropriate 
thromboprophylaxis for individual patients. The final decision to provide thromboprophylaxis is a 
clinical decision based on the number and type of VTE risk factors balanced against risk of bleeding, 
and is made in consultation with the patient.  
 
A VTE risk assessment should follow the following steps: 
 
 
 
 
Step 1 
• Assess the patient’s baseline risk of VTE, taking into account inherited 
and/or acquired risk factors.                                                                                                 
VTE risk factors include: age>40yrs, pregnancy, malignancy, previous VTE, varicose veins, 
marked obesity, prolonged severe immobility, use of oestrogen-containing therapy, inherited 
or acquired thrombophilia, type of aneasthesia, surgical complications. 
Step 2 
• Assess the patient’s risk of bleeding or contraindications to 
pharmacological or mechanical prophylaxis.                                                   
Risk factors for bleeding include: bleeding disorders, intracranial or spinal lesion, abnormal 
blood coagulation, thrombocytopenia, severe platelet dysfunction, active peptic ulcer, 
obstructive jaundice or cholestais, concominant use of anticoagulants, antiplatelets, NSAIDs or 
thrombolytic agents, regional axial anaesthesia or recent lumbar puncture, high risk of falls. 
Step 3 
• Select appropriate methods of thromboprophylaxis based on the risk 
assessment in consultation with the patient. 
  
The recommendations below are intended to encapsulate the available evidence on the prevention 
of VTE. However, they should only be followed subject to the judgement of clinicians caring for 
individual patients and patients’ own preferences. 
 
 
RECOMMENDATIONS BY CLINICAL PROCEDURE GRADE 
Total knee replacement  
Use thromboprophylaxis for all patients admitted to hospital for total knee replacement. GPP 
In the absence of contraindications, use one of the following agents for up to 14 days following surgery: 
• low molecular weight heparin 
• fondaparinux 
• rivaroxaban 
• dabigatran etexilate. 
 
A 
B 
B 
B 
Use one of the following whether or not pharmacological thromboprophylaxis is used, until the patient is fully 
mobile: 
• foot pump 
• intermittent pneumatic compression. 
 
 
C 
C 
Aspirin is not recommended as the sole pharmacological agent following total knee replacement. C 
Warfarin is not recommended for thromboprophylaxis following total knee replacement. B 
Total hip replacement 
Use thromboprophylaxis for all patients admitted to hospital for total hip replacement. GPP 
In the absence of contraindications, use one of the following agents for up to 35 days following surgery: 
• low molecular weight heparin 
• fondaparinux 
• rivaroxaban 
• dabigatran etexilate. 
 
A 
B 
B 
B 
Use graduated compression stockings, intermittent pneumatic compression or a foot pump until the patient is fully 
mobile, whether or not pharmacological thromboprophylaxis is used. 
If possible, use graduated compression stockings with a foot pump where pharmacological thromboprophylaxis is 
not used. 
 
B 
 
 
 
B 
Only use unfractionated heparin if recommended thromboprophylactic options are not available. B 
Aspirin is not recommended as a sole pharmacological agent for thromboprophylaxis. C 
Warfarin is not recommended for thromboprophylaxis following total hip replacement except where used for 
therapeutic reasons. In these cases, use adjusted therapeutic doses. 
C 
 
GRADE DESCRIPTION 
A Body of evidence can be trusted to guide practice 
B Body of evidence can be trusted to guide practice in most situations 
C Body of evidence provides some support for recommendation(s) but care should be taken in its application 
GPP Good practice point – consensus-based recommendations 
 
   
  
APPENDIX F 
SURGEONS AND THE ACCP 9TH ED. GUIDELINE 
 
 
 
This appendix includes the invitation letter sent to orthopaedic surgeons as well, as the survey itself. 
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